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Abstract 
Since the discovery of genetic inheritance by Mendel (1890) and the identified role of 
DNA in cell division (Crick/Watson 1950), scientists have worked to advance stem cell 
technologies to treat and cure human disease. The broad techniques of therapeutic 
cloning are gene therapy, stem cells growth and pharmacogenetics together constitute a 
complex and demanding science. Each involves the alternating and growth of new cells 
including the use of human embryos undifferentiated cells and a potential to grow into 
any organ and tissue type. 
This work explores the national context in which stem cell science is advancing in a case 
study between the UK and China using National Systems of Innovation (NSI) as a 
theoretical structure. NSI is defined by the literature, which includes economic 
performance, political and legislative structure, research investment, and societal values 
(Freeman 1997; Fagerberg 2004). Using ethnographic and statistical analysis, it 
compares the effect each National System of Innovation is having on the advance of 
therapeutic cloning. Diabetes is chosen as the clinical model because of its global 
prevalence, affecting over 200m people (BHF 2004) and accounting for 9% of mortality 
(WHO 2002). and the prediction that it will become the world's most major non-
communicable cause of death by 2025 (Atlas 2004). 
During this study, China experienced unprecedented economic growth underpinned by 
strong research investment, which is now three times the size of that in the UK (Wilsden 
2006). It has a permissive social culture for stem cell research (Mann 2003), having 
adapted much of the European legislation (Salter 2007) with much of its research led by 
doctors, enabling a quicker advance of stem cell therapies to the clinic (Prescott). The 
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UK is, in comparison, a global leader in stem cell science, having a prestigious record of 
achievements including the final mapping of the human genome (Goodfellow 2001), the 
cloning of Dolly the Sheep (PHGU 2002), and being first to legislate for such embryo 
research (HFA 1990). The UK's economic performance is also strong during this study, 
but well behind that of China, and neither does it enjoy the relaxed ethical stance of the 
Chinese structure. This is evidenced in its research investment, which has fallen as a 
proportion of GDP from 2.24 in 1990 to 1.78 in 2005 (National Statistics 2007), whereas 
China has increased from 0.7 to 1.31 (Wilsdon 2006). 
There is evidence in the literature of the importance of innovation to economic growth 
(OECDa 2004) and the relationship of this to GDP performance. This research explores 
the impact the National System of Innovation is having on the advance of stem cell 
research in the UK and China, using diabetes as a clinical model. 
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Chapter One 
Introduction and Context 
Introduction and Aims 
The research question is 'how will therapeutic cloning be influenced by the respective 
National Systems of Innovation (NSI) in China and the United Kingdom, using diabetes 
as a model?' The hypothesis is that NSI in China and the UK will determine the pace of 
translating stem cells into a clinical service - the null hypothesis being that the 
innovation systems of the UK and China will not adversely impact the advance of stem 
cell technologies. These technologies cover a range of processes, of which therapeutic 
cloning is one, involving the use of adult or embryo cells. The approach is a case study 
using the construction and comparison of the two National Innovation Systems to 
establish how stem cell research is progressing. The National System is constructed 
from the literature and taken to cover the economic, political, social, and research 
systems as they relate to stem cell science. National Systems of Innovation is the 
theoretical base used as a framework to explore the relative strengths and weaknesses 
within the UK and China. The clinical area of diabetic stem cell research is used as a 
model for comparison. Although other clinical areas are more advanced (most notably 
cancer), diabetes is chosen because of its major contribution to human morbidity and 
mortality and the prediction that it will become the world's most significant non-
communicable disease (WHO 2002). 
The comparison between the UK and China is taken from a UK perspective and chosen 
for a number of reasons. China is claimed to have a vast history of innovation, 
including claims of cloning a fish 37 years before 'Dolly the Sheep' and synthesising 
human insulin before its discovery in the late 1980's in Canada (Poo 2004). In addition, 
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the UK and China had a similar GDP by 2002, enabling easy economic comparison with 
China in research investment and spending on education and international trade. China 
has also adopted UK/European legislation and regulation for stem cell research (Salter 
2007) and published literature to advance their strategic objectives (Wilsden 2006). 
These create a permissive climate for stem cell research and a new partnership with the 
West that has become more apparent during the time of this research. Through the 
collection of evidence from within the UK, this study takes a UK perspective of China 
and offers an opinion from that vantage point. 
The United States might be considered a more natural comparison for the UK due to its 
evidential lead in the biotechnological market (Brown 2003 Zimmern/Cook 2000 PH 
Genetics 2001) and its historic policy influence in the UK. Its consumer-driven health 
market is also said to mean it is more likely to experience the impact of advances in 
genetic science ahead of the UK (Zimmern/Cook 2000). It is, however, like several 
Western economies, struggling with the ethical dilemmas of stem cell science. This 
struggle is due, in part, to the country's deeply religious orientation and the fundamental 
challenge to the creation of human life that therapeutic cloning elicits. Such concern has 
distinguished the research status of embryonic therapeutic cloning in the US from all 
others, resulting in the prohibition by federal law of the use of public research funds. 
Indeed, it has been interesting to observe over the period of this research the number of 
strategic alliances US scientists have formed with those working in China, as well as the 
UK's intention to extend these alliances (BBC 2008b). 
China experiences no such dilemma. Indeed, its ethical culture proactively promotes the 
scientific advance of stem cell technologies in permitting both human embryo and 
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primate research (Mann 2003 Yank 2004). In this way, China and the UK share similar 
motives to advance therapeutic cloning, very similar legislative and regulatory structures, 
and a similarly permissive scientific environment, albeit with social differences. 
These will be explored in more detail in this research, but first it is helpful to understand 
the business problem that stem cell technology seeks to address. This problem 
includes issues such as population health status, diabetes research innovation, research 
structure, and ethics. The business problem has a number of themes arising from 
these, including the medical and economic costs of treating people with diabetes and the 
untold costs of human suffering. 
The Business Problem: Health 
The underlying business problem is faced by every global government as they seek to 
maximise health spend with the health status of their population. Health spend is a 
major consumer of GDP for all Countries, with the UK spending 7.7% in 2003 compared 
to 5.8% in China. Public expenditure was 82.2% of total spend in the UK for the same 
year and 33.7% in China. In the United States, where health care is almost entirely 
privately funded and market-driven, it has achieved some of the highest survival rates 
for common diseases, arguably related to access to new drugs and technologies up to 
five years ahead of other countries, including the UK (Dyer 2003). They spent a greater 
proportion of GDP on health (13.3%) than the UK in 2003. In contrast, the UK has a 
predominately public-based system, which is revered across the world (Williams 1997). 
It operates an artificial market using containment strategies to ration and control access 
to services and new technologies (WHO 1998 Raftery 2001). The result of these 
systems is that the UK lags behind most of its international competitors in the 
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introduction of new health technologies (Wray 2004) and has correspondingly higher 
morbidity rates associated with common diseases such as heart disease, cancers and 
diabetes (Wanless 2002; WHO 2002). 
China, in contrast, moved away from public-funded health care in the late 1980's in 
favour of a market-managed system with serious inequality and health consequences 
(Watts 2004). Whilst morbidity data is not available, its non-communicable disease 
profile is similar to the UK in areas such as diabetes, heart disease and some cancers. 
It is at variance, however, in terms of a number of communicable diseases such as 
Tuberculosis and HIV/Aids. In addition, it has high levels of suicides, liver and stomach 
cancers, respiratory disease and accidents (Jin et al 1995; Beach 2001; Riley 2004). 
Access to and use of health technologies is also considerably different in China, being 
partly due to China's economic motivations being orientated towards export rather than 
domestic use. The main conclusion to draw here is that the prioritisation of treatment in 
China is not comparable with that of the UK (Fuller 1985 WHO 2002). These issues will 
be explored more closely in Chapter Two.. 
These differences are evidenced in average life span, which is 76 for men and 82 for 
woman in the UK compared to 70 and 73 in China. These figures mask morbidity, 
which is said to be 17 years on average in the UK (Acheson Report 1997) and undefined 
in China. The economic consequence of premature morbidity for diabetes is estimated 
to be up to five times more than its direct treatment costs (WHO 2002). Although 
China's treatment costs are about 20% of the UK's due to limited access to treatment, 
the health costs associated with treating diabetes in China in 2003 was £840,500,000 
(4,100,000 people were treated at an average cost of £205 per person) compared to 
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£2,720,695,692 in the UK. These are, however, only estimates as no accurate data 
exists. 
The distinction in funding stream is important as it is said to influence access to care, 
health status, and how new health technologies are introduced. This, in turn, has a 
fundamental impact on how new technologies are developed and their entry managed 
within the health market of each country. Stem cell research is a new technology defined 
largely in the research field, but affording untold potential to revolutionise treatment and 
health outcomes. This is of major interest to all governments because of its associated 
economic and social opportunity, although it will potentially bring into question the way 
new services become available to a population. 
The business problem facing both the Chinese and UK health markets is therefore 
twofold. The first issue is how to afford the treatment costs and economic loss 
associated with the forecast prevalence of diabetes (Atlas 2004). The second issue is 
how to compete in the international arena of genetic science to lead in making the 
research discoveries that afford the potential to revolutionise the treatment solution for 
diabetes and enable the associated economic and scientific status. To understand 
these implications it is necessary to explore the history of diabetes, its treatment and its 
relationship to therapeutic cloning. 
The Business Problem: Diabetes 
Diabetes is a metabolic disorder of multiple aetiology characterised by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, action or both (Alberti et al 1998). It currently affects an 
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estimated 200 million people, or 4.6% of the total world population, making it the most 
common non-communicative disease in the world (Marks 1996; Gatsby 2002; BHF 
2004). It affects all parts of the body and causes other conditions (most notably heart, 
renal and limb failures), with up to 80% of diabetics dying from heart disease or strokes 
(Fuller 1985). In virtually every developed society, diabetes is ranked amongst the 
leading causes of blindness, renal failure and lower limb amputation, and it is allied with 
huge socio-economic costs resulting from premature morbidity and mortality (Diabetes 
Atlas 2004). An estimated 339,035 people below the age of 65 died in the UK in 2000 
from diabetes, accounting for 757,096 years of life lost (Barcela et al 2003). It accounts 
currently for 9% of total mortality and is projected to be one of the world's leading 
causes of death by 2025 (WHO 2002). 
The disease is defined in two categories: type 1 being the early onset of the disease, 
usually occurring in children and young adults. Type 1 diabetes involves the complete 
failure of the pancreas to secrete insulin, and individuals with this type require insulin 
replacement therapy to survive. People with this form of the disease in the UK will, on 
average, die twenty years early (DoH 2001). In China these figures are higher, with 
many people dying within five years of diagnosis as treatment is limited to diet and 
homeopathic remedies (Reed 2000). 
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Type 2 (or late onset) diabetes is more common, accounting for 90% of diabetes cases, 
and involves deterioration in pancreatic function. It is treated by dietary change with oral 
medication for some. People with this type of the disease in the UK lose an average of 
ten years of life (Wanless 2003). In the UK diabetes accounts for 10% of all hospital 
expenditure, equating to 1.1 million bed days (Diabetes UK 2006). The data does not 
make a distinction between types 1 and 2, although costs and complications are more 
likely to be associated with type 1. The prevalence of diabetes has increased rapidly 
since the early 1990's, and it has more than doubled between 1960 and 1980 (Gadsby 
2002). The UK has experienced a 60% increase up to 1996, accounting at this time for 
just fewer than 2% in 1995 (Marks 1996) with current levels reported to be 3.9% of the 
total population (Diabetes UK 2003). 
China has also experienced major increases in diabetes, with 2.5% of their population 
affected by 1985, illustrating a three-fold increase over ten years (Pan et al 1997). Other 
heavily affected countries include India, the United States, Indonesia, Japan, Pakistan, 
Russia, Brazil, Italy and Bangladesh. In the United States in 1989, 10.4 million people 
were diabetic with demographic prediction estimating this to increase to 29 million (Boyle 
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et al 2001). The number of people affected worldwide is projected to double by 2010 to 
over 221 million (Gadsby 2002). This is variable across the world and across regions, 
with projections of an increase of 111% in Asia, 93% in Africa, 82% in Latin America, 
51% in and 35% in North America. (Gadsby 2002). The World Health Organisation 
estimated that 333 million people across the world will be living with diabetes by 2025. 
These rates of increase related largely to type 2 diabetes. Stem cell research, notably 
therapeutic cloning, has developed with a focus on insulin dependence where the 
greatest complications are seen. However a review in the British Medical Journal in 
2001 of adult, animal, embryo and therapeutic cloning concluded that therapeutic 
cloning would be of significance to both type 1 and 2 diabetes (Serup et al 2001). 
In the UK diabetes affects 2.4% of the population but consumes 8.4% of the total health 
resource (Marks 1996) with predictions taking this to 15% of the total heath resource by 
2011 (Bagust et al 2002). This consists of £5m each day (DoH 2005) spent on 
ambulatory care, 37% on hospital admissions, 36% on oral agent therapy, 4% on 
insulin, and 20% on other drugs (Gadsby 2002). Each year 600 diabetic patients require 
renal replacement therapy (costing in excess of £70m), 1.5% have serious retinopathy 
problems, 3.3% have ulceration of their feet, 1% have limb amputation (costing £15m), 
and up to 3.2% are diagnosed with ischemic heart disease. Of all people who die from 
heart disease, 55% will be diabetic (BHF 2004). 
Internationally, costs vary from 2.5% to 15% of total health budgets depending on the 
types of intervention and the health budget available (WHO 2002). In India the cost 
accounts for 25% of a family's income whilst the corresponding figure in the US is 
between 10% and 16% of its entire hospital budget (WHO 2002). Comparative 
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spending varies enormously across the world, depending on many economic features of 
a country and the availability of treatment. 
Spend in $ per diabeteic by Selected Country 
China 
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Denmark 
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Poland 
Sweden 
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2000 3000 
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5000 
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Western therapies are becoming available in China with the Pharmaceutical Industry (for 
example, Nova Nordisk Biotechnological Company commenced the production of insulin 
in 2003). The international costs of treating people with diabetes if prevalence rates 
grow at the predicted level will be up to $396bn (13% of international health expenditure) 
by 2025 (Atlas 2004). 
Projected Cost of Treating Diabetes in 2025 
Per 100,000 People with Diabetes 
China 
USA 
UK 
Austria 
Denmark 
France 
Germany 
Greece 
Italy 
Netherlands 
Poland 
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90 100 110 120 
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Data Source Atas 
Diabetes is an incurable disease with a relatively short treatment history. Prior to the 
discovery of insulin in 1921, people with type 1 (juvenile) diabetes died. Eli Lilly was first 
to purify insulin as a commercial product in 1923, but it wasn't until 1956 that products 
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for type 2 diabetes came on the market. Chinese scientists made this discovery earlier 
than Eli Lilly, but their discovery was neither recognised nor commercialised (Mann 
2003). 
By the 1960's the first human pancreas transplants were undertaken and, despite 
problems associated with anti-rejection drugs, the world's first successful human 
pancreas transplant was undertaken in 1966. Even today such transplants are restricted 
to seriously ill patients and still have significant associated morbidity (Robertson et al 
2000). In 1977 the first Islet Cell Transplant was undertaken, involving the injection of 
cells into the liver that then create their own blood supply and stimulate the production of 
insulin. By the 1980's, the first human insulin using recombinant DNA technology was 
created, the world's first insulin pump was developed, and glucose monitoring 
equipment was introduced. In 1987 the first genetic marker relating to type 1 diabetes 
was discovered, and by 2000 mice had been successfully bred with gut cells that could 
produce insulin (DTT 2001). British Surgeon James Shapiro carried out the first Islet 
Cell 
Transplantation in January 2001, and by the end of 2003 there had been over 10,300 
pancreas transplants across the world, 35 of these in London. Results show a 64% 
cure at 7 days and 47% at one year. If more than 30,000 islets are transplanted, the 
success rate rises to 71% (Diabetes UK 2003). However, cells from two human 
pancreases are currently required, which makes therapeutic cloning the only hope most 
people living with diabetes have for a cure. Stem cell research is being undertaken in 
both type 1 and 2 diabetes, and some suggest that its use to treat type 2 has shown 
evidence that cells can be re-programmed to secrete insulin (Smikodub 2006; Medical 
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News 2006; Serup 2001). Some scientists also believe that stem cell science will offer 
the greatest impact to those with type 2 diabetes, who make up approximately 85% of all 
diabetics (WHO 2002). 
Research to improve management of the disease continues alongside the development 
of implantable pumps with miniature computers, implantable glucose sensors, infrared 
light testing glucose, nasal transdermal, oral insulin and insulin analogues. In April 
2004, Chromosome 17 was mapped, identifying the fourth gene of the estimated twenty 
associated with diabetes (Guo et al 2004; Smyth et al 2005) and the Life Sciences 
Department at Newcastle University obtained the first UK license to clone human 
embryos for stem cell research (Pincock 2004). By August, work to identify a neonatal 
test for diabetes found a gene variant that intensifies immune response causing type 1 
diabetes SMU04, which controls the production of cytokines. By the following summer, 
a scientist in Japan had successfully transplanted islet cells from a mother to her 
daughter, thereby curing her diabetes (Manning 05 Science Daily, 2005). The type of 
diabetes involved in this case was caused by an illness rather than the usual 
autoimmune attack, making a wider application of its technique less likely. 
Research carried out between American and Brazilian scientists published at the end of 
2007 claimed to have cured diabetes using stem cells, but their trial focused on 15 
people who had been diagnosed within the six weeks of the trial (Voltarelli 2007). 
Therapeutic cloning remains the only long-term hope of a general cure for diabetes -
both types 1 and 2. 
Following its rejection in 2003, the National Institute of Clinical Excellence approved 
pancreatic transplants in a small number of UK centres after initial results showed 52% 
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of people who had undergone transplants were insulin free after 4 years, with a 
reduction of hypoglycaemic episodes from 87% to 5% (NICE 2008). 
The Business Problem: Research Innovation 
The importance of innovation to economic performance was recognised after the 
Second World War, although at this time it was interpreted simply as Research and 
Development (OECD 2004). Growth theory in the 1980's extended the definition to 
include those processes associated to R&D, which is now widely accepted in economic 
analysis (HM Treasury 2000). More recent thinking extends this concept to include the 
whole innovation system (OECDa 2005), including a range of factors from the 
conception of an idea through to the marketing of its related product and sales. These 
may be influenced by research investment, intellectual property structures, operational 
environment, workforce (OECD 2004dOECD 2005a) and knowledge flows between the 
public and private sectors McKeekin et al (2002). There is, however, no universal 
definition of the components of innovation but a shared agreement that its constitutional 
factors make the most important contributions to economic growth (OECDd 2004) 
(OECD 2005a). 
Analysis by the European Commission evidences that whilst R&D investment remains 
central to economic performance, there has been an accumulative decline in Research 
and Development investment across Europe since 2002. The UK announced in 2002 its 
intention to reach 2.5% of GDP by 2010, which appears unlikely to be achieved. The 
significance of this is that Europe may lose its opportunity to become a leader in the 
global knowledge-based market economy (Potocnik 2005) and be a less attractive place 
to carry out research (EC 2005). China, in contrast, has seen a four-fold increase in real 
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spending, making it the second highest research investor in the world (Wilsdon 2006). 
There are a number of reasons for these concerns, which are broader than just research 
investment. China is claimed to have used gene therapy to cure solid cancerous 
tumours in humans (Pearson Jia and Kandachi 2004) and to have begun human trials 
using therapeutic cloning to cure leukaemia (Hepeng 2005). This has a real and 
serious consequence for the interface with science, which is still reported to be the 
greatest source of economic growth (EU 2005 OECDa 2004). 
The biotechnological sector is argued to be the most important research area in leading 
innovation and economic growth (European Commission 2001 OECDa 2004). As such 
it is identified as a priority area of development for all governments (CEC 2002), with 
many economists seeking to design a model to capture the components incorporated in 
biotechnology innovation. One approach is the Instituted Economic Process and 
Complex Causality (Harvey 1999), building on Polyanyi's (1957) idea of instituted 
economic processes of supply, demand, competition, markets, exchanges and price 
being historically and socially driven. This model assumes market processes are 
framed by institutional structure, resulting in an institutional bias in the character, timing 
and adoption of innovation (Metcalf et al 2000). The basis of the argument as applied to 
biotechnological innovation is that competition within the research fields, as well as the 
organisational arrangements in which it operates, plays a part in economic growth. 
This has an interesting relationship to innovation theory in supporting the proposition 
that national dimensions can be stronger than the operational components, and it goes 
right to the heart of this research thesis, which seeks to explore these elements. 
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The United States has first-mover advantage in the biotechnology industry, securing 
high returns on its capital ventures and thereby attracting new industry (EC 2001). 
Evidence of this competitive advantage is seen in its co-location between companies, 
geographic specialisation and strong relationships with its universities and academic 
institutions. Europe, in contrast, is a late entrant with its markets largely defined by the 
US (ICC 2003). Its advantage is said to be specialist legislation, offset by limited access 
to venture capital, intellectual property and industrial development (OECD 2001). Other 
areas of weakness include an absence of integration between teaching and research 
institutions and an inflexibility of labour, which decreases knowledge flows (OECD 
2001). In Europe 50% of existing biotech companies are located in the UK or Germany, 
and the highest integration between technology and application is between the UK and 
France (OECD 2000). 
In the biotechnological sector, genetic science is distinguished by the magnitude of its 
potential to revolutionise the treatment and management of human disease (Dept of 
Energy Human Genome Programme 2003; Spink el at 2004). It offers the potential for 
personalised medication to create new therapies, to cure disease and, in time, to re-
grow or repair damaged organs. Genetic science also offers untold potential to expand 
the 479 known molecular targets against which all drugs in the world act (Zimmern 
2001) and to understand the interaction with the 40% that are ineffective on an individual 
basis (Melzer 2003). 
The pharmaceutical industry is an important component in biotechnology, providing 
major sources of investment and a pivotal role in influencing how genetic discoveries are 
translated into health care (Melzer et al 2003). The industry is responsible for 
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developing the majority of new drugs and tests and has strong economic drivers to 
produce personalised medicines in the form of pharmacogenetics (McCarthy 2001). In 
the UK the pharmaceutical sector produced exports of £11.9bn and imports of £8.3bn in 
2003 (Customs and Exercise) making it one of the highest exporters within Europe and 
an important source of revenue for the UK. 
In 2003 the average spend per head in the UK was £168 compared to £462 in the US 
(Office for National Statistics). Access to new medicines in the UK is tightly controlled by 
the National Institute of Clinical Excellence (NICE), leading to only 16% of new products 
entering the UK market compared to 50% in the US. In 2003 Medicines accounted for 
11.8% (£8bn) of the total NHS spend, £277m of this being on diabetics (ABPI 2004). 
Drug development research in the area of diabetes almost tripled between 1995 and 
2003 from 93 projects to 272, over 50 of which were stage 11 trials (Pharmaprojects 
2003). Pfizer and Aventis have stage 111 projects; Lilly has projects at stage 11. Such 
innovations are potentially greater than anything seen previously and represent a major 
shift from historically incremental adaptations. Exceptions are said to be penicillin, 
anaesthetics and anti-psychotic medication (NEMJ 2000). Investment in research trials 
is influenced by the estimated return, which is itself influenced by the regulatory 
framework of intellectual property. 
The Business Problem: Intellectual Property 
Intellectual Property Regulation (IPR) has an increasingly important role in the area of 
biotechnologies (OECDe 2004). The nature of patent rights allows owners to exclude 
others from making, using, selling, or importing the patented invention (Nottenburg 
2003). The biotechnology industry relies heavily on such protection to secure the returns 
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needed to offset vast research costs and associated production costs. Patents underpin 
the licensing deals between the biotechnology and pharmaceutical companies and 
permit monopoly control over new tests and treatments - even those not yet discovered. 
Patent registration is also vital in attracting venture capital, providing a proxy for 
knowledge flows and a potential measure of the impact of an invention (Brown 2003 
OECD1 2005). Citation data is a vital proxy for technological and economic value, and 
an indication of knowledge flow between institutions (EC 2001). They also underpin the 
licensing deals across the biotech markets, offering unprecedented monopoly control 
over new tests and treatments. This has a profound affect on how money and power 
are distributed both in and between countries (Baird 1998 ICC 2003). The nature of 
IPR allows patent holders to exclude others from making, selling, or importing the 
invention (Nottenburg 2003), thereby creating monopoly providers and price control 
mechanisms (Giannakas 2002). The numbers of filed applications has increased by 
over 40% between 1992 and 2002 in Europe, Japan and America (OECDe 2004). 
Despite this increase, over 85% of those relating to human genetics are owned in the 
US (Baird 1998). 
Patents are awarded by nations where interpretation of the legislation can differ, with lax 
enforcement suggested by some to be a deliberate strategy of governments to increase 
their international competitiveness (Giannakas 2002). Certainly China, prior to joining 
the World Heath Organisation in 2002 was so accused. Consistency between 
international patent laws is important in providing certainty to research and industrial 
investment. The most notable example is, perhaps, Pfizer's attempt to uphold its patent 
for Viagra in China. Patents are awarded for only 7.5 years in China, against the 
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European standard of 20 years, thereby undermining the perceived advantage to an 
investor. 
The European system of intellectual property evolved from consumer protection 
regulation and aims to separate the distinction between discovery and invention. 
European law states: The Human Body, at the various stages of its formation and 
development is not patentable making a distinction between discovery and invention' (Is 
this actually a direct quote?) (Burham 1997). American law requires similar compliance, 
but the definition is open to interpretation, often by the courts. Intellectual property rights 
create monopoly providers and price control mechanisms that enable premiums to be 
charged in the market. Infringement increases the competitiveness of domestic 
producers who use new technology and place compliant foreign producers at a cost 
disadvantage. 
In Europe the European Commission oversees the legal system of biotechnological 
invention across 25 Countries, providing a framework for consistency. Implementation 
in law is, however, an individual decision, but to date 21 of its member states have 
translated its recommendations to statute. The Commission recently reviewed the two 
most contentious issues surrounding the scope of IPR - genetic sequences of human 
DNA, and the patentability of human pluripotent embryonic cells and cell lines taken 
from them (EC 2005). At this time no prescriptive direction has been given despite calls 
for consistency from the industry (Jenson 2005). Consistency in Europe is said to be 
imperative if it is to compete as a serious world player, but this requires countries with 
very different religions and cultures to align their ethical concerns about scientific 
advance and global inequalities. On a more basic level, it requires consensus about 
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what each country accepts as patentable and coherent regulation of their respective 
research sectors. 
John Sulston (2002), Nobel Prize winner for the mapping of the human genome, 
believes this consistency should mean only actual products are eligible to be patented, 
leaving gene discovery available to all scientists (DNA 2003). The reality is somewhat 
different because most research is privately sourced (Phillips Dierker 2001), as 
evidenced in the agricultural sector where venture capitalists (Who are 'they'? 
Scientists?) wanted to secure a return on their investment (Graff 2003), a position 
supported by the European Commission (2001), who argues that reward is essential to 
stimulate investment. The charity, Cancer UK, established an important precedent in 
successfully reversing the patent registration by the US company Myraid for their 
predisposition breast cancer test BRCA 2 test in the UK in 2004 (PHGU 2004). 
Whilst the area of patents in genetic science remains largely unresolved, it is relevant to 
this research as it may provide a deeper understanding its impact on current research 
investment in the UK and China. 
The Business Problem: Stem Cell Research 
The science of genetics originates from the meticulous pea-breeding experiments of 
physicist Gregor Mendal in 1865. He discovered the constituent facts of biological 
inheritance, proving for the first time that characteristics are inherited in pairs of 
recessive and dominant alleles, one from each parent (Edelson 1999). Genetic science 
involves the study of biological information, its contribution to making an organism, and 
how this information is transmitted from one generation to another (Steward el al 2002). 
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Inheritance is enabled via the DNA, located mainly in the nucleus of the cell, being read 
by the cell and converted to RNA before transmission to those parts of the cell 
responsible for the creation of protein. A small amount is found outside the nucleus in 
the mitochondria, passed down the female line, and relates to the cell's metabolic 
function. 
DNA is a linear molecule with a long backbone of sugar molecules joined by phosphate 
groups. A nucleotide base, which may be one of four types, joins the sugar molecules: 
A (adenine), G (Guanine), C (Cytosine) and T (Thymine), forming together to make the 
double helices along the sugar backbone as discovered by Frankin, Francis and Crick in 
1950 (Fuller 2003). Information is coded in base pairs along 23 corresponding 
chromosomes, with one gene programming for one protein. Each gene contains 
regulatory instruction on when and where in the body the protein is to be created (Ridley 
1999). Cells divide to duplicate their DNA by unwinding their helices and copying the 
sequence of bases to form two that split to create new duplicate cells. 
Mendal's work was never published but ran concurrent to that of Charles Darwin who, 
unaware, presented his own hypothesis of inheritance, arguing it to be based on an 
underlying principle of survival of the fittest (Darwin/Griffiths 1998). In the century that 
followed, the knowledge emanating from these original discoveries translated into 
biotechnology, genetics and information research. The discovery of DNA in 1950 by 
Rosaline Franklin, James Watson and Francis Crick, led to the first stem cell processes 
in the 1960's. Technological advance has since enabled specific genes to be identified 
and mapped to human disease, for proteins to be isolated and for function and micro 
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array analysis to be used in sequence variations and structure. The resulting techniques 
fall into three broad areas of science: stem cells, gene therapy and pharmacogenetics. 
Stem Cell research produced its first results in 1968, with the successful bone marrow 
transplants of adult stem cells in immunodeficient patients. Berg cloned the first gene in 
1973 (Denoon 2004) and DNA was linked to specific genes five years later. By 1986, 20 
genes known to suppress tumours had been cloned with stem cell transplants used to 
treat leukaemia and lymphoma in 1993. By 1997 the gene for telomerase enzyme had 
been cloned and shown to cure cancer in mice (Ricchetti and Buc 1997). In 1998 US 
scientists became the first to grow embryonic stem cells from human embryos 
(Shamblott 1998 Thompson 1998), leading to a number of advances in cell 
development. This culminated in 2005 with South Korean Scientists announcing the 
world's first stem cell match for an individual treatment (BBC 2005) and British Scientists 
announcing the creation of its first cloned human embryo (Lawless 2005). These 
advances were set back in 2005 when the South Korean claims were found to be 
fraudulent. While Professor Hwang faces a lengthy prison sentence, stem cell 
programmes around the world reel in the wake of shock and public concern (Faiola 2006 
Williams 2006). 
Gene therapy, in comparison, involves the specific targeting of stem cells to repair or 
replace non-functional genes. The discovery in 1970 that retroviruses can make DNA 
copies from RNA made gene therapy feasible. A molecular vector)usually a virus 
modified to carry human DNA) carries replacement genes to the repair site. When 
successful, it results in the re-growth of new tissue, but the mechanics of this process 
remain unclear. The application of this knowledge affords major technological advances 
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in its ability to manipulate DNA using enzymes isolated from bacteria and 
electrophoresis to cut it in specific places, enabling the copying or cloning and the 
insertion of DNA sequences into the cells of a host organism. The complication is 
convincing the host that this forms part of its own natural replication process, with this 
achieved by joining to a vector or piece of DNA with all the necessary coding. This 
technique is currently being researched in the areas of Parkinson's, Diabetes, Heart 
Disease and Cancer (Hardy 2001, Yechoor & Chan 2005, Spink & Geddes 2004 and 
Gottesman 2003). 
The third area, Pharmocogenetics, is the stem cell science of personalised medicine. It 
offers the potential to engineer medication and intervention to gene type, affording 
individual and economic potential for that 20-40% of people for whom current medicines 
are ineffective (Ridley 1999). The technique involves identification of an individual's 
susceptibility to medicines from their genetic profile and creating a drug tailored to the 
molecular response. This pre-disposition testing is available for many monogenetic 
diseases, with 900 such tests available worldwide, 300 of which are in the UK NHS 
system (Watson 2003). One such example is Herceptin treatment for breast cancer 
where one out of four women are shown to have gene susceptibility (Dargie 2000). 
Each area of stem cell research offers opportunities for human health since the 1902 
discovery by Garrod that disease, or mutation in DNA sequences, can be inherited. At 
least 5.5% of the population will develop a genetic disease by the age of 25, rising to 
60% during their lifetime (DoH 2003). This variation is accounted for by the polygenetic 
nature of inheritance and differing susceptibility to environmental influence (Zimmern 
2001 BER 2004). Genetic science fits within the broader umbrella of biotechnology, 
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which, as illustrated in the map below, is dominated by the US. This is open to 
challenge (DoTI 2004 MRC 2006) with Singapore, South Korea and China all developing 
biotechnology industries with some of the best-equipped stem cell institutions in the 
world (DoTI 2004). 
1 
Examples in the Far East include Singapore, which has world-class research facilities 
and invests 2.2% of its GDP in research (DTI 2004). They have an integrated strategy 
between academic and commercial research and many business incentives, with stem 
cell research being made an explicit national priority. To date, Singapore has 
undertaken very little work on human embryos, and there is no evidence of outcome in 
the clinic setting (DTI 2004). South Korea has also established world-class laboratory 
facilities supported by a comprehensive government funding programme. They have 
produced some impressive results, being first to clone half-humanised pigs using 
somatic cell transfer for therapeutic cloning. Without the constraints of Western ethics, 
they have also been successful in cloning human embryos (DoTI 2004). They have, 
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however, suffered a set-back following fraudulent claims by Hwang Woo-suk (Faiola 
2006). 
China also recognises the importance of stem cell science to economic growth as 
evidenced in its increase in research investment from 0.7% of GDP in 1997 to 1.31% in 
2003. It is on target to meet its 2010 goal of 2.2% GDP spent on research (EC 2005), 
having invested heavily in the related technology with a published strategic aim of 
becoming a dominant partner on the world stage (Hsiao 2004). It also has the largest 
number of university students in the world (Wu 1991), has a low cost science base, and 
has the second highest spend in the area of Research and Development (DoTI 2004 
Wilsdon 2006). It enjoys substantial and long-term government support but its 
overriding success is in translating its science to clinical outcomes. Despite its 
historically low research investment, China is reported to have a prestigious history in 
innovation, having invented paper, printing, the magnetic compass and gunpowder 
(Temple 1972). They used iron and created tools 1000 years before the rest of the 
world, and some claim they cloned a fish some 37 years before the UK cloned 'Dolly the 
Sheep'. They are also said to have been first to synthesise human insulin (Poo 2004). 
The historic problem in China is similar to that in the UK in failing to translate discovery 
to commercial product, but for very different reasons. China's history of conflict and 
closed economy created a lack of academic recognition, preventing the translation of 
their discoveries to commercial advantage. This was redressed by economic reforms in 
the early 1980's, which introduced an open market economy, international trade, and led 
to substantial GDP growth (Wang 1999). Internationalisation has been encouraged by a 
number of financial incentives, leading to an increasing trend of overseas investors 
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locating their research in China (OECD1 2005). It is an explicit strategic intention of 
China to become a world leader in biotechnology (Jing 2003 Mann 2003) and to be a 
front-runner in international science by 2010 (Cong et al 2006). Therapeutic cloning is 
an explicit goal, with China hoping to maximise its strategic advantage in this field from 
its relaxed ethical stance (Yank 2004), access to both primate and human research 
(Chien 2004), and correspondingly lower research costs. 
China's historic global isolation brings an additional advantage for the Chinese people, 
since having bred largely within their own populations affords opportunities in 
researching genetic risk and biomarkers (Chien 2004 Yank 2004). Culture is at the 
heart of the most significant opportunity, with the Chinese having few moral objections to 
the use of embryos for research and therapeutic cloning (Yank 2004). Human life is 
considered broadly to begin at birth, not conception, with personhood achieved only 
concurrently to the ability to participate in society. To this way of thinking, the foetus is 
not recognised as human (Mann 2003). 
Research into therapeutic cloning is a priority for the Chinese Ministry of Science 
(Dennis 2002 Depeng 2004), who has begun work in a number of disease areas 
including diabetes. The goal is economically based around international trade, since 
associated treatment costs are likely to be prohibitive for most Chinese people. It is 
claimed China has already achieved a number of successes in stem cell science (Ning 
2005), including the world's first available gene therapy cure in 2004 for solid cancer 
tumours (Pearson, Jia & Kandachi 2004) and the treatment of Leukaemia in clinical trials 
in 2005, with explicit plans to extend this to diabetes (Hepeng 2005). For this goal to be 
attained China has a number of its own challenges to overcome. These include the 
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communication of their science, access to international specialisms (Yank 2004), 
investment in basic science (Hepeng 2002), and improvement to the quality of its 
published research (Wu 2004). In addition, it has a number of internal social and 
economic issues to address, most notably the failing of its health structure within its 
economic reform. 
The UK, in contrast, has the most sophisticated legislative framework for stem cells but 
has not advanced to human research trials. Its research regulation requires an explicit 
operational understanding before such techniques can be considered. Although the UK 
is considered a late entrant to the field of biotechnologies, it is said to lead in both 
scientific advance and permissive legislation (DoH 2003). It has world-leading centres of 
excellence, including Neuroscience at Oxford, Cancer at Dundee, and Genomics at the 
Sanger Centre in Cambridge. It is responsible for the cloning of Dolly the sheep (the 
first animal of its kind) in 1997, and is said to have the best regulatory framework in the 
world (PHGU 2002). Offering extensive tax incentives, the UK has a cost-effective 
research environment and has been working in the field of genetics longer than any 
other country (Best 2005). It led the final mapping of the human genome (Goodfellow 
2001), the computer technologies to read gene codes, and the development of 
haplotype mapping. It is said to be unique in Europe in having a high degree of 
organisational diversity across both government and non-profit research, leading to a 
disproportionately high share of main research breakthroughs (Brown 2003). It is 
responsible for 4.5% of the world's spend on science despite having only 1% of the 
population, produces 8% of the world science papers, accounts for 50% of all drugs 
under development (Guardian 2002), receives 9% of citations, and claims around 10% 
of internationally recognised science prizes (Dasgupta 1996). 
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The UK was the first country to legislate for human fertilisation techniques in establishing 
the Human Fertilisation and Embryology Act in 1991, creating the Human Fertilisation 
Embryology Authority in August 1991. It is said to have the most permissive legislation 
for embryonic stem cell research and to be responsible for setting up the world's first 
bio-bank to co-ordinate access to and use of genetic material across commerce and 
academia. In Europe there is said to be little comparative development, influenced in 
part by the September 02 announcement by the European Council of a one-year 
moratorium on embryonic stem cell research. This was superseded by guidelines 
allowing research on embryos created via IVF before June 2002 (Watson 2003j. 
Successively, the UK was the first country to licence therapeutic cloning at Newcastle 
University in August 2004 (Pincock 2004) and to create therapeutic cell clones (BBC 
2005). 
The main challenge facing the UK is the translation of its science to services. Of 
particular interest are the ethical and societal concerns (Knight 2004), comparatively low 
levels of research investment, and the length and cost of clinical trials (Dyres 2003). 
Research investment has fallen from 2.4% to 1.9% of GDP over the last twenty years, 
with the government contributing only 0.6% (EC 2005). This has reduced further to 1.76 
in 2005 (National Statistics 2007). Indeed, government investment consistently 
underperformed in G7 countries between 1980 and 1999 (OECD 2001). This contrasts 
with the US, where research expenditure between 1997 and 2002 has increased by five 
times that of Europe (EC 2005). In 1980, eight out of ten new discoveries were in 
Europe, where now eight out of ten occur in the US. Innovation (as measured by patent 
registration, new product innovation or manufacturing turnover) is also low in the UK 
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when compared to Europe. This is in-spite of its permissive legislative framework and 
strong productive science base, which are said to attract foreign research and 
development. This weakness is suggested to arise from poor historic collaboration 
between commerce and universities (Dasgupta 1996). 
The UK aims to redress these problems with a number of policy changes designed to 
improve them by stimulating partnerships across academia, health management and the 
private sector (DoH 2002; DTI 2002; DoH 2003). These include a statutory framework 
for the National Health Service to form Venture Companies (DoH 2002) in addition to a 
number of structural changes, such as the creation of Knowledge Parks linking 
commerce and universities. It set up the world's first bio-bank and has introduced new 
tax incentives to encourage research industries to locate their work in the UK (Graff 
2003). But even with these advances, the Department of Trade and Industry (2004) has 
warned further policy initiatives will be required if the UK is to strengthen its research 
base. 
The overriding challenge for both the UK and China remains therefore the translation of 
discovery into actual innovations in service. With a science market estimated to be 
worth 2,000bn Euros by 2010 (the pharmaceutical representing more than 25%) (Melzer 
2003), there are significant economic incentives to produce results (McCarthy 2001 
Feldman 2003). It is the pace at which both countries advance that is of interest in this 
research, with particular focus on understanding how their respective innovation 
structures influence this. A significant area to be overcome in advancing this is the 
management of the ethical issues as stem cell science ignites an ethical legacy of 
prejudice (Pinnick 2002), including concern about its potential to create weapons of 
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mass destruction (OECDc 2004). These concerns form a cultural climate for 
therapeutic cloning and dictate both the acceptance and timeframe of its associated 
research. In the UK, the Department of Health publicly promotes the opportunities of 
genetic science (DoH 2003), although the absence of any realistic service or timeline 
suggests the ethical concerns are still to be managed. China, in contrast, is 
comparatively free from these concerns - indeed, Chinese scientists are reported to 
have been creating therapeutic human clones since 1999 and attracting American and 
German scientists where such procedures are not currently permitted (Yank 2004). This 
absence of ethical objections is suggested to make China one of the leading nations in 
genetic innovation over the next decade (Dennis 2002I; Mann 2003; Jing 2003; Yank 
2004). 
The Business Problem: Ethics of Stem Cell Research 
Research in the UK shows public understanding and opinion of genetic technologies and 
their service implication to be poor. A survey carried out in Bio News found that around 
75% of people asked about the cloning of embryos for medical research purposes were 
not aware this type of work was permitted (June 2003). A separate study undertaken 
by the Nuffield Council concerning the ethics of pharmacogentics obtained only 84 
responses to 3000 questionnaires (Nuffield Council 2003). Aerni (2001) suggests this 
lack of understanding in the population is almost a pre-requisite to communication. 
Indeed, as Ridley (1999) points out, such inaction can be very significant in producing 
change exampled by IVF, which was never sanctioned by the public until Louise Brown 
was born. Ridley suggests therapeutic cloning may well happen, not because the 
majority approves of it but because only the minority act. 
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Whether people express a view or not, there are many implications arising from genetic 
science and its commercialisation. These include the communication and use of 
people's biological data, ownership of actual tissue, existing and future knowledge about 
an individual's and their family's health, and insusceptibility to treatments (particularly for 
some ethnic groups). Many argue that the public will expect certainty in all these areas 
before the potential advantages of genetic technologies are accepted (Vahakangas 
2001). Others suggest scientific expertise and benefits must be weighed against public 
perception (Aerni 2001), whist others simply say the economic argument is so great that 
governments will act regardless of ethical concern (Vahakangas 2001). Yet the reality of 
the consumer voice in biotechnology has already been evidenced, as its scientific 
knowledge began to enter the agricultural industry in the 1990's. 
The first genetically modified products entered the human food chain in 1994 (Phillips 
2003), creating differential uncertainty across global markets. Despite huge economic 
potential, the uncertainty about the science in Europe, exacerbated by food scandals, 
led to distrust in the regulatory institutions (Aerni 2001). The significance of this was a 
new generation of trade restriction (Eugenio 2003) resulting in major changes in the 
pattern of World trade (Phillips 2003). The transferable lesson for health genetics is that 
'regardless of science, if consumers decide not to accept a technology, the markets will 
adjust to different scenarios, to prohibition, market segmentation and product 
differentiation' (Eugenio 2003). 
In addition to ethical concern, there maybe psychological reasons behind the resistance 
people have to genetic services. Human nature is said to be resistant to change in terms 
of lifestyle and value systems, particularly if these present a challenge to nature and life 
itself. Cognitive research demonstrates that risks are socially constructed, influenced by 
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media coverage, depend on trust in public and private institutions, are socially conveyed 
and individually accumulated. This makes the relationship between knowledge 
construction, its use and communication complex for governments to manage, with 
much opportunity for mistrust. 
This mistrust, Aerni suggests, is directed at government, not science (2001). Psychology 
in the Western world regards trust as a prerequisite for social orientation. It is claimed 
that modern society trades off increasing complexity by transferring trust to the institution 
that takes responsibility for managing the complexity. The response to public concern 
therefore tends to be further regulation rather explanation, as evidenced in the 
agricultural industry (Eugenio 2003). Public perception and attitudes can thereby affect 
the economic and regulatory conditions under which an industry operates, can impact 
supply channels, the economics of production or product demand, and industrial 
technique. These concerns relate in part to 'subtle eugenic effect' of genetic 
commercialism, both in terms of its financial motive and the way drugs and therapies are 
controlled and prioritised (Caulfield 1998). Genetic predispositions will, for example, be 
different between ethnic groups, compounding ethnic division and inequalities. Perhaps 
of some comfort is the landmark agreement to cut costs of patented drugs and products 
to poor countries, offering some indication of how these difficult issues might in the 
future be managed (Fleck 2003). 
Understanding public perception and opinions about therapeutic cloning is vital to the 
research question, as they represent some of the most significant differences in the 
National Innovation System between the UK and China. 
Summary 
The business problem that underpins this research is two-fold. 
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The first is the economic and social challenge for both the UK and China in managing 
the major increase in the prevalence of both type 1 and type 2 diabetes and its 
associated morbidity and mortality. The drive to manage this change derives from its 
complexity, the cost of its treatment, and its predicted growth rates. The UK spends 
7.7% of its GDP on health (2002) while the corresponding figure for China is 5.8%. 
4.6% of the entire world population is already diabetic -- 3.9%, in the UK (Diabetes UK 
2006) and 2.5% in China. The Chinese figure may be an underestimation but already 
represents a three-fold increase since 1990 (Pan el al 1997). The cost of treating 
diabetes is projected to consume 13% of the entire world spend on health by 2025 (Atlas 
2004). The business problem is in funding a cure to ameliorate the significant 
human and economic burden of a disease that consumes 15% of all health costs (and 
five times the value in social costs) (BHF 2004), plus the untold cost of human suffering. 
These include both type 1 and 2 diabetes, and research evidence shows embryonic 
stem cell research is being undertaken to find a cure (Smikodub 2006/Serup 2001). 
The second area of the business problem arises from the unprecedented opportunity 
presented by stem cell research to cure diabetes and other human disabilities and 
disease. Therapeutic cloning is still at an early stage of development, although its 
research techniques have progressed to the use of human embryos, raising ethical and 
cultural concern that is very different in the UK and China. This is also important with 
respect to economic performance, as the literature shows clearly the link between them. 
In the UK there has seen a decline in research investment, reducing from 2.4% of GDP 
to only 1.9% (Dasgupta 1994). As a proportion of GDP, this has reduced further to 
1.76% in 2005 (National Statistics 2007). Although the UK is said to be receptive to new 
ideas and accessing global knowledge, it is slow to translate these to commercial 
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success (Dasgupta 1994). This is it problem the UK shares with China but for very 
different reasons. 
This research will focus on these differences between the two National Innovation 
Systems. The aim is to compare the strengths and weaknesses in China and the UK 
and consider how these, in turn, influence the development of stem cell research in the 
area of diabetes. The innovation system is taken to cover the political, legal, societal 
and economic factors and will be explored in detail in Chapter Two. This will cover the 
literature on innovation theory and offer further insight into the organisation and practice 
within the UK and China. The softer aspects of innovation, such as structure and culture 
will be explored in addition to the respective backgrounds in stem cell science, including 
China's claims to having cloned a fish (Mann 2003) and finding cures for cancers 
(Thomas 2006). 
Chapter Three will set out the methodological approach, covering the research design, 
data capture and analysis. After setting out the theoretical approach, it will explore three 
forms of analysis. The first form will be statistical analysis of economic data for both 
countries, showing the respective positions on research investment. The second and 
third approaches will be ethnographic, involving the collection of data from a survey with 
the general population and interviews with stem cell researchers in the UK and China. 
The public survey is UK-biased, as research in China was outside the scope of this 
study, with its validity justified within the methodology. In a detailed account, it describes 
the process of using data to compare progress in stem cell science between the UK and 
China from three distinct forms that enable a complete comparison of the innovation 
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factors. At the time of design it was a new approach, but a similar study has since been 
initiated at Anglia University (Salter 2006). 
Chapter Four discusses the approach to exploring the National Systems of Innovation 
for the UK and China and interprets the findings from the data. Drawing together the 
comparison from the three distinct approaches, it interprets the results and sets out a 
direction for measure and interpretation. Chapter Five concludes the review of how 
therapeutic cloning is being influenced by the National System of Innovation in the UK 
and China and sets out the policy implications of these. With two distinct cultures and 
histories, this work will review those aspects of the innovation system that are 
complimenting advances in stem cell technologies and identify policy considerations that 
arise from these. 
The Thesis will explore the business implications surrounding stem cell research and the 
impact its National Systems has on its advance. This study will take its place in the 
innovations literature in the field of clinical innovation, representing a new approach in 
the use of National Systems of Innovation. Its focus is on the development phase of 
innovation, which is the central part of the cycle covering invention, the generation of 
ideas, risk assessment and design. The invention phase is where stem cell science 
currently exists (aside from a small number of treatments using adult stem cells, such as 
bone marrow transplants). This focus on the invention phase of stem cell science is 
justified by its position in discovery within the innovation cycle. It will build on the work of 
Freeman (1997) in making a comparison between the systems of two Countries and the 
work of Edquist (1997) in understanding the importance of economic performance. 
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DBA - Chapter Two 
Literature and Conceptual Development 
Innovation 
Many researchers have sought to define innovation but there is no single definitive 
approach. According to Shackle (1979). Innovation is the 'imagined deemed possible', a 
by-product of invention, or an amalgamation of process from invention to practice (Tidd 
et al 2001). Klien and Rosebury (1986) suggested it is simply a characterisation of the 
problem to be solved. Schumpeter (1934) classified innovation by comparing it to an 
existing technology, suggesting that it could be defined in categories including product, 
methods, supply, markets and business organisation. He developed a Marx-
Schumpeter model, which argues that long run economic performance relies more on 
technological competition under capitalism than the influence of the firm or the traditional 
supply and demand model (Tidd 2001). In making these propositions, he sought to 
define innovation and identify its key characteristics. These he identified as the 
tendency for innovations to cluster in certain industries and time periods highlighting the 
importance of co-dependencies in success (Tidd et al 2001). He also identified 
uncertainty to be inherent in innovation (for example, a need to move quickly before 
someone else does), and he interestingly outlined the resistance to change from all 
levels of society (Tidd 2001). 
Schumpeter's work was significant in establishing both the importance of innovation to 
economic performance and in identifying some key features to its success. He classified 
innovation into five categories or stages, including new products, method, supply 
sources, market exploitation and business organisation. Many of these remain true 
today, offering valuable insights for this research topic in areas such as competition, 
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securing innovative solutions, and the role of culture and societal values in shaping 
permissible legislation. Schumpeter's model of innovation, although important in 
establishing the role of innovation in economic performance, was found in practice to be 
too simplistic, often leading to a difference between actual and projected growth, the gap 
becoming known as 'Slowo (is this meant to be Slowo or Slow?) Residual'. However, his 
approach formed an important foundation for others including Nelson and Winters 
(1982), who built on his work by introducing behaviour of and within organisations into 
the innovation process. They argued that firms are guided by routine that becomes 
practice, in turn being influenced by outcomes in a feedback system that leads to 
improvement. This they termed innovation or technological change, which they 
suggested was more significant than radical innovation in delivering improvements to 
economic performance. 
Following the Second World War, the political climate favoured an emphasis of 
innovation in economic performance but focused only on an unsophisticated model of 
research and development investment (Freeman 1997). Growth theory followed as 
evidence of the impact innovation has on economic success increased throughout the 
1960's (Freeman 1997). Over time the components of innovation were deconstructed. 
Hollander used one example (1965) in identifying the impact workforce was having on 
economic performance, most notably in its diffusion. Nelson and Winters' (1982) work 
introduced organisational behaviour and interactions into the innovation process, 
broadening further the factors said to be incorporated (Freeman 1997; Tidd 2001). By 
the 1980's, new growth theory had been introduced, describing innovation as a process 
and systems of networks rather than the more traditional labour and capital. One of the 
most notable features of this broader identification was the recognition of the 
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contribution of knowledge to productivity and efficiency (Plummer 2004). New Growth 
Theory opened up the debate on the constitution of innovation and introduced 
recognition of some of the less tangible contributions, such as knowledge accumulation. 
From the literature it is clear that the innovation system refers to an entire process 
including creativity and research of new ideas, studies to evaluate cost effectiveness 
and risk, design and development, marketing, and the introduction of new products 
(Branscomb 2002). The innovation cycle starts with the identification of an opportunity 
before clarifying objectives, researching the background, assessing feasibility and risk, 
designing and developing, creating the policy environment, and completing the ultimate 
stage of design and implementation. This cycle, simplistically described, covers 
creation, development and diffusion. This view is based on evidence accumulated from 
Europe, America and Japan which showed productivity to be influenced by more than 
traditional assumptions of research and development. In particular, the impact on 
performance by people involved in the implementation of change had started to become 
apparent, most notably amongst engineers, technicians and shop floor workers 
(Hollander 1965). At the same time, the relationships between firms began to show an 
influence on productivity and the diffusion of innovation (Freeman 1997). It is apparent, 
as these studies show; the focus of these was predominately industrial, with little or no 
focus on the service sector. 
This exclusion of the service sector is partly due to the varying nature between service 
and manufacturing industry. Service products tend to be intangible, interactive, 
consumed in the course of supply, and historically difficult to protect via patents. Their 
contribution to economic performance is complex, as they are in themselves said to be 
Gail Newmarch 41 
D B A Final November 2008 
agents of innovation transfer (Faberberg 04). However, advances in service-led industry 
and the introduction of Information Technology has increased the importance of focus on 
this less tangible but vital area of innovation. Growth in the service sector has resulted 
in its dominant position in current industrial economics with its understanding suggested 
to be fundamental to innovation (Fagerberg 04). There have been some innovation 
studies focused on the service sector but these are said to have taken a production line 
approach in exploration (Levitt 1972). Indeed, many service industries have emulated 
the lessons of manufacturing in the adoption and development of innovation in looking 
for examples of quality and efficiency. Metcalf et al (2000) explored this in their supply 
chain analysis of the ophthalmic industry. In their work they illustrate the importance of 
interdependences between the service and manufacturing industry in delivering new 
treatments. 
The influence of competition from rival firms is seen as the second main driver of 
change, influenced by the ability to exploit and access knowledge beyond current 
boundaries. Equally, implementation of innovation in the service sector needs to be 
systematic and standardised, as exampled by McDonald's and call centres whose 
operating processes are identical in separate units. The focus in this context is the 
interactions of product characteristics, customer proximity, relationships and networks 
(Metcalf 2000). These approaches produce economic efficiencies but are suggested to 
generate low quality (Faberberg 04). Implementation aside, understanding the details of 
the service sector is now said to be vital in identifying those aspects of importance in 
mutual interdependencies and success (Lundvall 1988; Van Hippel 1992). The final 
point of context is that innovations in the service sector are positive only where there are 
market options for adoption. In some government services innovation leads to 
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increased cost, as exampled in health where 'innovations in a health market often 
expand treatments creating an explosion of expenditure' (Weisbrod 1991). The overall 
value of innovation to economic performance is now widely accepted (OECD 2004) with 
the competitive focus, which Schumpeter argued to be important and evident at a 
national level. The issues of collaboration, competition and market strategies are core 
components of the regulatory environment, as are societal values and the status of the 
current science within the innovation process. Innovation is said to be the very basis of 
economic growth in stimulating competition, GDP growth, and technological change 
(Feldman 2004). The study of its contribution to economic performance began in the 
1950's with the work of Robert Slow, who was awarded the Nobel Peace Prize. He 
demonstrated that 87% of economic growth in the US between 1909 and 1949 was due 
to technological change. 
Innovation is said to be subtly different from technology, which is the embodiment of 
knowledge into its physical form (Feldman 2004). Innovation encompasses incremental 
improvement to something that already exists and is said to extract economic growth 
from advances in knowledge (Feldman 2004). Innovation is critical to long-term growth, 
although most is incremental. Sustained economic growth relies on radical 
technological innovations that disrupt markets and create new industries (Branscomb 
Auerswald 2002). In this regard innovation is seen to be far more about prospecting, 
mining, refining and adding value than it is about pure invention. Innovation is argued by 
some to be more important than invention (Branscomb Auerswald 2002), which is about 
discovery and the creation of something novel. The terms innovation and invention are 
often used interchangeably so it is helpful to understand the UK Parliament's definition 
of invention, which is said to be those things that can be patented whilst innovation is the 
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description for those that cannot (Feldman 2004). Schumpeter suggests that innovation 
could be described according to how radical it is compared to an existing process. In 
doing so, he defines innovation in terms of determinants and factors of influence (Ludvall 
1992; Nelson 1993). Tidd et al (2001) developed this concept in suggesting that the 
design space within the boundary (including relationships and interdependencies) need 
to be explored. 
In his work, Edquist (1997) defines innovation as any new creations of economic 
significance. These, he suggests, may be brand new or, more likely, a combination of 
existing elements and may include the process by which innovation is shaped. These 
changes occur over time, and are said to be complex in being influenced by many 
factors. A position supported by Ludvall (1992) and Niosi el al (1993) is one that defines 
innovation as the outcome of on-going processes of learning and searching which 
results in new products, markets, institutions, organisational change and techniques. 
Dosi (1988) adds an important dimension, which is that of historic context. In keeping 
with Schumpeter, he argues the importance of historical information and formal 
knowledge being incorporated and codified in problem solving. A position supported by 
Metcalf (2000) suggests that history is essential to understanding abortive pathways and 
past boundary changes. Historic contingency is suggested by others to be important in 
providing a context to past influences (Dosi 1988; Metcalf 2000; Fagerberg 2004). 
In their work, Oresnigo (1998) and Dosi move away from defining innovation by focusing 
on its characteristics instead, describing these as sector-specific knowledge, an ability to 
search and find knowledge, and their applications to a specific search goal. Freeman 
(1997) broadens these dimensions to include a social context, especially in the field of 
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technological policy, although there is little written to evidence such an approach. Tidd 
et al (2001) go on to describe innovation as a collection of all the processes that lead to 
the first attempt to put an invention into practice. History shows these can be separated 
by considerable time lags, either whilst an invention finds a place in the market or has 
been shown to be safe. This suggests innovation needs a context in real time. 
Leonardo da Vinci drew sophisticated drawings explaining the twisting mechanics of the 
human heart, yet his discoveries are only in the 21 s t Century finding a place in cardiac 
surgery (Wells 2005). He designed a flying machine in the mid 16 t h Century, some 400 
years before an engine was invented to make it fly, illustrating again the importance of 
context. This context is evidenced again in the present by claims that China cloned a 
fish some 37 years ahead of the rest of the world. 
With no single way to define innovation, it becomes necessary to understand the options 
for its capture and use in this research study. Carr (1986) suggests defining innovation 
by the use of a framework to capture and explain the multi causal and relative 
importance of various determinants to help establish a hierarchy of causes. Tidd et al 
(2001) suggested the use of a linear model to provide insight and interpretation to the 
activities involved in innovation. They classify this linear approach as research science, 
development, production, and marketing. Mina et al (2004) argue instead for a problem 
sequence to be used in constructing the innovation process. They suggest that since 
the goal of innovation is to solve a problem, one way to define the process is to explore 
the design space of path dependencies within a boundary set by the perception of the 
problem. Edquist (1997) simply divides innovation into two process categories: 
technological and organisational. A division is evidenced in the 20 t h Century economic 
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success of the United States, where change related largely to organisational innovations 
and, more laterally, to growth in new industries and mass production (Tidd 2001). 
Defining the core properties of this series is one suggested approach to articulating the 
process of innovation. This, according to Fagerberg, should include the investment and 
knowledge created, the relationships, connections and networks, process interactions 
and modifications through experiment and learning (2004). Mina et al (2004) go on to 
describe the innovation processes as systematic and interdependent on knowledge 
generation, which is greater than its components, requiring therefore an understanding 
of its connections and boundaries. They argue it is the ecologies that are important in 
innovation systems and the focus on regulation of the system misses the principles that 
underpin and connect innovation and its diffusion. The system of innovation is seen 
from the literature to be described in a number of complimentary and, at times, different 
ways. What is clear is that it is said to comprise a range of factors from the conception 
of an idea through to the marketing of its related product and its impact on sales or 
services. It also consists of those elements that influence its creation, including 
legislation, regulation, workforce and society (Freeman 1997; Fagerberg 2004). One of 
the challenges for Innovations Theory is to help understand which factors influence 
success and in what ways. 
Nelson and Roseberg (1993) and Nelson (1992) studied the process used to put 
innovation into practice, arguing that diffusion was one of the most important areas. 
Diffusion includes recognition of the impact on existing technologies and the systems in 
which they operate. This is said to bring change to an existing system, which evolves 
over time while the internal dynamics become part of the innovation sequence itself 
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(Mina et al 2004). Similarly to constructing a pattern to fit an outcome, the literature 
covers many complimentary and independent designs. Freeman (1997) suggests an 
approach using institutional networks to span the relationships between the private and 
public sector. Included in this he supports the examination of culture, political 
institutions, economics, social structures, interdependencies, wars, labour change, 
capital, and transfer of technologies. Edquist (1997) suggests that political aspects and 
policy are the most important of these. 
In designing an Innovation model, Edquist (1997) advises that innovation and learning 
need to be at its center. He suggests taking a holistic and interdisciplinary perspective, 
focusing on the interdependencies and non-linear relationships, and being historic and 
identifying differences and connections between systems. Sterlacchini goes on to 
suggest cost as a further dimension of innovation, including those associated with 
manufacturing set-up product design and organisational change. Mina et al (2004) 
states another way to define the process of innovation is to explore the design space of 
the path dependencies within a defined boundary that is set by the perception of the 
problem. Fagerberg (2004) suggests the use of a framework designed to encapsulate 
the components and relationships to be defined. Building on the work of Edquist (1997), 
she suggests the framework could include the impact of the research, identify links 
between universities and public research organizations, consider the strength created in 
the system, identify the proposed market, consider legislation and regulation, and define 
the boundaries. 
Each of the many ways to define innovation and its characteristics offers an approach 
and structure to design a study, most notably in highlighting the areas for inclusion in a 
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framework at a national level. Such consensus, as there is in the literature, 
demonstrates that innovation is a process far broader than traditional research and 
development, with its contribution greater than its historic value on a balance sheet 
(Sterlacchini et al 1999). Innovation is shown to involve both process and systems and 
to facilitate a framework with many design options from which to explore therapeutic 
cloning between the UK and China. 
Innovations Theory 
Innovations theory places an understanding of the innovative process at the centre of its 
analysis (Fagerberg 2004), making it ideal for a case study on therapeutic cloning 
systems between the UK and China. It is also said to be a useful structure against 
which to describe economic progress, historic trends and contextual change (McKelvery 
1996) - which fits well with the challenge of exploring the national context of stem cell 
science. There are a number of theories that can be used to explore the structures of 
therapeutic cloning between the UK and China. Evolutionary theory is an example of 
one, which is concerned with understanding the process and relationship between 
innovation theory and natural evolution. Many writers note the similarities between 
biological mutation to the evolution of ideas, hypothesises, and selection mechanisms. 
The assertion being that the process of technological innovation can be likened to that of 
biological development. The contrast is the trial and error of the discovery process in 
open-ended systems, which can be blind and involve a certain amount of path 
dependency (Gregersen 97). The comparator in technological innovation is the process 
whereby agents act to transform new knowledge, invention, or scientific techniques into 
economic value. This is seen through production or changes to the organisation, for 
example. 
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Darwin (1859) might, to some degree, be happy with an argument that aligns the 
innovative process to that of nature, believing humans to be very much part of nature, 
without privilege or God. His belief in the importance of relationships and mutual 
influences, such as those between organisms and the environment, fits well with an 
innovative systems approach. So too does his principle of competition over time and 
the suggestion of an apparent order to the selection process. Darwin's use of historic 
events to support his theoretical argument and his belief in interpretation of evolutionary 
progression within an environmental context fit well together. 
Innovation Theory, too, emphasises historical contingencies, patterns of change, and 
contextual interpretation. Correlating to human innovation, agents act to transform new 
knowledge, invention or scientific technique into economic value (McKelvery 1996), with 
the theoretical approach aiming to provide structure. The analogy of particular interest 
here is the process by which new variety or variation is introduced. Invention, as in 
evolutionary processes, introduces change by introducing new variety. McKelvery 
(1996) argues that the development and diffusion of information, done in a way simililar 
to that by which nature selects between alternatives, produces a strong analogy to the 
innovative process. The challenge is to understand what is happening at each stage of 
the comparable process and the influences made at each point of selection. This 
comparison applies equally to genetic science as do insight into the chemical codes that 
instruct the choice and behaviour of cells. 
This is an inductive comparison, no doubt, but one cautioned by Stephen Gould (2002), 
who argues the basic topologies of biology and culture to be different and the 
comparison to be misleading. In biology the chemical pathways are absolute and not 
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experimental. Science is seeking to understand how messages are deferred rather than 
options in the signalling pathways. Human innovation, by comparison, operates with 
some degree of free will, without pre-determined pathways and, often, without a clear 
outcome. Gould suggests the timeframes are distinct. Complex biology requires sex 
selection to determine the dominant, recessive or mutated influence to be evidenced, 
whilst human innovation is said to be culturally influenced, directly learnt, and quick to 
share. McKelvery (1996) suggests, however, that the comparison is still a useful one, in 
accepting that learning, however it occurs, is an important feature of both innovation and 
evolution. 
McMeekin et al (2002) support this analogy, pointing particularly to the role of learning in 
the innovation system. They argue that innovation is created and adjusted through the 
process of knowledge acquisition, and its system adjusts from these interactions. The 
systems themselves diversify, reinforcing the importance of the relational 
interdependences. This is comparable to biology, where cells take their instructions 
from adjacencies, specialising and developing, yet are dependent on the 
interrelationships such as the hormones from the entire body. The work of Metcalf et al 
(2000) on developing an ocular lens (in the clinical field of optometry) serves to illustrate 
these points in identifying the importance of interdependencies in successful innovation. 
Understanding the creation of innovation is one aspect of the whole system from within 
which it is created and diffused. Diffusion is the process by which innovations are 
introduced, organised and sustained through channels, over time amongst members of 
a social system (Rogers 1976). Nelson and Roseberg (1993) and Nelson (1992) studied 
the process used to put innovation into practice, arguing diffusion to be one of the most 
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important areas. Diffusion includes recognition of the impact upon existing technologies 
and the systems within which they operate. This is said to bring change to an existing 
system, which evolves over time while the internal dynamics become part of the 
innovation sequence itself (Mina et al 2004). 
The concept of diffusion originates from the 1903 French Sociologist Gabriel Tarde, who 
first plotted the 'S'-shaped diffusion curve. The rate of adoption, or slope of the curve, is 
the important feature, illustrating the rate of diffusion. In the 1940's a hybrid-corn study 
by Bryce and Neal Gross (1943) identified five segments amongst farmers adopting the 
hybrid corn seed. They labelled these Innovators, Early Adopters, Early Majority, Late 
Majority, and Laggards. The ability to diffuse innovation is said to be complex and multi-
faceted (Metcalf et al 2000), being correlated to many things including the economic 
influence between the performances of countries. Rogers categorised diffusion into four 
dimensions: an idea as perceived, means to communicate, an adoption rate over time, 
and interrelated social systems engaged in the problem/issue. Roger's work built on the 
premise that groups could be defined by characteristics he saw as evident in successful 
innovation. These included risk-taking, access to control of finance, understanding of 
complex knowledge, and ability to cope with uncertainty (1962). 
Extending the work of Bryce and Gross, Rogers described in detail the characteristics of 
each group. Early Adopters, he believed, tend to be an integral part of their local 
system, have some aspect of leadership, were successful, respected, and often acted 
as a role model. Characteristics of Early Majority he defined as being interactive within 
peer group, seldom in leadership positions, and prone to deliberation before adopting 
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new ideas. The Late Majority, he argued, was influenced by peer pressure, from a 
background of economic necessity, and tends to be sceptical and cautious. 
Research by Johnson and Vandan Ban (1959) found that discontinuance was twice as 
high in the Late Adopters group and this had nothing to do with a superior innovation, 
suggesting pressure to conform was only temporary. Rogers defined Laggards as being 
isolated without opinion, having limited control or resource and distrusting of change and 
innovation. He went on to describe how innovation is adopted within five stages, the first 
being Awareness. He believed individuals would first become aware of an innovation 
without having the complete information. The second stage he defined as interest. For 
some of those who become aware of the innovation there will be an interest in the new 
idea and a drive to discover more information about it. Next, he argued that the 
individual would evaluate the information available, mentally applying the innovation to 
future situations. His forth and fifth stages involve trial and then adoption of the 
innovation, including marketing strategies to be formed. 
His model is simplistic and appears to change from an individual focus to an 
organisational one by the time it reaches adoption. Various researches have pointed out 
that the diffusion of the innovation process can happen over several decades, although 
his model appears to suggest a shorter time. There is, however, universal agreement 
that the adoption process or the rate of diffusion can be chartered on an S-shaped curve 
regardless of the timeframe (Doggson and Bessant 1996). Rogers' work went on to 
define the process an individual goes through in deciding whether or not to accept an 
innovation. He summarised these as being from first knowledge of innovation to forming 
an attitude towards innovation, a decision to adopt or reject it, implementation of a new 
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idea, to confirmation of decision. Doggson and Bessant (1996) added the need for an 
individual to perceive an opportunity or a need at the beginning of the process. They 
also believe an ability to search, compare, select, acquire and implement information are 
integral to this process. 
Rogers identified and described a number of personal characteristics that would 
influence the decision-making process of an individual. These included experience of 
previous innovation, recognition of a problem or need for change, being comfortable with 
change, and for the innovation to fit in with their social norms (Rogers 1976). Rogers' 
work goes on to identify three types of knowledge necessary in the first stage of 
innovation. He summarised these as awareness, how-to knowledge, and knowledge of 
the underlying principles of the innovation. He went on to conclude that 'early knowers' 
have more formal education, a higher socio-economic status, more exposure to mass 
media and interpersonal channels, are change agents, and are more socially integrated. 
The importance of personal characteristics in the diffusion process is challenged in the 
work of Amendola and Gafford (1988). They compared the process of innovation with 
that of diffusion and examined the extent and speed at which a superior innovation or 
technique was implemented, concluding that economic process played a stronger role in 
the entry of a new technology than the absorption of if by the population. They 
suggested that Rogers; (1962) work on diffusion should include a definition of the 
degree of risk involved, identifying financial controls, defining areas of uncertainty, and 
understanding the complexity of the knowledge created. 
Sanson-Fisher (2004) used the work of Rogers (1983) to develop ideas about those 
characteristics necessary for successful diffusion of innovation in a clinical context. 
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They define the characteristics they found to be influential as research evidence, role 
models, relationship to existing procedures, and whether it is open to further 
modification. Similar work by Tamblyn et al (2003) includes further variability, gender, 
medical speciality training, time from graduation, location, practice workload, and patient 
demographics. Diffusion Theory is seen to offer a plausible explanation as to why some 
clinical activities are adopted rapidly whist others are not (Sanson-Fisher 2004). The 
distinction of this work in transferring Rogers' Diffusion of Innovation model to clinical 
practice is the recognition that the outcome is more than economic. 
Rogers' Trialability' and 'Observability' are found to be particularly important features 
influencing the take-up of new clinical innovation since visibility is critical in influencing 
clinical change. Denis et al (2002) suggest that this feature in clinical practice is 
reported to be highly influential, as peers perceive professional disadvantage at being 
left behind. Compatibility to existing clinical practice, values and experience are also 
important, as evidence shows diffusion in clinical practice can be rapid where innovation 
leads to an improvement of an existing procedure, as exampled by mammography 
screening and testing for prostate cancer (Goodman 2002; McDougall et al 2000). 
Sanson-Fisher (2004) developed Rogers' decision-making process for the diffusion of 
innovation and suggests five clinically oriented steps. This, they suggest, begins when 
researchers first acquire knowledge about a possible clinical change. An individual or 
group are then persuaded of the advantage of the change, leading to other clinicians 
learning about it. Innovation, it is said, is then adopted into routine clinical life, followed 
by reinforcement discussions with peers. This growth of knowledge involves the 
exploration of the systematic interactions of dispersed groups, channels, and incentives 
in a process distributed across time, space and epistemic domains. Correlating to the 
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nature of the medical problem and the search for a solution (Mina et al 2004), it involves 
the exploration of systematic interactions of dispersed groups, communication channels, 
and response to incentive structures. 
Many clinical innovators work at an international level, influenced by other aspects of 
relational power as identified by Sanson-Fisher et al (2004). They highlight the impact 
between professional groups that hold varying perceptions about the efficacy of new 
innovations, which can influence diffusion. The nature of communication chosen is also 
said to influence clinical innovation, with direct personal contact argued to be the most 
effective (Bero et al 1998). This model fits the historic approach to clinical innovations in 
the NHS (BMA 1995), but not the regulatory and policy context at each stage of 
adoption, particularly when noting the role of the National Institute of Clinical Excellence, 
who, since 1999, have had a powerful influence upon determination or otherwise of 
innovation into the NHS. Nor does it reflect the international context of medical 
innovation, as described my Mina et al (2004) in their work on the introduction of cardiac 
stent technology. It could, however, reflect less substantial innovations such as changes 
in surgical techniques learnt by one surgeon and picked up by others. The 
characteristics of clinical innovation fall into both categories. This is equally true 
historically for China, with current diffusion of health technology technically available in 
its market system, but, in practice, severely restricted by poverty. 
Diffusion is a central tenet of innovation theory, which is aimed at identifying the factors 
influencing its uptake. Although outside the remit of this study (as stem cell services are 
yet to be created), it allows an insight into the relationships and priorities in the research 
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field. Over time, understanding diffusion of the services from therapeutic cloning will be 
vital to understanding patient choice, expectations, and patterns of service delivery. 
Innovation Structures 
Understanding how innovation evolves and its systems occur requires a structure from 
which to explore. Regional Systems of Innovation is one such approach, in that it 
proves a geographic context. Cooke et al (1997) was first to introduce the concept of a 
Regional System of Innovation, which was further developed by Braczyk et al (1998), 
Cooke (2001), Asheim et al (2002) and Fagerberg (2004). It takes the same economic 
and algometric principles as a National System (Arcangelis 1993) when identifying 
factors at a geographic level. The Regional approach is said to have two types of 
constituents. Firstly, it has a shared component or commodity that links them and, 
secondly, a geographic relationship (Fagerberg 2004). Their systems are linked 
networks of activity with strong complementarities between components (Tidd 2001) 
within defined boundaries (Fagerberg 2004). 
Mina et al (2004) support this deconstruction of innovation theory to a regional level, 
suggesting that national boundaries fail to capture sufficiently the purpose and function 
of innovation. They support an approach that breaks down the evaluation to a system 
perspective, thereby enabling the examination of individual industries within their own 
boundaries. The regional or sectorial approach was first used by Malerba (1997) to 
examine the use of technology amongst a group of firms in a similar industry. 
Regional Systems illustrates the key features that structure an innovations research. A 
Regional approach does not fit the design of this study as stem cell research is 
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organised at a National level. National Systems of Innovation lends itself more naturally 
to this design. 
National Systems of Innovation 
National Systems of Innovation is one approach within the innovations literature, with an 
emphasis on understanding performance at a national level. In particular, this approach 
places emphasis on the political and policy boundaries (Edquist 1997) and enables an 
exploration of their national difference and application. Freeman (1997) defines these 
political structures as culture, political institutions, economics, social structure, 
interdependencies, capital infrastructure, and technology transfer. Understanding 
National Systems of Innovation is suggested by Edquist to be critical to predicting long-
term economic growth, as it is said to afford a powerful explanation of performance. 
National Systems of Innovation (NSI) is a relatively new theory based on the work of 
Freeman (1997), with its origins said to be in the work of Friedrich List (1841) and 
Joseph Schumpeter (1883-1953). Each made links between economic performance 
and the role of technologies in its advancement (Landes 1969; Plummer 2004). 
Schumpeter (1883-1953) extended this work by arguing technological competition was 
the driving force behind economic development, thereby placing innovation at the centre 
of growth (Tidd 2001). 
Joseph Schumpeter (1883-1953) was an economist, said to have ideas before his time, 
whose work focused on the relationship of learning and the application of new 
technologies to economic performance. He was critical of classical economists for what 
he saw as their scant attention to science and technology when considering issues of 
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national growth. He rejected the classical economist view that economic performance 
focused on capital and labour as the two most important factors of production (Plummer 
2004). Schumpeter wrote instead of the interdependences between foreign technology 
and the role of diffusion and imitation in performance (Landes 1969). His insights led to 
Germany delivering one of the best technological educations and training systems in the 
world, leading to their economic advance over Britain in the mid 19 t h Century. 
The National Systems of Innovation takes many of its features from previous economic 
and social analysis including network, power relationships, and organisational behaviour 
(Coombs et al 2001). Christopher Freeman (1997) was first to use NSI in his work, 
assessing the contribution of public policy to Japanese national performance. Freeman 
defined National Systems of Innovation as a collection of institutional networks spanning 
the public and private sector whose activities interact, initiate, import, modify, and diffuse 
new technology. The unit of analysis in explaining National Systems is national 
boundaries, the important features according to Edquist (1997) being the political and 
policy aspects. National System of Innovation is used to explain the performance of a 
country in terms of its special features and national boundaries. It is designed to provide 
a qualitative framework to conceptualise policy implementation and take explicit account 
of the systems and interactions. 
The ontology for NSI is that innovation is crucial for long-term economic growth, that 
successful industries tend to develop in geographic clusters and that it is a powerful 
explanatory factor behind differences in performance (Edquist 1997). The first major 
book was written by Bengt-Ake Lundval (1992), who focused on an empirical case study 
which looked at National Research and Development systems in Denmark. Richard 
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Nelson edited this work comparing the National Systems of twelve countries. His aim 
was to develop a more theoretical alternative to neo-classical economic tradition by 
placing interactive learning and user-produced interactions at the centre of the analysis. 
They sought to define innovation in terms of its determinants and factors at influence in 
the innovation process. Edquist (1997) gives a more general definition of National 
Systems of Innovation, describing it as an 'all important economic, social and political 
organisational and other factors that influence the development, diffusion and use of 
innovation'. (Is this a direct quote? If so, it may be worth checking to see if you've taken 
down the punctuation exactly as written.) Although there is no formal theoretical 
framework to describe National Systems of Innovation (Edquist 1997a; Holbrook and 
Wolfe 2000; Fagerberg 2004), there is broad agreement to a number of principles within 
it. Edquist summarised these as: 
• having innovation and learning at its centre 
• a holistic and interdisciplinary approach 
• focusing on Interdependence and non-linear assumptions 
• providing an historical perspective 
• looking at the differences between systems and non-optimality 
• assuming technologies and innovations are measurable 
with Fagerberg (2004) adding 
• Research and Development 
• New markets 
• Articulation of quality requirements 
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• Organisational consequence 
• Changing institutions, e.g. new regulations and laws 
• Financial innovation 
• Technology transfer 
• Boundary distinction of what is inside and outside 
The main strengths of NSI are said to be in placing innovation at the centre of evaluation 
and learning at the heart of change (Fagerberg 2004), thereby distinguishing it from 
other approaches where the role of technology in economic performance is said to be 
exogenous. This approach is said to be holistic and interdisciplinary, attempting to 
encompass a wide array of determinants in organisational, social, economic and political 
activity. It takes an historic and evolutionary perspective to enable comparison between 
real systems over time and space (Fagerberg 2004), emphasising the interdependence 
and non-linear activity of an organisation. These include internal and external 
relationships with their environment, their feedback mechanisms, and their relationships. 
Its main weakness is that, as a concept, it is diffuse; the framework and boundaries are 
not prescribed and its use to formulate conjecture for empirical testing is said to be 
limited (Edquist 1997). It is not a formal theory providing specific propositions regarding 
casual relations among variables and there are issues of interpretation in its language. 
The terms 'organisational' and 'institutional' have, for example, been used to mean 
different things. For example, Ludvall (1992) used the term 'organisation' to mean rules 
of the game, whilst Nelson (1993) used it to distinguish between different types of 
organisations. 
Edquist and Johnson (1997) describe organisations as formal structures consciously 
crafted for an explicit purpose, they regard whilst institutions as common habits, norms, 
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routines, established practices, rules, or laws that regulate the relations and interactions 
between individuals. This makes the explanation and classification of components in the 
research design vital. More recently its use has extended to the service industry 
(Fagerberg 2004). It has also been applied to research in a number of clinical areas 
including optometry, cardiology, and cancer (Metcalf 2000; McDougal 2000; Goodman 
2002; Mina 2004). It has been used in agricultural research to consider the impact of 
generic engineering and linked as a model to that of evolutionary theory. At the centre 
of each approach are a definition of the innovation that is being studied and a 
clarification of its boundary. 
The most striking feature of National Systems of Innovation is said to be the absence of 
any form of empirical framework (Edquist 1997). The unit of analysis is the National 
Boundary, with Edquist (1997) suggesting the associated political structures to be of 
fundamental importance. For this study, this means understanding the permissive 
status of government legislation, their investment strategies, and how these apply to the 
research question. There are a number of flexibilities and suggested approaches in the 
literature that provide options for defining NSI as they relate to the research question. 
Freeman suggests that the overall aim is to identify those activities which increase 
knowledge and those institutional rules that promote successful innovation. 
Mina et al (2004) support this in agreeing that the identification and definition of the core 
properties influencing innovation are critical to understanding growth and performance. 
He suggests the use of case studies as a means to develop NSI theory building on the 
earlier suggestion by Carr (1986). Fagerberg (2004) suggests that, in addition, there 
needs to be more focus on the non-tangible aspects of knowledge and agrees that a 
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framework and case study is the most useful approach. Ludvall (2003) suggests, 
however, that if the use of NSI is to be of assistance to policy makers its focus needs to 
be more realistic, particularly in defining the relationship between theoretical analyses 
and its related environment. 
The concept of national boundaries as a definition of innovation, although widely 
accepted, is also open to challenge. Such challenge is based largely around concern 
about the number of trans-national corporate successes that sit across and supersede 
national boundaries, with the examples of Coco-Cola and McDonald's cited. This is 
supported by Ohmae (1990), who suggests that the significance of national boundaries 
has been overwritten by the interdependencies of economies at a national level 
(Freeman 97). This suggests the definition of what is national to be unclear or to be 
reliant upon external factors other than the National Policies of a country. For genetic 
science within the biotechnology sector, it certainly transcends national boundaries in 
terms of co-dependencies in knowledge; specialist techniques, and discovery. Where 
national boundaries are distinct, however, and therefore relevant to this research topic is 
in the realms of legislation, policy, and the societal context of a country. These do, in 
fact, define what is acceptable in scientific research within a national boundary. One 
example of this is the patent law of a country, which can only bind itself, (as evidenced 
by Myraid's patent for the BRCA2 test in the US, which was successfully overturned in 
the UK) (PHGU 2004). 
Mina et al (2004) also question the usefulness of national boundaries as a basis for 
assessing innovation, arguing that this approach fails to provide sufficient focus on 
purpose or function. They favour the deconstruction of innovation theory to break down 
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the evaluation into a system and network, thereby enabling industries to be examined 
within their own boundaries. The issue of relevance and use appears, however, to 
depend on the topic of research, as many of the concerns are based on industrial-
related studies (Fagerberg 2004). It may be the future aligns with Ohmae's argument as 
the International Standards Organisation (ISO) and European Commission seek to 
agree upon international standards for genetic science, but as yet this is some way off. 
National Systems of Innovation theory has been applied in a number of clinical areas 
including optometry, cardiology, and cancer (Metcalf 2000; McDougal 2000; Goodman 
2002; Mina 2004). Although there is nothing to-date on stem cell research for diabetes, 
its application to a new clinical area fits easily with its flexible design and its recent 
transition to service areas. Many writers suggest future application of National Systems 
of Innovation Theory with Storper and Harrison (1991) asserting that despite the body of 
literature there needs to be a better understanding of how it can be applied as a 
structured model. They go on to suggest that the power dynamics need to be identified, 
with a view to indicating which are of most influence. Storper and Harrison also 
recommend a focus on those indicators that are shown to deliver change, overcome 
risk, and drive market performance. 
Freeman (1997) suggests the need for more research into the impact of NSI and the 
determinants that influence its development and diffusion. In particular, he suggests, 
those activities that increase knowledge and the identification of organisations that are 
key to its development or diffusion. Tidd et al (2001) argue that our understanding of the 
way knowledge and innovation operate at an organisational level is fragmented and 
needs further research to conceptualise why and how innovation occurs. They suggest 
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that one potential avenue for future research is to apply evolutionary and characteristics-
based approaches to service innovation. As with the previous suggestions, identification 
of key drivers is at the heart of the challenge. 
National Innovation Studies has, according to Fagerberg (2004), focused on traditional 
technological processes and the production of goods rather than organisational or 
service innovations. Fagerberg argues that this creates a strong reason to give more 
attention to non-technical and intangible aspects within the model. She supports Tidd et 
al (2001) in suggesting the application of evolutionary and characteristics-based 
approaches to service innovation. She also supports a focus on the impact of innovation 
within the marketplace with particular emphasis on the skills and capabilities required for 
effective implementation. This relates, in part, to earlier suggestions by McKelvery 
(1996), who described the challenge of NSI to be an understanding of what is happening 
at each stage of the innovation process, and how and what is being influenced at each 
point of selection. This, he suggests, will help identify the development process and its 
corresponding diffusion of information. 
The NSI literature includes a range of suggestions and arguments relating to its 
construction and use. In addition, it covers strengths, weaknesses, and opportunities for 
its development, including its links into related theory. Its recent application in the 
service sector - with several examples in clinical innovation - makes it an ideal choice for 
this research topic. The flexibility of its construct and its use in case study models is 
also relevant. The challenge will be constructing the research design in the absence of 
a defined structure for a national system of innovation in therapeutic cloning. Its 
structure and approach are, however, underpinned by a number of related innovation 
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theories set out in the literature, which are important to understand when constructing a 
model. Before moving to consider how this model and methodology is constructed, it is 
helpful to understand the background to the national innovation structures in China and 
the UK. 
Innovation in China and the UK 
China is reported to have a long and prestigious history in innovation, having invented 
paper, printing, the magnetic compass, and gunpowder (Temple 1972). They used iron 
and created tools 1000 years before the rest of the world and are claimed to have 
cloned a fish some 37 years before the UK cloned 'Dolly the Sheep' (Mann 2002). They 
are said to have been the first to synthesise human insulin, but this was not validated 
nor marketed (Poo 2004). China's complex history of wars and conflict is given as a 
reason for losing their innovative lead in the 18 t h Century. Other reasons include their 
historic isolation from the rest of the world and the absence of market mechanisms. 
Having had a prestigious history, China wants desperately to reclaim it and to achieve a 
Nobel Prize (Mann 2003; Qiming 2005). With the biotechnological industry recognised 
as the most powerful source of innovation (Geroski 1993; OECD 2000; DTI 2002; HM 
Treasury 2002), China has focused its strategy on gaining international collaboration 
within this field. From these objectives, China derived its strategic goal to be the front-
runners in international science by 2010, a leader by 2020, and ranked amongst the 
world greats by 2049 (Wilsdon and Keeley 2006). Within this aim they identify stem cell 
technologies as a priority. Their goal is to attain prestigious and economic prowess, as 
success in the biotechnological field would make China a world leader (Jing 2003; Mann 
2003). Early success is evident in internationalisation of their science and of overseas 
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investors choosing to locate biotechnological research in China (OECD1 2005). 
Incentives include a relaxed ethical stance (Yank 2004), access to both primate and 
human research (Chien 2004), and lower research costs. 
Culture is said to sit at the heart of their opportunities, with the Chinese having few moral 
objections to the use of embryos for research and therapeutic cloning (Yank 2004). In 
China human life is considered to begin at birth, not conception, with personhood 
achieved only when the person is able to participate in society. To this way of thinking, 
the foetus is not considered human (Mann 2003). Whilst the Chinese government is 
regarded as having the most liberal stem cell research in the world, it does not permit 
cloning for the purpose of human reproduction (Yank 2004). Despite their ethical 
stance, China has a number of issues to overcome. These include the communication 
of their science, access to international specialism (Yank 2004), investment in basic 
research (Hepeng 2002), and improvement in the quality of its published research (Wu 
2004). China has, in addition, a number of social and demographic features to reconcile 
if it is to achieve its goal of a xiaokang society. 
Being of similar size to America, China is home to 20% of the world's population (Riley 
2004), has a wealth of natural resource, and a health profile similar to that of a 
developed country (WHO 2004). Prevalence of diabetes affects about 2.5% of its 
population (Pan et al 1997), with cancers, respiratory disease, water-born infection. 
HIV/AIDS, and accidents all considered other major causes of death (Jin et al 1995; 
Beach 2001b; Riley 2004). In addition, SARS, a deadly respiratory disease, emerged in 
southern China with major political consequences (WHO 2004). 70% of the population 
live in rural villages (WHO 2004) and the entire population is subject to national birth 
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planning policies. This has led to an unnatural skewing in official birth statistics of the 
ration of male: female births (Watts 2005). 
The main environmental problems are water, coal, and land erosion. China is the 
world's largest producer and consumer of bituminous coal, most of it burned without 
emission treatment. It also suffers from a shortage of usable water, with water in only 
six out of 27 cities being drinkable (Smil 1996). The absence, for many, of a decent 
water supply leads to liver and stomach cancers skin disease, congenital deformities, 
and water-born infections such as dysentery (Riley 2004). The associated morbidity and 
mortality is greater in rural areas (Beach 2001a). Many of these have worsened since 
China's move to a market economy in the 1980's, leading to a predominately private 
health system (Riley 2004), leaving 90% of the rural community without medical support 
(Beach 2001) and 85% without health insurance (WHO 2004). 
A typical family earning $60 per year would pay 30% of their annual salary for one visit 
to a medical facility with hospitals demanding $181-$362 before admission. The 
absence of public facilities resulted in an increase in private facilities and a fall in 
government expenditure on health from 36% to 15% by 1999 (WHO 2004). To date, the 
government spends 12.8% of its budget on health, or $261 per person with 66.3% of 
health expenditure privately funded. This amounted to 5.8% GDP in 2001 (Lopez 2002), 
indicating that the investment in China's health care system has now fallen well behind 
China's economic growth (Watts 2005). 
Britain also has a prestigious and current history, being a world leader in genetic science 
and discovery (DoH 2003). It is a small island, densely population with limited natural 
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resources. The ethnic balance is largely white with 8% made up from minority races 
(mainly of Asian, African or Chinese decent). Its climate is mild and often wet, with 
overcast skies prevalent for 300 days of the year. As a consequence, it is lush and 
green with rolling plains in the south and east and rough hills and mountains to the west 
and north. Economically, it is highly developed, leading to high standards of living and 
an eminence in both art and science. It exhibits affluent trends in lifestyle, including fatty 
diets, smoking, and low levels of exercise. Infectious disease has declined since the 
early 20 t h Century, with current morbidity associated with non-communicative disease 
and comparatively poor health outcomes (Wanless 2003). There are significant 
inequalities in both mortality and morbidity across gender, socio-economic and 
geographic location (Wanless 2003). At least 5% of the UK population is currently 
known to have single gene disorders, with 60% developing a genetically related disease 
during their lifetime (DoH 2003). 3.9% of the population is currently known to be diabetic 
(Diabetes UK 2003 Atlas 2004) 
Economically, the UK has a mixed history, having led the world in overseas trade during 
the 19 l h Century. It was the first to revolutionise its industrial production in the 18 t h 
Century and the world's first society dominated by the middle class (Weisser 2005). 
Thereafter it faced persistent problems with its balance of trade, having to import one 
tenth of its food and many of its raw materials and manufactured goods. Industrial 
inefficiencies and high cost of nationalised industries in the first half of the 20 t h Century 
led to more problems, culminating with an unemployment rate of 11% in the 1980's. 
Since the mid 1970's, the UK has benefited from an economic upswing, growing at a 
rate of 2.5% by 1997, one of the highest in Europe (Weisser 2005). This prosperity has 
Gail Newmarch 68 
DBA Final November 2008 
enabled centres of excellence, including neuroscience at Oxford, Cancer at Dundee, 
and Genomics at the Sanger Centre, Cambridge. 
The UK is responsible for the cloning of Dolly the Sheep, the first such animal in the 
world. It has the best regulatory framework (PHGU 2002) and a raft of financial and tax 
incentives. It led the final mapping of the human genome (Goodfellow 2001), the 
computer technologies to read gene codes, and it developed haplotype mapping and 
accounts for half of all drugs currently under development. It is regarded as a cost-
effective place to conduct stem cell research and has been working in the field of 
genetics longer than any other country (Best 2005). As a direct consequence, it has the 
most comprehensive legislative structure, having established the Human Fertilisation 
and Embryology Act and created the Human Fertilisation Embryology Authority in 1991. 
It was the first country to licence therapeutic cloning at Newcastle University in August 
2004 (Pincock 2004) and has succeeded in creating therapeutic cell clones (BBC 2005). 
Access to new technologies and services has been strictly controlled by the National 
Institute of Clinical Excellence (Raftery 2001) since 1999. Linked to the Horizon 
Scanning Unit at Birmingham University and the National Co-ordinating Centre for 
Health Technologies in Europe, they review all pharmaceuticals, devices, diagnostics, 
surgical procedures and therapies. The outcome of most reviews is to restrict a new 
technology to a treatment of last option (Raftery 2001), with an allegedly economic 
motive (Claxton et al 2002). As a result, most new technologies take between five and 
twenty years to become available (May 1993; Dargie 2000; Raferty 2001; Wanless 
2002; Dyers 2003). Genetic technologies in the UK will be controlled by this mechanism 
unless they are marketed privately. They are likely to cost more to research and 
Gail Newmarch 69 
DBA Final November 2008 
develop than previous technologies and the ownership of their associated property rights 
are already predominately in the US private sector (Graff 2003). Already there is early 
evidence of genetic tests becoming available over the Internet (for example, sex testing 
in early pregnancy) (PHGU 2005). In addition to their structural innovations, both the UK 
and China are influenced by political and legal structures that influence their stem cell 
research. 
Politics of Innovation 
China has a Communist Government whose reforms of the last twenty years are aimed 
specifically at improving its economic and social well-being. Prominent in the 
government's strategy is the 'Five Co-ordinations': to coordinate urban and rural 
development, interregional development, socio-economic development (WHO 2004). 
(This isn't a list of five - are there others?) International trade and development in the 
areas of communication and biotechnologies underpin these policies. The government 
launched Science and Technology Parks in 2000, created a number of technology 
transfer entities to develop and diffuse common technologies (OECDb 2004), and 
opened a new tissue-re-engineering centre in Shanghai. Research funding is made 
available through a number of routes, including the Chinese National High Tech R&D 
Programme, National Natural Science Foundation, Ministry of Science and Technology, 
and Chinese Academy of Science (Hsiao 2004). A related initiative is to educate the 
entire population in the scientific agenda (Hepemg 2002), although public debate and 
open communications are in reality rarely seen (Poo 2004). 
Due to China's isolation from the scientific world for the last two centuries (Chien 2004; 
Poo 2004), its research structure was severely devastated (Wu 2004), resulting in an 
urgent drive for Chinese Scientists to become familiar with new discoveries (Chien 
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2004). By 2000 the number of biologists, government funded laboratories, and total 
number of publications had recovered to match those of the US, but the number of high-
impact papers was only 4% in comparison (Wu 2004). Research investment is skewed 
towards developmental research, resulting in only 5% of its research budget being spent 
on basic research compared to 16-22% in more advanced countries (OECD 2002). This 
undermines international recognition and transferability and is probably the biggest issue 
to be addressed. 
China has doubled its GDP spend on research between 1996 and 2002, increasing it 
from 0.6 to 1.2( although this is still significantly below that of the US) (OECDc 2004). It 
rose again to 1.3 in 2005 making it the second largest spend, taking over from Japan 
(Wilsdon 2006). 
$bn R&D % GDP Gov R&D 
China 12.5 1.1 0.28 
US 281 2.8 0.76 
Japan 96 3 0.64 
South Korea 20 2.7 0.64 
An interesting feature of the Chinese research system is the length of time research 
trials takes for new drugs in clinical trials. This is five years, compared to 15 in the US 
(Yank 2004) and 20 in the UK. With the average cost of $900m to produce one new 
drug in the US, this has proved historically prohibitive for research in China, resulting in 
over 97% of drug production in China being generic (Hepeng 2005). Large drug 
companies are motivated to set up in China due to its cost effectiveness and China's 
expertise in chemical research (Chien 2004). Dr Zhao Chunhua runs China's first stem 
cell research programme in Beijing with both government and public support, making his 
work and access to embryos much easier than in America. Cells taken from second-
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trimester terminated foetuses are used to treat diseases in ways that are not acceptable 
in the US and other parts of the world due both to the ethical concern and the absence 
of substantial clinical trials (DTI 2004 BBC 2005). 
There are already reported to be a number of commercial stem cell services available in 
China, including gene therapy for cancer and cord blood therapies for spine and 
neurological injuries and disease. In addition, stem cell research is being undertaken 
between a number of universities and commercial organisations (DTI 2004). The 
Ministry of Science and Technology is supportive of research into therapeutic cloning for 
a number of disease areas including diabetes (Hepeng 2004). Centres using embryonic 
cells to research diabetes are supported across China (Dennis 2002). By October 2004 
the following institutions were working on stem cell research in the area of diabetes: 
• University of Beijing 
• Chinese National Human 
• Genome Centre Shanghai 
• Shanghai Huashan Institute 
• Xiangya Reproduction and Genetics Hospital China 
• Sun Yat-sen University 
Economic performance in China advanced from reform in the 1980's from a 
centrally planned economy to that of an open market (Keidel 2001). This resulted in 
annual growth rates of 8-9% and a quadrupling in GDP. They became the second 
largest economy in the world, creating the fourth-largest import volume, resulting in a 
reduction in poverty rates from 31.6% at the beginning of 1980 to 3.5% in 2001 (WHO 
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2004). From 2000 to 2001 they achieved moderate economic performance, their budget 
deficits and national debt were manageable and foreign trade, debt, investment and 
reserves were excellent (Keidel 2001). 
By 2001 industry and construction accounted for 52.9% of the economy, 32.3% service 
and 14.8% agriculture (WHO 2004). The success of the Chinese economy is based on 
policy reforms aligning its internal programme with international priorities (OECDb 2004). 
These strategies replace traditional Greenfield projects with an internal market founded 
on mergers and acquisitions and a low production cost-base, making it attractive to 
foreign investment (Christiansen et al 2005; OECDa 2005). By 2004 China had 
achieved inward foreign investment of $54.9bn and developed exceptional synergies 
with the US (Hsiao 2004; OECDa 2005), all having a significant impact on their research 
environment. 
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Despite real term growth in GDP of 8% in 2002, state-owned enterprise made losses of 
36% (Wetzel 2003), leading to government policy to sell most state-owned enterprise 
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with the exception of national security (Wetzel 2003). To make its systems more 
flexible, the government has replaced its mandatory planning structures with one of 
direction and guidance, moving away from approving projects to a more functional one 
of evaluation. It has also streamlined its mechanisms for venture capital investment, 
procurement and tendering in favour of more open market processes (OECDb 2004). 
However, the Communist Party maintains its authority to approve all economic policies 
and managerial appointments in all financial institutions and major industrial enterprises 
(Wetzel 2003). 
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China has a comprehensive industrial base but lags behind in high technologies and 
modern management practice. The government sought to address this in 2000 by 
making explicit its intention to increase market shares in the technology industry 
(Christiansen et al 2005). Its goal was to improve exports and acquire overseas 
acquisitions aimed at stimulating the modernisation of its internal industry, exampled by 
the acquisition of IBM by Lenovo. 
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Foreign R&D investment has increased in line with the government strategy to become 
competitive in the field of international R&D, to develop world-class research centres, 
and to improve the scientific literacy of its people (OECDb 2004). Investment from the 
US alone has risen from $7m in 1994 to $500m in 2000 (OECDc 2004) with such 
reforms in its science technology and innovation being central to their policy. This policy 
incorporates a number of strategies to build capacity, optimise structures and rationalise 
existing systems. This is exampled by preferential taxation structure providing 50% 
returns for any business attaining 10% in real growth. 
Other incentives include tax holidays on technology transfers, technological 
constructions, services and training, communications, import of foreign advanced 
technologies, and pre-tax salaries (OECDb 2004). In addition, the Chinese government 
has introduced changes in legislation, more resources for scientific research, standard 
evaluation processes for science and technology, and flexibility in their workforce 
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structures. Human resource is regarded as the primary source of innovation, with 16 
million students registered in higher education in 2002. China has 100 priority 
universities, 30 with international reputations (Qiming 2005). Its universities admitted 
30.25 million students in 2002, including 202,600 postgraduate research students 
(OEDCb 2004). Recognising that many Chinese graduates are educated abroad, their 
government has policies to encourage this. It supports them to work in international 
Knowledge Parks, thereby expanding channels of communications and bringing the 
expertise back to China. 
Economic performance in China, in terms of inward and outward investment as well as 
in levels of established research, all show strong improvement. There are, however, 
alternative ways to measure economic improvement in research, one being the 
nationality and number of registered patents (OECD1 2005). These are directly linked to 
the legislative structure for research. 
The Chinese legal system is a complex amalgamation of custom and statute, based 
largely around criminal law, which has had a rudimentary Civil Code since July 1 s t , 1987. 
Historically, the Chinese had insufficient systems or experience of Intellectual Property 
as they related to research institutes (OECDb 2004). The process of patent registration 
is governed by the Regulations of the Management of National Science and Technology 
Programs and Projects of Intellectual Properties. The State may, under special 
circumstances, retain its right to freely use and exploit a discovery. Until recently there 
was a loophole in their patent law that permitted Chinese companies to copy drugs with 
foreign patents. An intellectual property system that is respected and trusted is an 
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essential aspect to research innovation, so China has had to respond quickly to make 
improvements. 
Firstly, China introduced a systematic approach to guidance and demonstrations aimed 
at stimulating the internal accumulation of property rights and to accelerate the 
conversion of its findings to actual products (OECDb 2004). Secondly, they joined the 
World Health Organisation, which improved their international standing, particularly in 
the area of enforcement (Hsiao 2004). The Patent system in China shows relatively low 
numbers of registrations, but higher numbers for design and utility. This may in part be 
explained by the relatively short time it takes to market a product, and the fact that 
patents used only to be awarded for seven and half years (Qiming 2005). Despite 
recent improvements, patent enforcement in China remains a difficult issue, with many 
Western companies withholding details of their products in their patent registration for 
fear of fraud. Pfizer, for example, had their patent for Viagra suspended due to 
allegations that incomplete details of the product had been filed. As a result, 90% of 
Viagra sold in China is either counterfeit or fake (Mooney 2004). 
The UK government, in contrast, is democratic and based on historically constituted 
laws. Its legislature is made up of a House of Lords, the House of Commons and the 
Monarch. The prime minister is Chief Executive, and member of commons consists 
largely of Ministers, some of whom head public departments (such as the health 
department). The government has established six Knowledge Parks linked to 
prestigious universities to lead the interface on partnerships, knowledge creation, and 
other legal, social and ethical issues associated with stem cell research (Milburn 2002). 
Public accountability for genetics is delivered by a number of formal structures within the 
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Department of Health and private partnerships with the Wellcome Trust, the Medical 
Research Council and Commercial Industry. One example is the world's first Bio-Bank, 
its management overseen by the National Institute for Biological Standards and Control, 
which opened in April 2003 to hold and make available stem cell lines for research 
(MRC 2003). 
The UK Government has made a number of policy statements in support of stem cell 
technologies: Investing in Innovation (DTI 2002), the NHS as an Innovative Organisation 
(DoH 2002) and Our Inheritance: Our Future (DoH 2003). Further, the UK is regarded 
as a cost effective place to conduct research having a longer cumulative history in the 
field of genetics than any other country (Best 2005). Its approach to building 
infrastructure, protocols and capacity means it is consistent with European standards 
and well placed for the introduction of global standards that are expected in due course 
(Best 2005). The UK research sector in genetic stem cell technologies is defined by its 
legislation, regulation, partnerships funding and organisational structures. A new centre 
devoted to stem cell research was opened at Cambridge University in July 2004 and 
research at Newcastle University is reported to be producing results. Having taken eggs 
from eleven women, it has produced therapeutic cloned cells that were a perfect match, 
thereby eliminating the problems of rejection (BBC 2005). 
It is this difference in regulation governing product licensing that varies between 
countries and explains why Gene Therapy is reported to be available in China, many 
years before it will be in America and parts of Western Europe (Luck 2004). The UK 
systems require a stem cell process free from animal products, an understanding of how 
the technologies work in the human body (Dyers 2003), and a clinical trials process that 
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takes up to twenty years and a policy assessment by the National Institute of Clinical 
Excellence (NICE) before any procedure will become available in the UK. To date, 
NICE has reviewed a small number of genetic technologies offering some insight into 
how these might be managed in the future. The first, an orthopaedic repair adult stem 
cell repair 9Chrondracyte Transplantation), was rejected on the basis that there is an 
adequate alternative in the form of a prosthetic knee replacement (Rafety 2001). The 
second was the use of herceptin for breast cancer, which was approved subject to the 
use of a genetic test first to prove susceptibility. The third is islet cell transplantation to 
cure diabetes where guidance reports the benefits in 2003 to be insufficient to approve 
(NICE 2003). This has subsequently been approved (NICE 2007). 
Innovation Policy for stem cell research in the UK is underpinned by research 
investment strategies which have in the UK been seen to decline as a proportion of GDP 
from 2.8 to 1.9% of GDP (OECD 2002). 
Spend on Research in the UK as a % of GDP 1985 to 2001 
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In 1980 eight in ten new discoveries were made in Europe, and now eight out of ten are 
made in the USA. This historic under-investment in UK research has led to privately-
driven investment and ownership of new technologies. An absence of government 
strategy and investment in public research has also resulted in the majority of genetic 
research being privately resourced and owned within the US (Caulfield 1998; Graff et al 
2003). There is much speculation that these economic factors will drive the private 
sector to market and supply new genetic technologies (as is already evidenced in the 
field of genetic predisposition testing) (HGC 2003). The Human Genetic Commission is 
in favour of appropriate legislation to prevent this (HGC 2003b), but others suggest this 
would be anticompetitive. The government has yet to decide (DoH 2003). 
In July 2004 the UK government indicated its commitment to new genetic technologies, 
pledging an extra £50m. This covers upgrades to genetic laboratories, support for 
research trials, research into personalised medicine, and support for a new research 
centre at Birmingham University (Mednews 2004). In addition, it announced an increase 
to the science budget from 3.9bn in 2004 to 5bn by 2008 and a target increase in GDP 
to 3% by 2014 (Brown 2004). Its permissive legislation supported the first European 
licence for embryo research and therapeutic cloning (MedNews 2004). This was 
enabled by its comprehensive legislation for genetic research set out in the Human 
Fertilisation and Embryology Act (1990), which established the license and monitoring of 
fertility treatments and the creation of embryos for therapeutic cloning. The act also 
makes legal the creation of human embryos for the purpose of research and to carry out 
somatic cell nuclear replacement, thereby cloning the donor nucleus. Human Cloning 
has been explicitly banned under the Human Reproductive Cloning Act of 2001. The 
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HFEA merged with the Regulatory Authority for Fertilisation and Tissue in 2004 and 
relaxed the rules on pre-implementation screening for saviour siblings (PHGU 2004). 
The Patent Act (1997), in addition to the European Convention and European Directives 
on legal protection of biotechnological inventions (98/44/EU), set out conditions for 
registering patents related to genetic discovery. These state that the human body and 
its elements are not patentable, but those elements that can be isolated from the body 
may be. It is a complex area of law with many biotechnology companies already 
staking claims to parts of the human body through patents on human genes, cells, and 
other tissues for commercial use (Juma 2003). In 1998 the associated human rights 
were clarified. Article 2 set out the rights to life, Article 3 the freedom for degrading 
treatment, Article 8 the right to privacy, and Article 14 freedom from discrimination in the 
enjoyment of these rights (HRA 1998). This developing protection is evidenced by the 
withdrawal of patent protection for the US giant Myraid in February 2004 (PHGUb 2004) 
Genetic products will be within the scope of the Medicines Act (1971), which gives the 
Committee of Safety of Medicines responsibility for ensuring drug safety. The Medicines 
Control Agency is responsibility for licensing pharmaceutical products and Medical 
Devices Agency for medical devices including diagnostic tests. Genetic services and 
products can also be approved under European Directives on Medical Devices. A 
product licence is then needed to market from either the European Medication 
Evaluation Agency (EMEA 1995) (this is an obligatory route for biotech products and 
treatments related to AIDS, Cancer, neuro-degenerative disease and diabetes) or the 
Medicines and Healthcare Products Regulatory Agency (MHRA), in which phase one 
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studies require authorisation for medical products manufactured to good standard. A 
product must have an identified sponsor to be considered for a clinical trial. 
Summary 
Innovation theory provides a context to study stem cell research between the UK and 
China, as there are demonstrable comparisons between biological and human systems. 
From the literature it is shown that NSI affords flexibility in constructing a structure and 
the opportunities for exploring influence within this. As a relatively new theory, the 
literature covers a number of approaches, with National Systems of Innovation being 
chosen for this study because it enables a comparison between two independent 
nations, it suits a case study approach, and it has a focus on the political and economic 
systems within which innovation is constructed. This enables national dimensions of the 
regulatory and research environments for stem cell technologies to be compared whilst 
also supporting a construct for a framework around which to fit the softer aspects of 
cultural and societal value. From the literature, the innovation systems in the UK have 
made a number of significant steps in advancing stem cell research, including 
permissive legislation, enabling policy, and increased investment. The UK was the first 
country to approve, under license, the use of human embryos for research and has 
made a number of policy and investment changes to improve the climate of such work. 
There are 20 universities involved in stem cell research, three of which are working 
directly on diabetic issues, in addition to a number of pharmaceutical companies. The 
underpinned business priority is to reduce morbidity and mortality for diseases such as 
diabetes. 
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China also knows the opportunities of stem call science and knows big change leads to 
big fortune. They want tomorrow's biotech tycoons to speak mandarin (Mann 2003) and 
are counting on the West's cultural difficulties to build their lead (Mann 2003). Their 
innovation system is underpinned by a relaxed ethical stance, with many suggesting 
such advantage will ensure they become a world leader in biotechnologies (Mann 2003; 
Hsiao 2004). China's innovation structure has a number of obstacles to this, including 
the reliability of their patent system, reliance of their clinical trials, and the recognition of 
their scientists (OECDb 2004). 
The essence of this research study is to understand which aspects of the National 
System of Innovation in the UK and China are of advantage to the advance of stem cell 
science and how these compare with each other. The next chapter will set out the 
methodological approach used to explore the research question. 
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DBA 
Chapter Three 
Methodology 
Introduction 
The research question is: how will therapeutic cloning be influenced by the respective 
National Systems of Innovation in China and the UK using diabetes as a model? 
The Hypothesis is that the National Innovation Systems in China and the UK will 
determine the pace of scientific advance and the translation of therapeutic cloning into a 
clinical service. The null hypothesis is that the innovation systems of China and the UK 
will not adversely impact the advance of therapeutic cloning. 
The questions to be answered are: 
• What are the strengths and weaknesses of the National Innovations Systems in 
the UK and China as they relate to therapeutic cloning? 
• How does the National Systems of Innovations in the UK and China influence the 
translation of stem cell science into the clinical treatment? 
• Because of its National System of Innovation, which country will be first to 
develop a stem cell cure for diabetes? 
Justification: Policy and Rationale 
Economic performance is widely accepted to be more complex than historic analysis, 
which focused on labour and capital (HM Treasury 2000). The economist Friedrich List 
(1841) is said to have been first to make the link between the impacts of technologies on 
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economic performance. He was critical of classical economists and wrote widely about 
the influence of science in national growth (Landes 1969 Plummer 2004). Joseph 
Schumpeter (1883-1953) held similar views, arguing that the Marxist position of 
capitalism ignored the influence of technological competition, which he believed drives 
economic advancement (Tidd 2001). Schumpeter went on to define these components 
as innovation, which he termed as a new combination of existing resources, pointing to 
case studies as the methodology for studying these (Tidd et al 2001). Robert Slow 
advanced the study of innovation, demonstrating that 87% of GDP growth in the US is 
attributed to technological change. Innovation, he showed, was the embodiment of 
knowledge into a physical form of technology (Feldman 2004), with sustainable 
economic growth shown to rely on this (Branscomb Auerswald 2002). 
Stem Cell science is one area of biotechnology said to make the largest contribution to 
economic growth and therefore impact on innovation (European Commission 2001; 
OECDa 2004). This sector includes genetically modified food, advances in new 
knowledge-based industries, and a contribution to world health. Genetic science is one 
aspect, and it is the part on which this research is focused. This is distinguished from all 
other technologies by its potential to revolutionise the treatment and management of 
human disease (Spink el at 2004). It offers the potential for personalised medication to 
create new therapies to cure disease and, in time, to re-grow or repair organs (BBC 
2007). It is a competitive and controversial area of science, made more so by the recent 
use of human embryos in its research techniques. In the UK this became legal in 2004, 
raising fresh debate to concerns of eugenics, abuse of knowledge, and societal division. 
China began this work in 1999 with no such concern (Yank 2004). The difference in the 
Western world is based around concerns of biological warfare, the destruction of human 
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life and the unknown consequence for future generations caused by manipulated 
mutations of cell structures. There is no way of knowing how a mutated cell will behave 
in future generations, and therefore no absolute guarantee of safety. 
In the UK, many of these concerns are speculative since the majority of therapeutic 
cloning is limited to animal models. There are currently two research teams working on 
human embryos under licence at the Newcastle Life Sciences and Kings College 
London. Whilst in China, the use of human embryos, primates and aborted foetuses are 
widely used in stem cell research, which advanced to human trials commencing in 
February 2005. Cancer is expected to be the first clinical area to benefit from stem cell 
research; indeed China is reported to have announced success in the world's first cure 
for solid tumours in 2004 using gene therapy (Pearson Jia Kandachi 2004). Diabetes, in 
comparison, is a complex disease, positioned as a research priority due to its 
international prevalence and unprecedented growth rates evidenced over the last 
decade. Prevalence has doubled in the last eight years, and is predicted to affect 333m 
people by 2025. It already consumes between 2 and 15% of a country's total health 
budget depending on the interventions available, with associated economic loss put at 
five times the financial one (WHO 2002). 
The justification for this research is therefore part economic and part social. Genetic 
science affords untold economic and social advantage from the research underway for a 
stem cell cure for many common diseases, including cancer, heart disease and diabetes 
(Thomas 2006). 
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Theoretical Approach to Research 
The business problem is how the National Innovation Systems of the UK and China will 
influence the goal of securing a stem cure for diabetes. This research has an objectivist 
approach, an ontology position of realism and a positivist epistemology, requiring a 
structured theoretical approach (Burrell & Morgan 1997). These assume the world to 
be tangible, and that it may be interpreted and explained. Assumptions about the 
environment are deterministic, believing the environment itself to be involved in the 
creation of what is perceived. The research is functionalist, objective, and seeks to 
explain. It assumes the world is managed, definable, that nature works to ordered 
principles, and that it can be understood and manipulated. Indeed, the very essence of 
genetic science supports these principles as it seeks to interpret and influence the order 
of nature by controlling the mutation in cell division to selected advantage. 
This is a social research study and, as such, it comprises qualitative research methods, 
which is an umbrella term covering a range of techniques that seek to describe, code, 
translate, and provide an interpretation of meaning (Cassell 1999). Its epistemological 
and theoretical stance is interpretive and deductive, with meaning being ascribed from 
the data collected, emergent themes, and idiographic description. Methodologies include 
questionnaires, interviews, focus groups, and interpreting text. It can be distinguished 
from empirical methods in using language as its main communication and measure, 
which gives rise to a number of criticisms. Miller (1997) suggests its measures are often 
elusive, with Hawkins (2001) adding a lack of precision and definition, researcher bias 
(Frost 1992 Silverman 2002), and data production, which is less objective (McCarl 
1990). 
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Silverman identifies its separation from theory, its limited measures, and a lack of 
transference. The main advantages of qualitative research methodologies are in 
enabling a social context and its use of methods, which are inclusive and study people in 
a natural setting. With the aim of research, whether qualitative or quantitative, being 
analytical integrity, McCarl (1990) argues it is the outcomes that are important. The 
concerns can be mitigated somewhat by a number of strategies. In using interviews, 
Silverman (1993) cautions the interpretation of what is actually being said because 
language is historic, figurative, specialised, interpretive, culturally transmitted and 
encoded (Coffee 1997). Questionnaires, which May (2001) argues are imprecise, can, 
it is suggested, be strengthened by pre-testing and triangulation of data (Miller 1997). 
Silverman (2002) suggests the researcher, being aware of his position in the design of 
the study, can address the issue of bias. The importance of consistency and loss of data 
in the questions can be assisted too by pre-testing (Lowe 1993; Silverman 2002). 
Researchers can also be trained to be aware of personal bias, can use an open 
systematic approach and use different methods of data collection (Miller 1997). 
The theoretical basis in this work is the National Systems of Innovation (NSI) theory, 
chosen for two unique characteristics. The first is its relationship to historic 
understanding, where the events of the past are reviewed in order to understand the 
opportunities of the future. The second is an inherent assertion in its ontology that 
linear methods of prediction are insufficient and there needs instead to be an 
understanding of the related components (Freeman 1997; Fagerberg 2004). This 
second feature of National Systems of Innovation requires a definition of a boundary and 
identification of the important features within it. National Systems of Innovation is a 
relatively new theory based on the work of Freeman (1987) with its origins said to be 
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from new-growth theory. Its most notable feature is described by Edquist (1997) when 
he summarised its approach as being more like a series of related assumptions than an 
empirical framework within which to place research. This lack of formal structure offers 
an opportunity to shape its design and relates directly to the research question. Indeed 
the flexibility of its design is argued by many to encourage new and different innovation 
approaches, thereby affording new areas and opportunities for its use (Storper and 
Harrison 1999; Ludvall 2003; Fagerberg 2004). The challenge of this approach, for this 
research, is that all the components (including the research topic), access to data, and 
the theoretical design make new contributions to knowledge. 
Research Design 
There are a number of views in the literature directing the structure of an innovations 
study (in this case, looking at China from a UK perspective). In part, these depend on 
the area of innovation being considered and the level of its development or 
implementation. This work looks at the innovations structure at a national level for the 
UK and China, from a UK perspective, in stem cell technologies (specifically, therapeutic 
cloning), and takes a number of propositions in its design from the existing research 
material. A case study approach is to be used, as suggested by Schumpter (1934), 
underpinned by a framework to capture and explain the key relationships in the study as 
recommended by Carr (1984), Edquist (1997), Freeman (1997), Fagerberg (2004), and 
Mina et al (2004). There is no single approach to define a framework to explore 
innovation, so the literature suggests using the problem to define the boundaries. The 
literature also suggests that not all the components of the problem need to be included, 
but the boundaries and relationships within it must be defined (Fagerberg 2004). The 
validity of this approach is taken from the economic design of national innovation policy, 
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which requires these descriptions to be more than geographically delineated and to 
explain the relationship nationally constructed and the power so attached (Fagerberg 
2004). The strength of this is said to be in capturing patterns of specialisation and 
innovativeness, its weakness being its broad generalisation. 
In this work the framework is designed to capture the core factors of innovation as they 
related to the research area of therapeutic cloning. The framework also describes the 
boundaries of this work and the relationships within it. In this study the core aspects of 
the related innovation are: 
• Political Context 
• Government Legislation and Regulation 
• Research Investment 
• Intellectual Property Regulation 
• Public opinion, culture, ethics 
• Demography/morbidity and mortality history and trends 
• Current Treatments or Diabetes 
• Economic Performance 
• Research Underway/evidence 
• Current knowledge/evidence to date 
In defining the framework, the boundaries are set by the respective regulation and 
legislation for therapeutic cloning at a National level. These cover the range of 
permissible stem cell research within the UK and China and an examination of progress 
as this relates to diabetes. The financial structure will be defined by research 
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investment and the relationship with economic performance and demography, whilst the 
societal boundary will be set by public position and culture. Research evidence, historic 
economic performance, morbidity and mortality trends, workforce and culture for 
therapeutic cloning will be explored within the boundary of permissible legislation. This 
is set out in the table below, which also indicates the research methods proposed to 
collect the supporting data. 
Data Table Public Researchers 
1990-2002 Questionnaire Interviews 
Economic Performance 
GDP X 
Trade in Goods and Services X 
Inflation X 
Balance of Payments X 
Spend on Education X 
Spend on Health X 
Spend on Research X 
Political Influence 
Legislation X 
Regulation X X 
Investment Strategies x X X 
Patents X X 
Social 
Population Size X 
Prevalence and trends in diabetes X 
Treatment Regimes X 
Workforce X 
Research 
Spend on Research X X 
Research Underway X 
Evidence to-date X X 
Computer Ownership (proxy for technology) X X 
Culture 
Current Knowledge X 
Investment in research X 
Opinions on therapeutic cloning X 
Ethical Stance X X 
The structure of this table incorporates advice from Edquist (1997) to place innovation at 
the centre, as it is holistic, interdisciplinary, and enables the interdependencies and non-
linear relationships in the data to be explored. Edquist recommends an historical 
perspective, which is reflected in the economic analysis from 1990 to 2002. This 
approach reflects that recommended by Fagerberg (2004), who suggests the inclusion 
of R&D, the impact of innovation on legislation and regulation, and the relationship 
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between economic and social performance. Hollander (1965) and Fagerberg (2004) 
also recommend the inclusion of workforce, the impact of knowledge (Plummer 2004), 
and a context that is real-time (Tidd 2001). The overall unit of analysis are the national 
boundaries of the UK and China (Edquist). Tidd (2001) recommends that the process 
that puts innovation into practice is included in the study. As therapeutic cloning has not 
yet advanced to service transfer, this is taken to cover the ethical context, clinical trials 
regulation, and legislation of the actual research. Validation of this research construct 
can be taken from work led by Professor Salter in his policy study using Innovations 
Systems between the UK and China (EESCN 2007), although he started three years 
after this study began. The structure he has used for his research is similar, providing 
further validity to this approach. 
The relationship of the research design is set out diagrammatically below. This shows 
the independent variables and the main factors of innovation at a national level. These 
are the economic and social systems that set the context in each country for stem cell 
research and are moderated by the influences of a number of performance areas 
including the economy, investment strategies, and societal boundaries of acceptance. 
The outputs in the final column are the influence on economic performance and its 
achievements in stem cell science. 
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Structure of Relationships 
Economic 
Systems 
Investment 
Strategies 
Political Systems 
Legislation 
Social Systems Prevalence of 
Diabetes 
Research 
Environment 
Permissive 
Regulation 
Culture & Ethics 
Societal Acceptance 
Economic 
Performance 
Achievements in 
Stem Cell Science 
Data Capture 
Data against this framework will be collected from three sources. The first is 
economic and demographic data for the UK and China collected between 1990 and 
2002. This includes population data, economic performance (including GDP spends on 
education), health research, and morbidity trends in the area of diabetes. These data 
sources will be used to provide trend and correlation analysis. Sources of trend data for 
China is not easily available, but this study will aim to build this profile, as the national 
economic context is an essential component of the framework of innovation for 
therapeutic cloning. This part of the work will be looking to explore the relative strengths 
and weaknesses over time of the economic structures that underpin research 
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investment and structure at a national level. This will include: 
• Research spend and trends 
• Patents registration and trends 
• Education spend and trends 
• Cost of health care and trends 
• Clinical staff and trends 
• Economic performance in terms of trade, balance of payments, and inflation 
• Historic and predicted levels of diabetes 
• Morbidity trends for diabetes 
• Population growth 
(A summary of the data table is set out in appendix D) 
The second area of data capture is to survey the general population to gain data on 
those areas of the research question where there is no existing data source. The focus 
for this view is within the UK population, as access to people in China was unfortunately 
unsuccessful. This approach covers many of the softer interpretations of the public's 
current knowledge of genetics and their opinions on what they believe to be acceptable 
and unacceptable in stem cell research. The population groups will be distinguished by 
ethnic origins, gender, age, employment status, and whether they or a family member 
are diabetic. The questions cover the areas of government investment in research, 
views about access to new stem cell technologies and questions to gain an ethical 
context to their opinion. The questionnaire will be piloted first on a sample of thirty to 
check the validity of the questions. The full study aims to get two hundred returned 
questionnaires. A copy of the questionnaires is attached as Appendix A with a summary 
of the areas it covers set out below: 
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Classification Questions 
Gender 
Religious beliefs 
Diabetic status 
Age 
Occupation 
Context: Questions (10) 
Views & Knowledge on: 
Cloning 
Stem Cell Research 
Chinese Research 
Human Cloning 
Licensing 
Cure for Cancer 
Boundary Questions (4) 
Gov spending on Research 
and stem cell research 
Potential Impact Questions (3) 
Impact of genetics 
Affording new technologies 
Knowledge Created Questions (2) 
Views on investment and embryo research 
Relationship to Existing Services (1) 
Replacing existing therapies 
Risks (3) 
Timeline 
Incentive Questions (5) 
Motivation in UK 
Use of Internet 
Ethical Questions (4) 
Views on embryo research 
Pace of change and ethical stance of Access on the NHS 
population 
Becoming available abroad first Views on genetic tests 
Going abroad for treatment 
Concerns about treatment abroad 
Acceptance Questions (2) 
Views of potential outcomes 
Who will lead discovery 
Legislative Questions (4) 
Discoveries and access to technologies 
The target population for the questionnaire is the general population, including sixth form 
college students, university students, a stakeholder group for diabetes, magistrates, gym 
members, office workers, clinicians, the unemployed or retired, and senior managers. 
The groups selected aim to cover a spectrum of the population between the ages of 16 
and 70 within definable population groups. Magistrates are, for example, considered to 
be a fair cross-representation of the adult population. The stakeholder reference group 
for diabetes is representative on the disease area. Gym members are generally 
considered to be the fittest society members, and each of the other groups offer an 
alternative view for three employment areas. 
The third component of this work involves researching all the current biotech companies 
involved with stem cell research in the UK and China, identifying those specifically 
involved in diabetic research. A similar approach will be taken in researching the 
institutional arrangements in China. The aim is to access views of researchers in the 
political, research, and ethical environment in which they work. A detailed search across 
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published literature, research institutions, universities, and commerce will be undertaken 
to build a directory of these, including contacts and emails. Contact will be made 
electronically with the aim of collecting idiographic responses in the following areas: 
• The advantages and disadvantages of their current research environment 
• Views of their legislative framework, including patents 
• Will China lead in producing a cure for diabetes? 
• Is the ethical stance of the East a substantial advantage? 
• Will people go abroad for treatment if it is not available in the UK? 
Statistical Analysis of Data 
The data collected from these three approaches will be both qualitative and quantitative. 
The questionnaire will be translated into numerical values depending on the answers 
and analysed to show themes and their relationships to variables such as age, gender 
and prior genetic condition. A Likart scale of 5 will be used and the questions closed. 
The pilot sample will be reused in the final questionnaire to provide a reliability test and 
compare validity. T-tests will be used to explore differences between genders. The 
questions will be closed. 
The hypothesis to be tested in the statistical data is: 
• The UK is stronger in the core economic components of its National System of 
Innovation covering GDP, trade, inflation, spend on research, health and 
education, and balance of payment. 
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• The National System of Innovation does not influence the advance of stem cell 
science 
• UK will be first to produce a stem cell cure for diabetes 
The data will be checked initially for distribution and normality. Cronbach's co-efficient 
alpha will be used to test consistency in the measurements between items. Pearson 
Correlation will be used to measure the relationship between the variables and measure 
the strength of relationship as one variable increases. Multiple regression will be used 
to test the size and strength of the mean in comparing the data for the UK and China 
against each other with an Independent T-test and Levene's test used to measure equity 
of variance. 
The third area of this analysis gathers opinion from research and policy leaders in the 
field of stem cell science about the national boundaries , their research work, views on 
legislation including patents, and ultimately their views on the respective opportunities 
between the UK and China in therapeutic cloning. 
Limits of Research 
There are many limits and risks associated with this research. This area of research is 
new and there is no obvious existing research study with which to compare this. 
Collecting economic data over time to assess its innovation structure is not 
straightforward, as data of the range required is not readily available for China. Data 
since 2002 is, however, easier to find since China joined the World Health Organisation. 
In China there is very little certification of death, therefore statistics for the prevalence 
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and mortality from diabetes are not available (Yang et al 2005). The difficulties of 
economic data are also evident in the policy work of Professor Salter (East of England 
2007). There are a number of research papers that have estimated prevalence rates, 
and these will be used to estimate numbers (Li et al 2005). Economic data for China on 
a trend basis is not routinely available, but through the search of databases and 
research papers, the figures will be collected and pieced together. The economic data 
will be translated into US$ to enable comparison. 
The second challenge will be succeeding in getting the questionnaire completed, as 
previous research of this nature has shown a reluctance of people to provide this 
information (Nuffield Council 2003). Access to the Chinese population has been 
unsuccessful despite two attempts. Contacting Chinese researchers that are not based 
in the UK has also been made more difficult by Korean fraud and the reluctance now of 
many Eastern scientists to discuss their work. Other limits include the focus area of 
innovation being therapeutic cloning, which is in the research stage itself. This work is 
further limited in its focus on diabetes. Stem Cell research is underway in a number of 
other clinical areas including heart disease, Parkinson's, Osteoporosis and cancer. 
Although success is predicted in some of these areas before diabetes, it has been 
selected, as explained earlier, as its prevalence rates make it a greater threat to human 
health now than heart disease (BHFS 2004). 
The research design is constructed using existing research in NSI theory. Using a case 
study model, the data is to be collected from three sources to form a picture of the 
national factors of innovation between the UK and China in the area of therapeutic 
cloning research. These data sources are new, but together they provide the detail at a 
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national level of the major factors influencing therapeutic cloning research. The 
justification of the core areas has been taken from the theory, and it covers the political 
and economic structures, social, cultural and existing research (Edquist 1997; Freeman 
1997; Fagerberg 2004). 
This research is planed (planned?) in three parts. Together they explore the influence of 
the National Innovations Systems in the UK and China on therapeutic cloning. The 
hypothesis is that National Innovation Systems in China and the UK will determine the 
pace of scientific advance and the translation of therapeutic cloning into a clinical service 
in the area of diabetes. The null hypothesis is that the innovation systems of China and 
the UK will not have an impact on the outcome of therapeutic cloning in the clinical area 
of diabetes. 
Part One: Public Questionnaire 
The questionnaire was piloted on a sample of 70 people, with 34 providing a return. The 
pilot covered 11 males and 23 females within an age range of 14 to 77. The mean age 
was 33. It was constructed to take ten minutes to complete, and to capture opinion and 
knowledge at a particular moment in time. The pilot was used to test the validity of the 
questions, identify outliers in the analysis, and gain an estimate of the likely level of 
response, as advised in the qualitative literature (Miller 1997 May 2001 Silverman 2002). 
The sample was constructed from students and their families at Essex University. In 
returning the questionnaire, some people indicated their discomfort with the content, 
which fits with the experience of other social researchers in genetics (Nuffield Trust 
2002). 
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The results were tested in a number of ways to check both the validity of the questions 
and the ability of the data collected to answer the research question. Reliability analysis 
showed all minimum and maximum values to be within an expected range for the 39 
questions and six categorical questions around gender, occupation, age, health and 
nationality. Preliminary analysis was used to describe the characteristics of the data, as 
well as to check variables for violation, frequency, descriptive and explore. Descriptive 
analysis was used to review the range, mean and standard deviation and explore were 
used to assess normality. All the questions in the pilot scored above 0.05, confirming 
normality in their Kolmogorov-Sminov score. The Cronbach's alpha coefficient score 
was 0.8595; confirming reliability of the scale for the questions and that none of them 
violated the reliability test, confirming good internal consistency and validity (Pavot, 
Diener, Colvin and Sandvik 1991). 
Correlation was used to test the value and contributed to the overall score of each 
question, with all found to have a value over 0.3, confirming consistency of the questions 
within the scale. Finally, histograms were used, as recommended by Gravelter and 
Wallnow (2000), to explore the distribution of the responses. These are set out in 
Appendix B. From these it can be seen that the pilot cohort believed strongly that Dolly 
was the first cloned creature, that human cloning was illegal, and uncertainty about 
whether or not the UK led the world in stem cell science. They did believe the UK 
government spent enough on research, had a strong legislative framework, and that 
ethical concern will slow progress. 
Although the pilot is too small to draw any substantive conclusions, it did show 
consensus that stem cell therapies will be available in the UK within ten years for 
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diabetes and that such therapies would be available abroad first. There was agreement 
that embryo research would lead to cures for human disease that genetic discoveries 
should be available on the Internet, that finding a cure for diabetes is worth the financial 
investment, but that ethical concerns in the UK will slow progress. There was no 
consensus on whether there should be more human embryo centres in the UK or if 
genetic discoveries and tests should be available on the Internet. Neither was there 
agreement on whether the creation of embryos for research in order to find a cure for 
diabetes was worthwhile or essential. The pilot cohort had the widest variation in 
answering whether they would go abroad for stem cell treatment not available in the UK. 
Questionnaire 
The final questionnaire was revised following the pilot to include categorical data on 
occupation, origin, religious beliefs, and genetic diseases other than diabetes. A 
number of questions were also rephrased. The target population for the final 
questionnaire includes sixth form college students, university students, a stakeholder 
group for diabetes, magistrates, gym members, office workers, clinicians, unemployed, 
retired professionals, and non-professionals. This aims to cover a spectrum of the 
population aged 16 to 70 within definable population groups. An application was made 
to the NHS North Essex Ethics Committee to allow the inclusion of NHS staff and 
clinicians in this study, but this was rejected on the basis that this study was not 
considered suitably focused on the NHS. 
From a distribution of 400, 157 questionnaires were returned. The age ranged from 17 
to78 with a mean of 41.66. Every age between 16 and 70 was represented. Of these, 
eleven people are diabetic and nine indicated they had another genetic illness. Forty-
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nine said they have a family member who is diabetic, and thirty-four that a family 
member had another genetic illness. The population who responded were evenly split in 
terms of religious beliefs, with 73 indicating they had such beliefs. In terms of 
occupation, there are 22 students, 10 clinicians, 48 other professionals, 34 non-
professionals, and 43 others. The majority of responses are from people of British 
nationality (144), with two Americans, four Europeans and seven others. 
Without taking these categorisations into account, the basic data for the entire 
population shows: 
• Half of the people believe Dolly was the first animal cloned 
• More than half are not sure if the UK leads the world in stem cell research or 
whether China was first to clone a fish 
• Almost 80% know human cloning is illegal in the UK but almost 60% were not 
sure if it was legal in China, with 50% believing therapeutic cloning to be illegal in 
the UK. Almost 70% knew human embryo research is legal in the UK, suggesting 
an issue of terminology 
• Nearly 70% were not sure if the UK had the world's first licence for therapeutic 
cloning, although 49.4% said the UK is highly motivated in new innovations 
• Over 60% did not believe that China has produced a gene therapy cure for solid 
cancer tumours and 73% do not believe China will lead a cure for diabetes 
• 75.8% agree that genetic advances will cure existing diseases, but only 48.7 that 
it will find a cure for diabetes, with 65.4% saying the cure for diabetes will be 
found in the UK and 14.8% saying China. 32.7% believe such advances will not 
be available on the NHS 
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• 60.2% do not think the UK government spends enough on research, 48.7% 
believing it spends less than other countries, although 34.4% think the amount 
spent has increased in recent years. 57.1% say the UK needs to spend more on 
stem cell research 
• 53.2% say the UK has a strong legislative framework for stem cells but that more 
centres should be licensed 
• 69.9% say genetic discoveries should be accessible over the internet but only 
29.1% said they would use the internet in this way 
• 43.6% agree that the creation of human embryos for research is worthwhile to 
cure diabetes, increasing to 63.2% who believe such advances will be available 
abroad first 
• 47.4% had no opinion on whether such potential cures would reduce the 
availability of existing therapies 
• 58.3% had no view on whether such advances would happen in the next ten 
years, with 29.5% believing a cure for diabetes would be found within this time 
• 70.05% of people said they would go abroad for treatment that was not available 
in the UK, although 35.3% said they would have some concerns about this 
approach 
• 56.5% agree human embryo research is essential to finding cures for existing 
diseases, but only 28.2% believe these are the views of the UK population 
• 87.5% believe the ethical concerns in the UK will slow progress 
• 52.3% support the use of patents as essential to this area of science 
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Summary of Responses 
Q u e s t i o n s T r u e F a l s e Not S u r e 
Dolly the sheep was the first animal cloned 49 31.8 19.1 
The UK lead the world in stem cell research 17.8 28.7 53.5 
China cloned a fish 30 years before Dolly 21 19.7 59.2 
Human cloning is illegal in the UK 79.6 10.2 0.6 
Human Cloning is legal in China 19.1 22.3 58.6 
The UK has the world's first licence for therapeutic cloning 15.9 15.3 68.2 
China has produced a gene therapy cure for cancer 9.6 28 62.4 
China will lead the world in producing a cure for diabetes 13.5 12.8 73.1 
Therapeutic cloning is legal in the UK 28.2 22.4 48.7 
Human embryo research is legal in the UK under licence 67.9 9 18.6 
Strongly No Strongly 
Agree Agree Opinion Disagree Disagree 
The UK government spends enough on research 3.2 12.8 23.7 44.2 16 
UK spend on research has increased in recent years 3.8 30.6 41 21.8 2.6 
UK government spends as much as other countries 3.2 12.8 35.3 44.2 4.5 
UK government needs to spend more on stem cell 12.2 44.9 33.3 9.6 0 
UK has a strong legislative framework for stem cell 8.3 44.9 32.7 13.5 0.6 
More centres (should?)be allowed to carry out human embryo 9.6 44.9 20.5 21.8 3.2 
Genetic discoveries should be available on the internet 19.9 50 10.3 15.4 4.5 
Human embryo research will cure existing disease 15.4 60.3 21.2 3.2 0 
Human embryo research will cure diabetes 5.8 42.9 46.8 4.5 0 
A potential cure for diabetes will?not be affordable on the NHS 6.4 32.7 39.1 19.2 2.6 
Curing diabetes is worth creating embryos 12.8 43.6 21.2 17.9 4.5 
A stem cell cure would replace existing diabetic therapies 7.1 31.4 47.4 12.8 1.3 
A stem cell cure for diabetes will be available in 10 years 1.3 28.2 58.3 11.5 0.5 
Stem cell therapy for diabetes will not be available on NHS 3.8 37.2 32.1 25.6 1.3 
Stem cell therapies will be available abroad before UK 11 63.2 23.9 1.9 0 
The UK is highly motivated to find new innovations 5.8 49.4 22.4 20.5 1.0 
I use the internet to find out about health abroad 5.2 23.9 20.6 38.1 12.3 
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i would buy genetic tests using the internet 2.6 19.9 14.1 41 22.4 
1 would go abroad for treatments not available in the UK 15.4 55.1 14.1 14.1 1.3 
No concerns accessing stem cells treatment abroad 7.1 28.2 18.6 37.8 8.3 
Human embryo research essential to cure disease 10.3 46.2 24.4 16.7 2.6 
UK population supports human embryo research 1.9 26.3 32.7 35.3 3.8 
Ethical concerns will slow progress in the UK 9.6 67.9 12.2 9.6 0.6 
Patent registration is essential to support discovery 11 41.3 33.5 12.9 1.3 
Human embryo research will find a cure for diabetes 4.5 44.2 45.5 5.8 0 
The UK will be first to cure diabetes 6.4 59 32.7 1.9 0 
China will be the first country to cure diabetes 2.6 12.2 75 10.3 0 
The answers for people that are diabetic show that most did not know if therapeutic 
cloning is legal in the UK, and that most agree that there should be more centres 
undertaking embryo research and that genetic discoveries need to be available on the 
internet. They didn't think the UK government spends enough on research or that it 
spends as much as other countries and they had no opinion about whether such spend 
has increased. They did believe more money needs to be spent on stem cell research 
and that such research is essential. They are not sure if therapeutic cloning will cure 
diabetes or if a cure will be found within the next ten years, and, if so, whether such a 
cure would be available on the NHS. They believe ethical concerns in the UK will slow 
progress, although they agree that there is strong motivation to find new innovations. If, 
however, a cure were found, they believe it would be available abroad first but that they 
would not be willing to travel to access this. Indeed they would have concerns about 
therapeutic cloning abroad. They would not use the Internet to find out about this or any 
genetic tests that may become available. They agree patents are necessary in this 
area of science and have no view on whether China will lead in a cure for diabetes. 
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Analysis of Variance between Categories 
One-way Anova was used to establish if any of the answers between the various 
categories showed a statistically significant variance (with regards to age, status, 
gender, occupation and health). 
Diabetes 
Homogeneity of variance is above 0.05 and therefore does not violate the required 
assumptions for this test. For the people with diabetes, variance of mean scores was 
found in the following questions: 
• When a stem cell cure is available for diabetes it will not be available on the N H S (0.012) 
• T h e first country to cure diabetes will be China (0.04) 
• Embryo stem cell research will find a cure for diabetes 
• Finding a cure for diabetes is worth the creation of human embryos for research 
The test of variance was then applied to those with a family member with diabetes. This 
found variance of mean in the following questions: 
• The amount the UK government spends on research has increased in recent years (0.036) 
• Human embryo research in time will produce a cure for diabetes (0.025) 
• A stem cell cure would replace existing therapy for diabetes (0.025) 
• Embryo stem cell research will find a cure for diabetes (0.002) 
These results show that people with diabetes are far more optimistic about the 
leadership of China in finding a cure for diabetes through therapeutic cloning than the 
rest of the population group, who strongly believe it will be the UK. Both people with 
diabetes and those who have a family member living with the disease believe more 
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strongly than the rest that human embryo stem cell research will produce a cure for 
diabetes. Those with diabetes also believe more strongly that the creation of embryos 
for such research is worthwhile. They do not believe the potential cure will be available 
in the UK. 
Variance of mean was then carried out on the results for people with other genetic 
illnesses. The only difference statistically shown in this category was that they believed 
more strongly than the main cohort that the UK spends as much on research as other 
countries (0.019). Interestingly, when this was carried out on those with a family 
member with a genetic illness other than diabetes, they believe more strongly (like those 
with diabetes) that China will be first to find a stem cell cure for diabetes. Variance of 
mean test was applied to those with a religious belief where two questions were found to 
be outliers to the main population. These were that human embryo research is legal in 
the UK, suggesting that people with religious beliefs know less about what is legal in 
terms of embryo research. The second area related to the use of patents to protect 
discoveries, suggesting this group is less supportive of the patenting of such material. 
Variance was then tested by occupation. In this group there were: 
• Student=22 
• Clinical=10 
• Other professional=48 
• Non-professional=34 
• Other= 43 
The variation in occupation was knowing whether human embryo cloning is illegal in the 
UK (0.032) and whether stem cell therapies will be available in the clinical area of 
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diabetes within ten years (0.036). In terms of nationality, the only question which had a 
variance was whether stem cell therapies would be available abroad before becoming 
available in the UK (0.013). 
Half of people responding said the UK has a strong legislative framework for therapeutic 
cloning but more centres should be licensed to undertake this research. Nearly two 
thirds do not think the UK government spends enough on research and needs to spend 
more on stem cell research. Half believe other countries spend more, with only one third 
saying the UK had increased spend in recent years. Just over half of people believed the 
patenting of discoveries in this area were necessary. In terms of current knowledge 
about genetics, half believed Dolly was the first animal cloned, but over half were not 
sure whether China had cloned a fish. Most did not think China had cured solid cancer 
tumours or that it would find a cure for diabetes. Most people, however, knew human 
cloning was illegal in the UK but were not sure if it was permitted in China. Occupation 
was shown to make a statistical variation in knowledge about stem cell legislation. 
Just over half of the respondents believe human embryo research in the UK is essential 
to finding cures for existing diseases, but less than a third believe this to be the universal 
view of the UK population. Two-thirds say genetic tests should be available over the 
Internet, but less than one third said they would access genetic tests via the Internet. 
Over 70% of people said they would go abroad for stem cell treatments that were not 
available in the UK, although half of these said they would have some concern in doing 
this. Only one third of people believe there will be a cure for diabetes in the next ten 
years, with almost 90% of people saying the ethical concerns in the UK will slow 
progress. Only 43% of people in the UK believe the creation of human embryos for 
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research is worthwhile. However, people with diabetes or those with family members 
with other genetic illnesses do believe China will lead the world in advancing a cure. 
Relating these findings to the factors of innovations, they show the political structure 
covering legislation and regulation in the UK to be strong, although China's systems are 
considered by the UK population to be less so. There is support for the patent system in 
this area, but people with religious beliefs are less supportive. Investment strategies for 
stem cell research are thought to be weak compared to those of other countries with 
more resources for stem cell work, and these strategies are said to be needed in the UK. 
Only half of those surveyed support the use of human embryos in therapeutic cloning 
research. Only 15% believe China will lead the world in curing diabetes, although 
people with diabetes or with a family member with other genetic illnesses are shown 
statistically to believe that China will be successful. 
Part Two: Economic Analysis 
Introduction 
This second part of the analysis involves a comparison of the economic performance of 
the National Innovation System between the UK and China. This work is measured 
against data collected for the UK and China on economic performance, workforce 
trends, health spend, prevalence of diabetes, and computer ownership, constructed in a 
time series from 1990 to 2002. These factors form the economic influence to the 
development of therapeutic cloning at a national level. The data is also transposed into 
a categorical form between the UK and China to enable additional comparison. The 
aim of this section is to explore the first part of the research question and provide an 
understanding of the relative strengths of the economic aspect of the National Innovation 
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Systems in the UK and China. 
The data is constructed using SPSS for 1990 to 2002 from a search of a range of 
literature and database sites across the UK and China. Two areas where trend data 
could not be found were the cost of treating diabetes in both countries and patent 
registrations in China for some dates. Data on diabetes has only recently been 
attributed in this way in the UK and, in China, where treatment is limited for many, it has 
not been collected. The second area was for patent registrations between 1990 and 
1995 in China. The statistical tests take account of missing data and treatment costs 
were excluded from the analysis. All the financial data were transposed to US dollars 
(the values are included in the table) to enable comparison between the UK and China. 
Inc luded in S p r e a d s h e e t 
• Year 
• Population 
• Number with diabetes 
• Percent of Population with diabetes 
• Cost of diabetes (only 2002 data) 
• G D P growth a s a percent 
• Total N H S Spend 
• G D P spend on health 
• Health spend per head of population 
• G D P per head of population 
• Total value of G D P in U S $ 
• Percent of heath spend that is private and from government 
• Total health spend in U S $ 
• Spend on research a s % of G D P 
• Total value of research spend in U S $ 
• Number of doctors 
• Number of nurses 
• Number of researchers 
• Number of patent registrations 
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• Balance of payments in U S $ 
• Change in trade position year on year 
• Total value of trade 
• Inflation 
• Spend on education as % of G D P and total value in U S $ 
• Ownership of computers per 1000 population 
• Import and export values a s % of G D P 
Preliminary Analysis 
The data were analysed to check the symmetry of its distribution (skewness), 
peakedness (kurtosis), and to check normality in its distribution. The trend data ranged 
between seven samples in the case of Chinese patents to twenty samples in relation to 
population and trend. These numbers are small, and therefore kurtosis is expected to 
be flat. High kurtosis can result in an underestimate of variance (Tabachnick and Fidel 
1996). For all the indicators, the Kolmogovor-Smirov levels are over 0.005, indicating 
normal distribution. Explore was then used to review the probability plots for the data. 
The data is plotted against a line of normal distribution, which is for all the data except 
the number of doctors and nurses in the UK. The reasons for this appears to be two 
long periods of very slow growth followed by a period of significant increase, most 
notably in nurses. The preliminary analysis is set out in Appendices G and H. 
Reliability Analysis (ALPHA) was used to check the reliability of the scale to ensure the 
same underlying construct is being measured. The Cronbach's alpha coefficient score -
when taking the data for the UK and China for populations, total spends on research and 
education, numbers with diabetes and total spend on health - is 0.8353. As this is over 
0.7, the internal consistency is confirmed. The alpha value when reviewing the UK data 
for total population, numbers with diabetes, GDP, NHS spend, total spend on health, 
percentage of health spend by government, numbers of doctors and nurses, patent 
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registration, balance of payment, total trade, inflation, import, exports, spend on 
education, and total spend on research is 0.7636, again confirming consistency in the 
data. For China, corresponding measures show the alpha score for total population, the 
numbers with diabetes, health spend, total spend on research and education, total GDP, 
exports and imports, doctors nurses, inflation, and balance of payments to be 0.7256. 
These tests collectively confirm the dataset to be normal and reliable. 
Graphs were used to investigate the size and trend shapes for the economic factors on 
innovation in the UK and China as set out in Appendix D. This show: 
• China has a declining population compared to growth in the UK. 
• Diabetes has increased rapidly in both countries but more notably in China 
• Health spend has increased in both countries most significantly since 1996 in 
China 
• Private health spend has increased four-fold in China and remained consistent in 
the UK 
• Total value of GDP is now equal in both countries 
• Total spend on research has increased five-fold in China to about one-third that of 
the UK 
• Spend on research as a % of GDP has risen to 1.5% in China and 1.9% in the UK 
• GDP growth has been around 8% in China and between -2 to 4% in the UK 
• Doctor numbers, have increased in China while the number of nurses has 
decreased 
• Doctor numbers have been constant in the UK with a substantial increase in 
nurses 
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• BofP has improved substantially in China and remains negative in the UK 
• Inflation in both countries has been volatile, with China reaching 24% in the mid 
90's and reducing this down to 2%. The UK has gone from 9% in 1990 to 3.5% in 
2004 
• GDP spend on education has increased in China and both are now around 5% 
• Total value of GDP has risen rapidly but most significantly in China 
• Ownership of Computers has risen ten-fold in China to be half that of the UK 
For China, these indicate a strong economic context for stem cell research, having low 
inflation, strong GDP growth of 8% annually, a positive balance of payment, an increase 
in education to 5% of GDP, and research investment, which has doubled against GDP in 
the last 12 years. These translate to growth in available research funds and a 
prosperous environment to enable stem cell research. The economic framework for the 
UK shows spend on education is equal to that in China, as is the total value of GDP. 
Total research spends as a proportion of GDP has fallen from 2.24% in 1990 to 1.98 in 
2003. Balance of payments is negative and GDP growth varied between 2% and 4%. 
Computer ownership, taken as a proxy for technology, is still twice that for China despite 
their ten-fold increase. 
The population of China is seen to be slowing by the shape of the curve in the graph. 
The prevalence of diabetes has doubled in both countries, with over 40 million people 
now affected in China. Spend on health has increased in China following a massive fall 
in the early 1990's culminating in a drop to only 2.7% of GDP in 1996. The increase in 
the following years is due to private investment, resulting in only 41% of spend now 
provided by the government. UK health spend, in contrast, has seen a massive 
increase in government contribution from 6% of GDP in 1990 to 7.7% in 2003, with a 
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projection of 9.2% to be achieved by 2010. Total spend on research in China has 
increased four-fold in terms of actual spend and doubled as a percent of GDP. The UK 
still spends more on research than China, but the proportion of GDP is increasing rapidly 
(though this remains 0.5%, below that of the UK). GDP performance over the time 
period has seen the most marked and consistent change in China where growth has 
averaged 8% compared to 2.5% in the UK. 
Total GDP in the UK and China 
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In relation to workforce, the number of doctors has grown by 35.7% in the UK compared 
to 18.3% in China, and 5.9% for nurses compared to 29.25% in the UK. Chinese 
balance of payments and trade in goods and services have increased rapidly since the 
mid 1990's. 
The UK has seen major increases in both these indicators, but overall performance in 
each is negatively balanced. Inflation is shown to have been most volatile in China, 
reducing from 24.10% in 1994 to 0.4% in 2001. The UK, whilst more stable, had 4.9% 
inflation in 2002. China has matched the UK on proportion of GDP spent on education, 
with the actual amount in US$ showing a four-fold increase over the period. The UK, 
however, spends 40% more on education in actual expenditure. Ownership of 
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computers is shown to have increased ten times over in China to just over half of that 
per 1000 people in the UK. 
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Innovation and Prevalence of Diabetes 
As set out in Chapter One, the numbers of people who are diabetic has more than 
doubled in both the UK and China over the last ten years, making it important to 
understand its relationship to innovation in this study. Although the treatment regimes 
are different leading to a differential cost base, the rapid increase in both the UK and 
China presents both social and economic challenge. This part of the analysis is aimed 
at establishing any statistical relationships between those factors of innovation being 
studied and the prevalence of the disease. This relates to the third part of the research 
question involving who is likely to lead in producing a stem cell cure for diabetes. It 
might provide an indication of the internal motive of a country to tackle this disease. 
The relationship between GDP per person and the numbers of people with diabetes was 
investigated using Pearson-moment correlation coefficient. Preliminary analysis was 
performed to ensure no violation of the assumptions of normality, linearity, and 
Gail Newmarch 115 
DBA Final November 2008 
homoscedasticity. For China this shows a strong positive correlation between the two 
variables (r=.96, n=15), with the numbers of people with diabetes increasing in line with 
wealth, as measured through GPD per person. The UK position is almost identical at 
(r.=97, n=15). The relationship between spends on research and the prevalence of 
diabetes was investigated using Pearson-moment correlation coefficient. Preliminary 
analysis was performed to ensure no violation of the assumptions of normality, linearity, 
and homoscedasticity. For China and the UK this shows a very strong positive 
correlation between the two variables (r=.95, n=15 for China and r=.95 for the UK), 
again suggesting the number of people with diabetes increasing in line with increased 
investment in research. 
The co-efficient was used to test whether the strength in relationship is real or a function 
error. The co-efficient of determination, which measures the variation between 
variables, was 90% for China and 88% for the UK, confirming the relationship. The 
relationship between spends on education and prevalence of diabetes produced less 
clear results between the two countries. For China the Pearson moment correlation 
coefficient was r=.96, n=15, suggesting increases were also related to rises in 
education. This is also supported by the co-efficient of determination results, which are 
96% for China and 81% for the UK. These results confirm there is a statistical 
relationship between increased national wealth and investment in research and 
diabetes, but it does not exclude the possibility of influences outside the calculation. 
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Innovation and the prevalence of diabetes in China - Regression 
The impact of the factors of innovation in China on the prevalence of diabetes is shown 
to be ownership of computers, followed by education, then inflation. None were shown 
in this test to make a statistically significant contribution. 
Innovation Factors Correlation Collinearity Standardised Significance 
Tolerance co-efficient of contribution 
Total spend education 0.985 0.001 -1.182 no value 
Total spend research 0.959 0.003 -0.137 no value 
Total GDP 0.994 0.001 no value no value 
Computer/1000 pop 0.977 0.001 2.048 no value 
Inflation -0.894 0.052 -0.449 no value 
Patent Registrations 0.924 0.012 -0.114 no value 
When the test is carried out for just GDP this is shown to make a statistically significant 
contribution to the prevalence of diabetes in China. 
When all the economic factors of innovation are used in the T-test calculation, 
education, GDP performance, medical workforce and ownership of computers are all 
found to have a relationship to prevalence in diabetes. Nursing workforce and inflation 
are shown to make a statistically significant contribution to the prevalence of diabetes in 
China. 
UK - Multiple regression analysis was used to compare the factors of innovation and 
supports the earlier findings using correlation, again showing for the UK the GDP 
performance gives the greatest indication of prevalence in diabetes followed by 
ownership of computers, inflation, then education. None of the contributions are 
statistically significant. 
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Innovation and Prevalence of Diabetes in the UK 
Innovation Factors Correlation Collinearity Standardised Significance 
Tolerance co-efficient of contribution 
Total spend education 0.902 0.049 0.181 0.747 
Total spend research 0.954 0.038 0.062 0.9227 
Total GDP 0.976 0.004 0.885 0.641 
Computer/1000 pop 0.947 0.004 -0.393 0.850 
Inflation -0.880 0.050 -0.304 0.596 
Patent Registrations -0.427 0.272 0.009 0.969 
When this test is repeated for only GDP contribution, it is shown to make a statistically 
significant contribution to the prevalence of diabetes in the UK. When the multiple 
regression calculation is repeated using all the economic factors of innovation, total 
spend on research, followed by total trade and balance of payments, are shown to make 
the greatest contribution to predicting prevalence in diabetes for the UK. None of the 
variables are shown to make a statistically significant contribution. 
Summary - Correlation provides an indication that there is a relationship between two 
variables but cannot indicate that one variable causes the other. This analysis shows 
for both the UK and China the prevalence of diabetes is closely related to those 
innovation factors that indicate prosperity and growth. When using correlation it is GDP 
for the UK that offers the best indication of prevalence in diabetes, but for China it is the 
number of doctors. This might be explained by China's doctor-led health structure 
(WHO 2002). This point is illustrated using multivariate analysis of variance MANOVA, 
where a strong positive correlation is found in the relationship between the prevalence of 
diabetes and ownership of computers. Having examined the statistical relationship 
between innovation and prevalence of diabetes, a paired sample T-tests were used to 
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compare the findings between the UK and China. In terms of prevalence levels for 
diabetes between 1990 and 2002, the probability value was shown to be less than 0.05, 
confirming that there is a statistically significant difference between the two countries. 
The mean score is higher for China with the eta squared, indicating this difference to be 
large. This result confirms that prevalence in diabetes is not equal in the two countries. 
The statistical calculations are set out in Appendix I. 
If prevalence of the disease continues to develop in line with projected wealth as 
predicted by the World Health Organisation and Atlas (2002), the drive to find ways to 
manage or even cure diabetes becomes an urgent economic and social challenge. 
This represents a major policy area for both Governments. 
Comparing Innovations between the UK and China 
This section aims to extend the comparison to cover each of the innovation factors 
between the two countries. The research question being explored relates to the relative 
strengths and weaknesses of the respective economic national systems of the UK and 
China. The hypothesis is that the economic factors of innovation are stronger in the UK. 
The statistical calculations for this section are set out in Appendix I and cover: 
• GDP 
• Trade in Goods and Services 
• Inflation 
• Balance of Payments 
• Spend on Education 
• Spend on Health 
• Spend on Research 
• Workforce 
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• Patents 
• Education 
• Technology (proxy computers) 
Total Spend on Research - T-test analysis shows statistically significant differences 
between the UK and China on research expenditure. This might reflect the historically 
low levels of investment in China or that the UK has reduced it's spend in real terms 
since the 1990's while China has increased rapidly. 
Total Spend on Research and Balance of Payment - A paired sample t-test was 
conducted to evaluate the difference in total spend on research and the balance of 
payments for the UK and China. This showed a statistically significant difference 
between research and balance of payment in the UK (probability of 0.0), but in China the 
two are statistically related (probability 0.05). This suggests there is a strong link in 
China between research investments and their improved trade performance. 
Total Spend on Education and Balance of Payments - A paired sample T-test was 
also conducted to evaluate the difference in total spend on education and the balance of 
payments for the UK and China. This showed a statistically significant difference 
between education and balance of payment in both the UK and China. 
Economic Factors of innovation and GDP performance - When testing to find which 
of the economic factors makes the greatest contribution to GDP performance in the UK, 
the standardised co-efficient is used from the T-test to indicate the size of contribution 
each of the variables makes towards GDP performance. Workforce and total spend on 
research are seen to make the largest contribution, but all the measures of significant 
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contribution are over 0.5, suggesting that none make a statistically unique contribution. 
Total spend on research in China is shown to make the largest contribution to GDP 
performance. The number of doctors, total spends on workforce, and the proportion of 
the population owning computers also contribute. Spend on research (0.029), the 
number of doctors (0.000), and computer ownership (0.002) all make a statistically 
unique contribution. 
Health spend and total Trade in Goods and Services - Health spend in the UK does 
not make a statistically significant contribution to total trade in goods and services in the 
UK. This means the impact of increased health spend is not shown to translate to 
overall performance in Trade for the UK. In China the percent of GDP spent on health 
care and the percent of that spend contributed by the government is shown to make a 
statistically significant impact on their trade in goods and services. This is likely to 
reflect the social structure, wherein 70% of their population lives in rural areas and many 
cannot afford to pay for health care. With a substantial decrease over the last decade in 
the government's contribution to health care, this result suggests that unless this is 
reviewed the impact may be evidenced in their performance on trade. 
Impact on GDP and Balance of Trade by investing in research - Investment in 
research in the UK is shown to have a statistically significant impact on total GDP, but 
not on trade in goods and services. Investing in research in China has a statistically 
significant impact on total GDP but not in trade of goods and services. 
Impact on GDP and Balance of Trade of investing in education- In the UK, 
investment in education makes a statistically significant contribution to total GPD but not 
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on trade in goods and service. Investing in education in China also makes a statistically 
significant contribution to performance in GDP but not in trade in goods and services. 
T-Tests - Economic Comparison 
T-Test analysis was used to explore the relative strengths and contribution of the 
economic factors of innovation in the UK and China. The analysis shows there is a 
statistical difference between the UK and China in terms of total research investment 
over the period from 1990 to 2002. When the test was repeated to include balance of 
payment there was a significant difference for the UK but not for China. This suggests 
China's recent improvement in its trade balance is closely related to its increase in 
spend on research. When the impact of total spends on education and balance of 
payments was tested, both countries showed significant differences. Investment in 
health care was not found to make a statistical contribution to total performance in goods 
and services in the UK. 
In China, both healths spend and the proportion contributed by its government was 
found to make a statistical contribution to total trade in goods and services. For both the 
UK and China, spend on education and spend on research were found to make a 
statistical contribution to overall GDP performance, but not to trade in goods and 
services. The data file was then transposed into a categorical one for the UK and China 
to enable comparison of the data on continuous variables between the economic factors 
of innovation. 
Comparing the Economic factors of Innovation Using ANOVA 
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In the table below, the results for the factors of innovation are compared using an 
independent sample T-test, Levene's tests for equity of variance. This is used to test the 
research hypothesis that the UK is stronger in the core economic components of its 
National Innovation System. 
Factor of Innovation 
in Mean 
Equal Variance Equality of Mean Significant difference 
Nos with diabetes N 0 Y 
Total health spend Y 0.038 Y 
Nos of nurses Y 0 Y 
Total population N 0 Y 
Nos of Doctors N 0 Y 
Patent Registrations N 0 Y 
Total Balance of Trade Y 0 Y 
Inflation N 0.574 N 
Total GDP N 0.104 N 
Total Education N 0.007 Y 
Total Research N 0 Y 
Total Computer Y 0.012 Y 
Using Levene's test for equity of variance, the mean score is below 0.05 in all variables 
except inflation and total GDP. For all other variables, equal variation of the mean 
scores cannot be assumed. The variables were retested using one-way ANOVA. 
The factors of innovation for the UK and China that were shown to have ANOVA values 
of below 0.05 are indicating in the table below that there is a significant difference in the 
mean scores for all variables except inflation and total GDP (Tabachnick and Fidell 
1996). 
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Factors of Innovation Homogeneity of var. Anova Levene's 
effect 
Between subject 
Total spend on health UK and China .060 .032 .022 .026 
Number of doctors in the UK and China .000 .000 .001 0 
Number of nurses in UK .344 .000 .270 0 
Trade balance total in $ UK .721 .000 .531 0 
Balance of Payments UK and China .106 .000 .019 0 
Inflation UK and China .002 .574 .002 .835 
Total GDP in US$ in UK and China .033 .104 .213 0 
Total spend on education in the UK in US$ and China .019 .007 .020 0 
Total spent on research in the UK in US$ and China .015 .000 .082 0 
Total no computers in the UK and China .176 .012 .161 .022 
Levene's test tests the null hypothesis that the error of variance of the dependent 
variable is equal across the factors of innovation. The Wilk's Lambda test gives a 
significant value of 0, indicating that there is a statistical significance between China and 
the UK in the factors of innovation. Because there is a statistical difference a Bonferroni, 
adjustment was made to the alpha value to help prevent finding a significant result when 
there is not one. This sets a higher alpha value - the number of dependent variables 
(10) and becomes 0.005. 
The between-size effect shows that for seven of the factors of innovation that there is 
statistically significant difference in the scores. A one-way between groups multivariate 
analysis of variance was preformed to investigate these differences. The independent 
variable is the country. Preliminary assumption testing was conducted to check 
normality, linearity, univariate and multivariate outliers, homogeneity of variance-
covariance matrices, and multicollinearity with no serious violations noted. On 
inspection, using the estimated marginal mean, it is clear that the gap is large. 
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The table below summaries the size of the variation between the mean values of the 
factors of innovation between the UK and China. 
Estimated Marginal Mean 
Size 
Difference 
Total number of doctors China 2X greater in cn 
Total number of nurses China 0.38 greater cn 
Trade Balance in China 4.6Xs greater cn 
Balance of Payments China 5Xs greater cn 
Total GDP UK 1.48 greater uk 
Total Education UK 2.11 greater uk 
Total Research UK 3.79 greater uk 
Part Two Summary 
This part of the analysis involves testing the hypothesis that the UK has stronger 
economic factors of innovation than China. The factors of innovation are those identified 
as having an influence over the advance of therapeutic cloning. The T-test analysis 
shows that the mean scores for most of the variables are different, with the exception of 
inflation and total GDP. One-way ANOVA is used to assess the differences in the 
variables and, importantly to this work, the variation in mean scores. This shows that for 
the period between 1990 and 2002 the UK had a GDP of 1.48 times that of China, 
education spend of 2.11 times greater, and a spend on research of 3.79 times greater. 
China, however, had a trade balance of 4.6 times and a balance of payments of 5 times 
that of the UK. 
This shows that historically the UK is stronger in the economic factors of innovation as 
they relate to therapeutic cloning, most notably in the area of research investment. 
When, however, the rate of change during the time period is considered, China is seen 
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to have increased it's spend on research four-fold and is fast approaching an equal 
position to the UK. 
Part Three - Research Interviews 
Introduction 
The third part of this analysis involved examining the opinions of researchers and policy 
makers working in the field of stem cell science. It provides context to the overall 
research question in capturing the views of those working within their National Systems 
of Innovation in stem cell research. A data table was constructed after a wide search of 
the Internet, policy documents, and stem cell research centers, particularly in the area of 
diabetes across the UK and China. These cover all those organisations receiving 
government research funds as well as the private sector. This information is set out in 
Appendix J. Each organisation was contacted - twice by email and, where willing, by 
telephone. The overall response rate was low in terms of numbers but was successful 
in receiving contact from some of the most eminent stem cell researchers in the UK and 
China. These people and the questions asked are set out in Appendix K. 
Conventional qualitative research would involve the recording and transcribing of 
interviews to ensure accuracy and limit personal bias (Silverman 2002). In this 
approach some interviews were conducted over the phone, some in person and some 
via email. To ensure the same high standards of validity the notes of each transcript 
were returned to the interviewee for validation and correction. In this way it was possible 
to ensure an accurate transcription as recommended by Cassell (1999) and limit 
personal bias by triangulation, as recommended by Miller (1997). 
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An acknowledge goes to Professor Cathy Prescott from Avlar Bio Ventures Limited in 
Cambridge who facilitated many of these contacts. 
Each person was asked the same questions taken from the areas identified in the 
research design. These were: 
• views on the advantages and disadvantages of the research environment for 
stem cells in the UK and China 
• views on the current patent system for stem cell research 
• views on whether achievements in translating stem cell technologies into clinical 
therapies will occur first in China 
• views on any associated risk if such therapies were to be available in China 
Quotes were used from all the interviewees in the reporting of opinion against each of 
the relevant research questions. The issue of personal bias discussed by the likes of 
Silverman (2002), Cassell (1999), Hawkins (2001), May (2001), and Miller (1997) were 
reduced as direct quotes were used that had been validated following translation by the 
interviewee. 
Investment Strategies 
Considering first investment in stem cell research, Young (Business Relations Manager 
at the Department of Trade and Industry) says, "UK Government investment in stem cell 
research is okay". He goes on to explain that the funds available to the Medical 
Research Council and others are underpinned by strong technology programs, run by 
the Department of Trade and Industry. This is a view supported by many, including 
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Professor Clarke from the Oxford Center for Diabetes, Endocrinology and Metabolism. 
She explains that although research investment is short, "many researchers share 
support" to maximise its use. Professor Minger from Kings College London suggests, "it 
is the longer term commitment that is needed and early indications of this will be 
forthcoming". Holland, Chief Executive of Cord Blood London cautions, however, that 
the "cost of stem cell research is high in the UK compared to other parts of the world". 
These views are not universal with Professor Przyborski, Director and Chief Scientific 
Officer at Re: innervate Limited, saying "the position is terrible". However, he reports that 
planned changes in the UK government funding strategy for stem cell science towards 
larger projects may help. He suggests funding needs to be focused towards projects 
with tangible commercial outcomes. Surani from the Cambridge and Wellcome Institute 
of Cancer and Developmental Biology agrees that funding is a constraint, a view 
supported by Professor Minger who reports "very few disadvantages in the UK except 
perhaps funding". Professor Bobrow, Nuffield Council on Bioethics, Head of Medical 
Genetics at Cambridge and former Deputy Chair of the Wellcome Trust says, "the UK 
spends less on research than its major competitors", but suggests that whether more 
money is needed "is in doubt". This view is supported by Dr Archer, who says "money 
is not the limiting factor in this case as stem cell science does not require enormous 
capital investment or complex computers or machines for analysis". Professor Rimoldi 
from Imperial College London goes on to suggest that "funds are wasted on managers". 
Moving on to broader aspects of the investment strategies, Professor Murdoch from the 
Newcastle Life Sciences highlights the UK's regulatory structure as a strength, saying, "it 
explains clearly what can and can not be done", reporting this to be "a big issue for a 
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number of other countries". Stacey, Chief Executive of the UK BioBank, confirms the 
UK regulatory system"is generally facilitative of stem cell research whilst retaining 
careful controls, i.e. allowing therapeutic cloning and use of embryos for research 
coupled with stringent regulation". Professor Minger from Kings College London agrees 
the UK is "very supportive unlike the current situation in the United States". This is a 
position supported by Professor Bobrow, who says, "the UK has a very supportive 
research environment". 
Holland, Chief Executive of Cord Blood London (a private organisation dealing in adult 
stem cells) adds the dimension of strong academic links in the UK with independent 
research that is prestigious and has easy communication channels. Professor Prescott 
from Avlar Bio Ventures Limited agrees, saying "UK centers of excellence are very 
positive in enabling a critical mass for stem cell research". She explains stem cells 
research is technically demanding and "the proximity of expertise is therefore essential". 
She reports the centre at Newcastle as one of the most important and currently the only 
place in the UK working on laboratory-based translation therapeutic cloning. The UK is, 
she reports "very strong on biological innovation but reticent to move forward into the 
clinic". Dr Archer, Chair of the East England Stem Cell Network, reports the UK in 
"punching well above its weight in all areas of research methods" and has "university 
departments of international standing". She says the UK has a "good culture for 
communicating results" and "an honest and transparent regulatory and trials system". 
Mountford, Chief Executive of Stem Cell Sciences, adds further context to the UK 
investment strategies in reporting them to be multi-national, which enables his business 
to manage issues specific to different countries within their UK work. 
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The corresponding strategies in China are said to be permissive legislation, access to 
primates and humans for research, access to human embryos and aborted fetuses, 
access to long-term research funds, state-of-the-art laboratory facilities, and a 
permissive cultural environment. UK research investment for stem cells is said to 
contrast to China, where its government has made major investments and provided 
some of the best-equipped laboratories in the world. Their funding streams are reported 
to be long-term, affording commitment and security to its research. The corresponding 
disadvantages in China are said to be a lack of investment in basic research and a 
predominate focus on developmental research. They also reportedly lack credibility in 
their absence of published research. Dr Archer suggests, "historically Chinese scientists 
were not considered to be so creative in thinking", but "China is now motivated to 
produce results because stem cell therapies can be cheap". 
Legislation 
Patents are one aspect of the legislation that influences investment strategies. 
Young, from the UK Department of Trade and Industry confirms, "they have not had any 
patent issues raised". Minger reports, "the patent system seems okay but broad patents 
impede field work". Some, however, feel the current system is inadequate for the 
complexities of stem cells. Stacey suggests that "the suspension in the 1600's by the 
King of England (in that case, due to corruption) needs to happen again and the process 
restarted from scratch". His believes we may again be approaching a situation where 
the patent system requires reform. Professor Wang from Newcastle Life Sciences 
confirms "all universities and stem cell centers have their own dedicated patent office 
with scientific support. The problem she suggests is "knowing what could or could not be 
patented and how far to take this". Murdoch reports a push "to achieve patent 
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registrations" although "historically we have not been good at exploiting these". Holland 
points out that the process of IVF resisted patenting. 
Professor Prescott agrees the patent system for stem cells is "horribly complicated with 
many tiers, fragmented, and dominated by the US". One way forward, she suggests, is 
to expend licensing, but this requires new legislation. In the US, patents of specific stem 
cells are permitted, which is argued by many to be wrong. Walker - Business 
Development Director at St John's Innovation Center - agrees, describing the patent 
system as "a minefield and far from adequate in its current status". Mountford, Chief 
Executive of Stem Cell Sciences, reports "researchers in the UK seem satisfied to allow 
patents on how to produce or use stem cells but not on the base material - it is too 
broad in application and patents slow development". Przybroski is involved in patenting 
the technology that enables stem cell science rather than the cell technology itself and 
agrees that only the technology that enables the process should be patentable. 
Patents are a bigger problem in China where, despite joining the World Health 
Organisation in 2002, enforcement and infringement are major problems. Although 
China has strengthened its legal framework for intellectual property, amending its 1984 
legislation in 1992 and 2000, 70% of the world's counterfeit is produced there. This is a 
worry for the Chinese government, which desperately wants to encourage international 
investment. Companies are now being taken to court on a daily basis for infringement, 
although detection remains a problem. Dr Bennett, who leads a task group on public 
perception, suggests it is not just patients that it concerns, but that "all aspects relating 
to the management of stem cell research have become a priority for the Chinese 
government", a situation made worse by the Korean fraud. 
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Researcher opinions on the Chinese regulatory system appear to depend somewhat on 
whether researchers have visited or worked there. Both Prescott and Minger, having 
visited China, report the Chinese approach as" robust and open". Their scientists 
reportedly work within clear legal guidance in terms of what is and is not accepted. 
Regulation 
The regulatory system in the UK is said by Young to be "sorted and stable" in relation to 
embryonic stem cells, including therapeutic cloning. Researchers know where and how 
to apply to the Human Fertilization Embryo Authority for a license, which he says is in 
contrast to the United States, where there is still no control on investment in this area. 
The quality of science and scientists is regarded as high with many centers of 
excellence, most notably at Newcastle, Cambridge, and Edinburgh. Young goes on to 
explain that from the Department of Trade perspective there are no obvious bad things 
about the UK regulations. This position is supported by Dr Minger, who confirms the 
UK has "the best regulation for stem cell research in the world". He goes on to explain 
that "the details are the tightest and are not dependent on the source of money as they 
are in the United States". He explains that "the UK has a pragmatic approach that 
requires everybody, whether a private company or academics, to operate within the 
same rules". He ascribes this rigor to the 2001 Select Committee consultation. This, 
he says, has led to "a considered legislative structure that sets out the UK landscape for 
stem cell and therapeutic cloning research". 
Surani, from the Cambridge and Wellcome, agrees the UK has "a good and stimulating 
working environment with clear guidelines and possibilities for recruiting high quality 
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students and post-doctoral students". Holland agrees, "the UK has made the most 
significant inroads into reviewing and implementing the appropriate regulatory 
environment". Walker adds, "there is a good critical mass of researchers across a wide 
range of stem cell projects in the UK". There are also close links between researchers 
and clinicians willing to pull developments into the clinic". Przyborski agrees that the UK 
"has the best clear-cut regulation in the world and researchers know exactly where they 
stand". Murdoch from Newcastle Life Sciences highlights one tension within the 
regulatory system, drawing an analogy linked to the justice system. She likens the 
tension between prison officers and inmates, saying they are 'always assuming you are 
doing something wrong or bad. It is the process of regulation that is the problem at the 
moment". 
Despite speaking well of the UK, some UK researchers appear to envy the permissibility 
of the Chinese regulation for innovation, pointing out that the strict clinical trial regulation 
across much of Europe means that the pioneering experiments on percutaneous 
angioplasty that produced the advance in heart surgery would no longer be possible 
here (Rimoldi). This is an obvious concern for the future advance of stem cell science, 
with Rimoldi suggesting this complicated area of concern belongs more in social than 
medical science. 
Diabetes 
Stem cell research in diabetes is led in the UK at Newcastle Life Sciences, whose work 
is currently focused on adult stem cell transfer rather than embryonic. Clarke explains 
that the work on diabetes at Oxford is focused on a number of independent groups 
working on the biological and biophysical aspects of diabetes, but that they are not 
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currently involved in stem cells. The contrast is explained by Professor Zhang from 
Xuan Wu Hospital Cell Therapy Centre in China, who is leading work into a cure for 
diabetes. Although reluctant to speak, he does explain that his team is already able to 
expand progenitor cells within human or monkey pancreatic islets and make large 
numbers of artificial islets in test tubes. He acknowledges this has been done in other 
places but that the advantage they have is using diabetic monkeys in their studies. His 
team aims to establish the optimal number of differentiated islet cells necessary to cure 
diabetes in monkeys. Although huge sensitivities exist in this work, he is confident of 
success. 
Prevalence and associated economic and health costs for diabetes are serious 
problems in both China and the UK. The issue is whether people will be willing to travel 
to places like China in the future in search of a cure. With many stories of people already 
traveling abroad for stem cell treatments, Dr Bennett hypothesizes, "if you have 
diabetes, hear of a treatment in China, have the money and are a risk-taker, an 
individual may choose to get treatment", but he cautions "this can not be generalised to 
the majority". Young suggests, "most people are suspicious of this", with Murdoch 
adding, "people who might choose to go abroad will not necessarily understand". 
Walker describes the health risk of deciding to go abroad "to be far less of an issue than 
managing patient expectations". "If patients travel to less regulated markets for 
treatment and are disappointed, this will have a negative impact on the entire field", she 
cautions. "The Chinese environment is not well understood, as there is very little 
published research". 
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Societal Acceptance 
China reportedly has excellent animal research facilities, resulting in cheaper research 
than invitro models. The associated risk Bennett, suggests, is that "their findings may 
not work in humans". Others claim the ethical controls are too loose in China and worry 
that not all doctors guarantee safety. Professor Wang agrees that Chinese doctors 
"tend to be a bit more adventurous, especially on patients with end stage conditions", 
although Professor Prescott who has visited China on several occasions confirms "all its 
studies on patients are ethically approved, far more so than appreciated. Their work is 
very carefully controlled with many of their researchers having trained in the US". 
Indeed, she reports that "the Chinese are aware that there is great suspicion following 
the false claims from Korea". Dr Wang acknowledges that the ethical controls are clear 
and proper in China, suggesting it is compliance that is the issue. Professor Minger 
points out that the ethical stance in China means "if somebody is sick and there is a 
possibility a new intervention may help it is almost criminal to withhold it". From his 
experience he agrees that China is responsible and "there are no concerns about the 
ethics of their stem cell research". Indeed many, including Professor Rimoldi, suggest 
that the comparison of ethical constraints in the UK is "unhelpful to the research". 
Because of (or in spite of) the ethical context in the UK, Young reports the biggest 
challenge is "its lack of ability to commercialise stem cell research or to even take steps 
towards this". He predicts a very long wait before the outcomes of this work are seen in 
the UK market. Professor Wang provides context in having just come back from visiting 
several stem cell laboratories in Shanghai. She suggests, "the UK advantage is in terms 
of mechanisms", but explains that China has the advantage in terms of application. She 
confirms China is already using stem cell therapies in clinical settings and is very keen 
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to develop collaboration with the West. She explains, "doctors in China are undertaking 
procedures on patients that clearly work, but they lack the basic understanding about 
how or why". 
The reason for this difference is largely around UK regulation and the clinical trial 
process, which require an understanding of the mechanisms before human research 
trials. Professor Minger confirms the "UK is cautious and is not yet transplanting". 
Professor Wang suggests that may in fact be a better approach for patients. Professor 
Prescott describes the contrast between the UK and China, explaining the reason 
progress is being made rapidly in China is that "most of the research is carried out by 
clinicians". This gives, she explains, significant advantage in "understanding how to 
translate the findings in the laboratory into in a clinical setting". Many say it will be 
decades before stem cell therapies become available in the UK, especially in brain 
disease. 
Whether China is placed to advance a lead on the world, therapeutic cloning is an area 
that attracts many views. Surani suggest such an achievement depends on the quality 
of their basic research, which is improving as they are recruiting people from overseas 
(especially Singapore). Young says "I wonder, China has different regulations and 
ethics but also lots of biotech expertise, but I am not sure how successful China is in 
turning this into treatments. The Korean scandal has affected the standing of science in 
the East badly". Professor Murdoch agrees, reporting that "the Korean fraud has put a 
big stop to progress in East Asia. Until this the Far East was expected to lead". 
Professor Clarke suggests, "the experience from Asia has engendered distrust and it will 
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be a while before the scientific world recovers". She suggests patient demand in the US 
is more likely to drive success. 
Professor Wang is clear from her work in both the UK and China that "therapies will be 
available in China before the West". Mountford takes an opposing view, saying simply 
"no, China will not lead. The time limiting challenge is scientific, not ethical". Professor 
Minger sees both points of view, saying "yes and no. India is already working in 
embryonic stem cells without any regulation. China has more restrictions and is moving 
quickly to the clinic". Professor Rimoldi points out that even if China did find a cure for 
diabetes and patients choose to flock to China in search of a miracle therapy, the 
evidence-based approach to medicine would remain a requirement for the West. 
Holland takes a more extreme view in saying 'there is no real future for embryonic stem 
cell therapy in any country. The technical, medical, legal and ethical and religious 
objections are too great. "I doubt China would take the lead, and if they did their 
techniques many not be acceptable". 
Professor Precott says "absolutely yes. China is clinically driven, has lots of money and 
has an ethical context and will produce therapies well ahead of the West". Others, 
including Walker and Professor Przyborski, support this position, but they suggest their 
lead will be more to chance and lack an understanding of how or why. One example is 
that bone marrow stem cells are currently transplanted into the heart, resulting in an 
increase in the output of the heart, but nobody yet understands how or why this 
happens. Professor Przyborski suggests the really important question is does it matter 
from a patient point of view? Whilst academics are hesitant to take a leap into the clinic, 
the Chinese doctors and stem cell scientists are already treating people with notable 
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success. The risks, he suggests, is "if it all goes wrong" like the gene therapy treatment 
of leukemia in France where blood bone marrow led to cancer. 
Internationally there are many countries undertaking "unregulated tissue procurement all 
over the world" (Professor Minger), with concern highlighted in Barbados, the Ukraine, 
and India. He reports China and the Far East as "a small part of what is happening". 
Explaining the advance in China, he says, "none of this will be permitted to operate in 
the UK", as evidenced to date by the cord blood companies. Professor Clarke agrees 
that legislation in the West requires that evidence be produced locally before any clinical 
acceptance can be made. Whilst she cautions that "less ethical institutions could adopt 
stem cell treatments", she suggests these are unlikely to present a large-scale risk. The 
absence of any international regulatory body to police this work is said to be a risk within 
the current research and Professor Minger hopes the World Health Organisation will 
take on this role. 
Summary 
This research is structured to explore the National Systems of Innovation in the UK and 
China as they apply to stem cell research. The specific areas to be answered are what 
the strengths and weaknesses of the respective systems are, how they influence the 
translation of stem cell science to treatment, and which of the two countries are most 
likely to lead in curing diabetes. Diabetes is taken as a clinical example against which to 
make this assessment. A definition of the composition of the National System of 
Innovation is taken from the literature and includes economic, legislation, research 
investment, and softer aspects of culture and public opinion (Edquist 1997; Freeman 
1997). From this, it was clear that a range of data structures were necessary to explore 
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the research question in detail. This was designed in three parts to explore all the 
economic components of the National System in an historic trend that enabled 
comparison over time between the two countries. The economic table was constructed 
to bring together a range of data sets that had not previously been gathered or 
compared from 1990 to 2002. The details of data collected and structure of the table 
and analysis are set out earlier in this chapter. A summary of the data set is attached in 
Appendix D. 
This analysis shows that between 1990 and 2002, the UK historically had stronger 
economic factors of innovation, although by 2002 China became its equal, as a 
proportion of GDP was spent on education. China in addition has far stronger 
underlying factors of innovation, evidenced by the country's positive balance of 
payments and the size of their trade in goods and services. Spend on research also 
increased rapidly and, as a proportion of GDP, had increase by 2005 in China to 1.35 
and reduced it in the UK to 1.76 (National Statistics 2007). The softer aspects of culture 
and opinion could not be assessed from economic statistics and required the formulation 
of a public questionnaire. This was designed to capture opinion from a UK perspective 
from a representative sample, which broadly showed that people think the government 
needs to spend more on stem cell research, and that human embryo research is more 
widely supported than appreciated, with a strong correlation between religious belief and 
concern. During the time of this study the understanding of what is happening in China 
may have changed, but this work found very little knowledge of the Chinese 
achievement in this field. 
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China is applying its scientific knowledge in a clinical setting, enabled because its 
clinicians lead much of its research. It is said to be tightening up its patent and 
enforcement systems, although detection is still said to be an issue. It has large animal 
facilities, including access to primate research, which makes its research costs lower. 
Indeed work to cure diabetes in monkeys is undertaken with reports due imminently on 
the optimum numbers of islet cells to produce a cure. The ethical stance of its country is 
reported to be more adventurous, often trying new procedures on people at the end 
stage of their disease. The opinion on whether China will use its advantages to lead the 
world in therapeutic cloning is mixed. Certainly those scientists who have visited China 
and seen first-hand its investment, state-of-the-art laboratories and practices believe it 
will. China is reportedly curing solid cancer tumors, treating leukemia with stem cells, 
and has publicly announced its intention to cure diabetes (Pearson et al 2004; Hepeng 
2005). However, such claims are challenged by some due to the absence of published 
research evidence. 
The UK has a strong international reputation in stem cell science, having led in 
establishing legislation to enable human therapeutic cloning. In doing so, it is said to 
have provided the clarity that is necessary for discussion and understanding and to have 
strong government support. The funding structure for stem cell research in the UK is 
not reported favorably by all, with some claiming the short-term nature of the current 
system is limiting and lacks a focus on projects with planned tangible outcomes. 
However the UK is reportedly changing some of this and turning its strategy towards 
support for larger projects and longer-term strategies. The UK is also reportedly reticent 
to move into the clinic, due to the complexity of the science, clinical trials regulation, and 
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societal concerns. This area of science is said to be expensive, its patent system 
horrifically complicated, and predictions are for a long wait before any services result 
from its stem cell science. 
Views are mixed on which country will lead in curing diabetes. Some researchers, with 
first-hand experience in China, are clear that it will lead. Some argue this to be 
speculative and call for concrete evidence. What are available are the changes in 
economic performance in China, which are shown to be underpinned by increasing and 
long-term investment in research and education. History is often a useful predictor of 
the future. The UK has a strong research background and is a global leader in science 
and innovation, but there is clear and continued evidence of a decline, as a proportion of 
GDP in research investment (National Statistics 2007). 
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Chapter Four 
Discussion 
Introduction 
This is an interesting time to be writing about stem cell research in both the UK and 
China, not least as the news carries daily yet another story of its potential to cure 
disease. Last week it was heart disease, this week it's muscular dystrophy, and 
tomorrow maybe diabetes. Even UK dramas are getting in on the act with story lines 
showing a motor neuron sufferer travelling abroad for stem cell treatment (Holby City 
2006). The reality is whatever the science may deliver; it will be a long time before 
these are available in the UK (BBC 2005). 
In China, advances in genetic science are also reported in explicit advertising of stem 
cell treatments that offer cures for a whole range of disease. Indeed UK national news 
carried the story of gene therapy treatment for cancer in China (BBC 25/5/07). China's 
move to the clinic has happened quickly, having cloned their first human embryo in 1999 
(Yank 2004) one year after the world's first was achieved in the United States 
(Shamblott and Thompson 1998). It was 2005 before the UK matched this achievement 
in cloning its first human embryo (Lawless 2005). This and its permissive legal and 
social culture have enabled China to move quickly in transplanting stem cells in humans 
(Ning 2005). China claims to have delivered the world's first gene therapy cure for 
cancer (Pearson Jia and Kandachi 2004), started the first human trials for leukaemia, 
and published explicit plans to extend this to diabetes (Hepeng 2005). In addition, China 
is reported to have successfully cloned hybrid embryos in 2003, an achievement the UK 
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is yet to match (Chen 2003). This research found evidence of the Chinese successfully 
curing diabetes in primates some two years ago. 
China is reported to be using adult stem cells to cure brain disease, and has cloned 
goats, pigs, cattle, mice, rats, and established a network of cord blood (Times 2005). 
Their research spend is now the world's second highest (Lombardi 2006), representing a 
four-fold increase over the last ten years. China's approach is underpinned by an 
explicit strategy to become an international leader in technology (Mann 2003; Wilson 
2006). Their motive is to gain prestige and economic growth, as genetic science affords 
the potential to become the most significant contributor in the biotechnological industry 
(itself identified as the most important aspect of economic growth) (EC 2001 OECDa 
2004). 
This study used NSI as a framework for exploring the factors of innovation influencing 
progress of stem cell technologies in the UK and China. The definition of NSI was taken 
from the literature, the most significant being Freeman (1997), Edquist (1997), and 
Fagerberg (2004), who in summary suggest a definition that includes political context, 
government legislation/regulation, research investment, society/culture, economic 
performance and current evidence. These offered a framework against which a 
comparison of stem cell innovation between the UK and China is afforded. Both the UK 
and China have published policy intention for stem cell science in China in its 15-year 
scientific strategy (Cong 2006) and DoH 2003 in the UK. 
The focus is on therapeutic cloning which is one area of stem cell research whose 
technique involves the transplantation of cells from human embryos, human cord blood, 
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or adult stem cells to repair damaged or diseased cells. Embryo cells are said to have 
an advantage in being undifferentiated and potentially able to grow into any cell type 
(Moore 2004), although how this happens is beyond current knowledge. That 
advantage has more recently been disputed as Western scientists seek to find 
procedures that do not involve the destruction of the human embryo (BBC 2006). 
Indeed such is the concern in America that the use of government funds is still 
prohibited by law except for embryos created for use in IVF treatment prior to August 
2001 (Bush 2001). 
The UK has managed to temper such an approach by introducing clear legislative and 
regulatory processes that control the approval and management of the science (Leather 
2005). The Human Fertilisation and Embryology Authority has taken this one step 
further in issuing the first licence in the UK to Newcastle Life Sciences to invite non-
beneficiary egg donors following its public consultation in October (HFEA 2006). This 
enables women to become egg donors outside of the current IVF process, a policy 
publicly criticised by Dr Minger (Dreaper 2006). China, in contrast, is largely free from 
such ethical concern, having different beliefs about when human life begins (Yank 
2004). 
The science of therapeutic cloning, in whatever culture, is aimed at finding cures for 
human disability and disease (Spink et al 2004). The basis is that stem cells can be 
transplanted into diseased or damaged tissue where they can either be reprogrammed 
before transplantation or take instruction from their host cells. This research discovered 
that how this science translates to therapies depends as much on the innovation system 
in which it develops as the skill of its research team. This includes its government's 
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legislative and research strategies, its economic system; it's ethical and social structure, 
and the complexity of the disease to be treated. 
Research Design 
This is a case study researching how therapeutic cloning will be influenced by the 
National Systems of Innovation in China and the UK, using diabetes as a model. 
National Systems of Innovation is defined in the literature by Edquist (1997), Freeman 
(1997), Fagerberg (2004), and others. This includes a political context, legislation, 
research investment, intellectual property, public opinion, ethics, demographic trends, 
economic performance, and current research. The definition and boundaries of 
National Innovation in this field are validated by a study that began after this work, led by 
Professor Salter at Anglia University. In this, he too uses the Innovations literature to 
frame his study of stem cell technologies between the UK and China and uses very 
similar categorisation to this study. 
National Systems of Innovation Theory is concerned with the political and economic 
factors at a national level. It does not have an empirical framework (Edquist 1997), so 
the use of a framework designed to fit the research challenge is one suggested 
approach (Freeman 1997; Fagerberg 2004). Its application in the service sector has 
been historically limited (Fagerberg 2004), although there is recent evidence of its use in 
a number of clinical studies. Perhaps the most relevant aspect for this study is that 
suggested by Storperand Harrison in 1992, and Freeman in 1997, who recommended 
using NSI in studies that focus on factors that influence delivery of innovation or change. 
Freeman also recommends its use to identify those activities that increase knowledge 
about those aspects that make innovation successful. These fit this case study, which 
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makes comparisons between the national innovation systems as they relate to 
therapeutic cloning between the UK and China. 
The approach to the research is shown diagrammatically below. The independent 
variables in the NSI for stem cell science are those forming its structure such as 
legislation, political structure, and societal values. The influences that moderate these 
are their translation to operational values such as available resource, actual 
legislation/regulation, and what society is prepared to accept. The outcomes are those 
that the science is able to advance within the respective structure for the UK and China. 
Independent 
Economic 
Systems 
Social Systems 
Research 
Environment 
Culture & Ethics 
Political Systems 
Moderating Influences 
National 
Investment 
Legislation & 
Regulation 
Morbidity/Mortality 
Prevalence 
Investment 
Strategies 
H Societal Acceptance 
Outcomes 
Economic 
Performance 
Achievements in Stem 
Cell Science 
The study is designed in three parts. The first covers economic data on populations, 
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demography, patent registrations, and investment strategies constructed in a 
quantitative data-table covering the period from 1990 to 2002. This approach is 
supported by the literature in enabling interdependences and non-linear relationships in 
the NSI to be explored (Edquist 1997). A public questionnaire is used to collect the 
less tangible areas of information covering individual opinions, culture, current 
knowledge, and ethics. The sample for the questionnaire is taken from a range of 
community groups that represent the UK population as explained in the research design. 
This sample represents the population in covering nine key groups. These include 
students, unemployed people, people working in professional and non-professional 
roles, stakeholders with diabetes, gym members, retired people, and magistrates who 
are selected as a representative sample of the population. The validity of this approach 
is seen in the results, which show a representative mix of age, gender, religious belief, 
employment status, experience of diabetes, and ethnic origin in the results. Although 
two routes were tried to use the questionnaire in China, these unfortunately failed. This 
was redressed in the third data collection method where access to Chinese researchers 
was successful. 
Telephone, email and interviews are used in the research sector across the UK and 
China to explore the political and regulatory environment, culture, and stem cell research 
underway. These contacts were initiated from a database that was built covering all the 
stem cell research being funded at that time in the UK and China (Appendix J). 
Together these three approaches incorporate the recommendations of Fagerberg (2004) 
to include the relationship between R&D, legislation, and economic performance and the 
impact of knowledge created (Plummer 2004). Tidd (2001) recommended the study be 
in real time, which is evident in both the questionnaire and interviews. Workforce 
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productivity was something that researchers and the competitive focus Schumpeter 
(1934) suggested to be important in these studies, as they are reflected in the 
investment and regulatory strategies, the societal values, and the status of the current 
science in each country. 
The overall research question is how will therapeutic cloning be influenced by the 
respective National Systems of Innovation in China and the UK using diabetes as a 
model? The hypothesis being NSI will not adversely impact the advance of stem cell 
science. This breaks down into three specific questions to be answered: 
1. What are the strengths and weaknesses of the National Innovation Systems in 
the UK and China as they relate to therapeutic cloning? 
2. How do the National Systems of Innovations in the UK and China influence the 
translation of stem cell science into the clinical treatment? The hypothesis is that 
NSI of each country has an influence on the advance of stem cell technologies 
3. Because of their National System of Innovation, which country will be first to 
develop a stem cell cure for diabetes? The hypothesis is that one of the countries 
will have a more permissive NSI. 
1. Strengths and Weaknesses: National Systems of Innovation in the UK and 
China 
There is no published study using NSI to explore therapeutic cloning, yet the content of 
the literature supports its application to new areas in being flexible and outcome 
focused. The structure of the framework that underpins this research is formed from the 
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literature and populated by three methods of data collection. This approach is 
supported by current research being undertaken by Professor Salter (EESCN 2007). 
The research structure is underpinned by a review of the UK and China in Chapter Two. 
For China this illustrates a highly innovative history, with comparatively little commercial 
advantage, set within a major demography challenge. Home to 20% of the world's 
population, it suffers from many natural hazards including earthquakes, drought, 
tsunamis, land subsidence, and air and water pollution. These are somewhat offset by 
huge natural wealth, including coal, iron ore, natural gas, and the world's greatest supply 
of hydropower (Riley 2004). Its health profile is similar to that of a developed country, 
but there are considerable variations and massive poverty in the rural populations (Watts 
2005). Led by a Communist government, it has since the early 1980's achieved rapid 
economic reform (Keidel 2001), enabling many advances including a four-fold increase 
to its GDP spend on research (OECD 2004c). Within this, China is shown to struggle 
with credible and accountable regulatory systems for stem cell research (DTI 2004; BBC 
2005; Williams 2006). The government leads investment in stem cell infrastructure 
within a population with little, if any, ethical concern as the foetus is not considered 
human (Yank 2004). 
Reputation for the UK is contrastingly high, having led the world in genetic science and 
discovery (DoH 2003). Like China it has an impressive innovative history, having led the 
world in innovation until the mid 19 t h Century (Weisser 2005). With a democratic political 
structure, it has used its position to provide a cost-effective and comprehensive structure 
for stem cell research (Best 2005). Economically it is highly developed, with strong 
public health structure leading to high standards of living. Strong economic growth since 
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the late 1990's has led to strategies to increase research funding, although this reduced 
significantly from 2.4% of GDP in 1981 to 1.9% in 1997 (OECD 2002). Policies to 
increase this to 2.5% by 2010 are in place (DTI 2002). Access to new technologies for 
health is controlled by a government agency (National Institute for Clinical Excellence), 
which results in controlling access to new technologies by up to twenty years (May 1993; 
Dargie 2000; Raferty 2001; Wanless 2002; Dyers 2003). As a developed country, it 
operates within a mixed religious base where the relationship of the human foetus to 
God is, for many, intrinsically linked. 
Economic Analysis 1990-2002 
The first approach covers the economic data at a national level and includes economic 
performance, research Investment, education, health spends, workforce trends, 
demographics of diabetes, patent registrations and computer ownership. Its structure is 
taken from the innovations literature and used to provide a quantitative framework to the 
research. 
Analysis shows for the research period 1990 to 2002 that China has a declining 
population compared to that of the UK. Diabetes has increased rapidly over the 
previous 12 years, most notably in China. Health spend has increased in both countries, 
most significantly in China since 1996 with private contributions increasing four-fold in 
China whilst remaining static in the UK. The value of GDP is equal between the two 
countries whilst spend on research has increased five-fold in China and the percentage 
of GDP spend has fallen in the UK. Growth in GDP remains constant at around 8% in 
China and between -2 to 4% in the UK. The number of doctors has increased in China 
whilst the number of nurses has decreased, with doctors remaining static in the UK as 
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the numbers of nurses increasing. Balance of payments has improved substantially in 
China whilst remaining negative throughout the period in the UK. Inflation in both 
countries has been volatile, with China reaching 24% in the mid 90's and reducing down 
to 2% by 2002. The UK has reduced from 9% in 1990 to 3.5% in 2002. GDP spend on 
education has increased in China to match that of the UK at 5%. Total value of GDP 
has risen rapidly in both countries but most notably in China. Ownership of computers 
has risen ten-fold in China to become half the level per head of population in the UK. 
This analysis shows China had a lower level in many of the economic factors of 
innovation, such as research investment and education, but by 2002 had equalled the 
value of total GDP and its spend on education with the UK. Whilst research spend is still 
much lower at 1.3% compared to 1.98% of GDP for the UK, China is on target to equal 
UK investment by 2010. Whilst China has doubled is spend on research in the last six 
years, the UK spend as a percent of GDP has declined. China has also seen an annual 
GDP growth of at least 8% compared to 3% in the UK, has a positive balance of 
payments, compared to the negative value for the UK, and its trade balance is out-
performing the UK by 4.6 times. Inflation appears to be in control in both economies but 
is lower in China at 1.6 compared to 4.5 in the UK (2002). 
These show that many of the economic indicators in the Chinese National System of 
Innovation are now comparable to the UK, with overall performance, as indicated by 
total GDP, outrunning that of the UK by some 5% annually. For China these afford a 
strong economic context for stem cell research, having low inflation, strong GDP growth 
of 8% annually, a positive balance of payment, 5% GDP for education, and a four-fold 
increase in research investment. There is evidence that the increase in research spend 
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has led to investment in state-of-the-art stem cell labs (DTI 2004). 
The corresponding position for the UK shows GDP spend on education and total GDP 
are equal to China. Total research spend as a proportion of GDP has fallen 2.24% in 
1990 to 1.98 in 2003; balance of payment is negative and GDP growth has varied 
between 2% and 4%. Computer ownership is still twice that for China despite their ten-
fold increase. These factors together suggest a strong, stable economic environment, 
but one, when compared to China, that shows comparatively little growth. 
Statistical analysis of the national economic factors of innovation was used to establish 
which variables were contributing statistically to economic strength of GDP. In the UK 
the results shows that spend on research and education make a statistically significant 
contribution to GDP performance. When repeated for China, total spend on research is 
shown to make the largest statistically significant contribution to GDP. The number of 
doctors, total spends on workforce, and the proportion of the population owning 
computers also contributes toward GDP performance in both countries. Spend on 
research, the number of doctors, and computer ownership all make a statistically unique 
contribution. These findings are supported by the literature, which reports the 
importance of research investment to economic performance (OECD 2004) and the 
workforce on GDP performance (Schumpeter 1934). China's strong economic growth 
is shown in the analysis to underpin its research investment. 
Computer ownership, when taken as a proxy for technology, is shown to have a strong 
impact of GDP performance in both countries. When testing the impact of spend on 
health on trade in goods and services in the UK, health spend is not shown to have a 
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statistically significant impact. Repeated for China, the percent spend of GDP on health 
care and the percent of health care contributed by the government are shown to have a 
statistically significant impact on trade in goods and services. This suggests the health 
system is having a far greater influence on economic productivity in China than the UK. 
Research investment in both countries is shown to have a statistically significant impact 
on the country's GDP, supporting the literature in substantiating the importance of 
research investment in economic performance. Investment in education in both 
countries is shown to make a statistically significant impact on both GDP performance 
and balance of payment. 
The use of correlation to assess a linear relationship between variables is useful in 
establishing a relationship but neither proves a direct link between two variables nor 
causality (Carter 1984). Its use in establishing statistical significance in the above 
summary is in providing a strong indication of patterns between the variables (Easterby-
Smith 2002). The factors of innovation were then tested for relative strength between 
the UK and China, using an independent sample T-test. There was no significant 
difference in the scores for inflation and total GDP. Total health spend, number of 
nurses, total population, number of doctors, patent registrations, total balance of trade, 
total education, research, and total computers are all significantly different as indicated 
by the Wilk's Lambda test. Levene's test and a one-way between groups' multivariate 
analyses were used to find the equality of variation across the factors of innovation and 
to establish the relative strengths in each. Collectively, these tests show the UK had 
stronger factors of innovation from 1990 to 2002 in most areas, including spends on 
education, research, health, and overall GDP performance. These statistical tests 
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focused on historic trend data which, in order to be predictive of future performance, 
would require the economic factors to remain constant. 
Summarised in the table below is can be seen that China has a trade balance over 4.5 
times stronger than the UK, to employ more health staff and have a balance of 
payments 5 times greater than the UK. Extrapolation of these results suggests the UK 
has a stronger national economic infrastructure to enable the advance of therapeutic 
cloning. This is taken to include current research investment, workforce-to-population 
ratios, and GDP performance. However, based on the rate of change within the data, 
this suggests that the Chinese economy is on the verge of surpassing UK performance 
in areas of research investment spend on education and total GDP. 
Estimated Marginal Mean 
Size 
Difference 
Total number of doctors China 2X greater in cn 
Total number of nurses China 0.38 greater cn 
Trade Balance in China 4.6Xs greater cn 
Balance of Payments China 5Xs greater cn 
Total GDP UK 1.48 greater uk 
Total Education UK 2.11 greater uk 
Total Research UK 3.79 greater uk 
The respective strengths of the NSI for each country are further explored using 
qualitative methods. 
Qualitative Analysis of Strengths in NSI for UK and China 
Public questionnaire and email/telephone interviews with researchers were used to 
explore the relative strengths and weaknesses in the NSI. This approach provides a 
qualitative measure of NSI taken from a UK viewpoint. The areas covered by this 
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approach link the structure set out in the literature and research design in Chapters Two 
and Three, covering political influence, including legislation, regulation, investment 
strategies, patents, and culture - including current knowledge and views on therapeutic 
cloning and research investment. 
Of those people responding to the questionnaire, 52.2% believe the UK has a strong 
legislative framework for therapeutic cloning, 79.6% believe that human cloning is illegal 
in the UK, but 19.1% think it is legal in China. 28.2% believe therapeutic cloning is legal 
in the UK, although 67.9% believe it is legal under license. In terms of investment for 
stem cell research, almost two-thirds (60.2%) do not believe the UK spends enough on 
research, with one in three saying spend has actually decreased in recent years. Only 
half (48.7%) believe the amount the UK invests is similar to other countries, with 57.1% 
saying the UK needs to spend more on stem cell research. Just over half (55.2%) 
acknowledge the UK as being highly motivated to find new innovations, but only 15.9% 
believe the UK had the first license to undertake therapeutic cloning when in fact it did. 
Half (49%) believe Dolly the Sheep was the first animal cloned, with 59.2% not believing 
China cloned a fish 37 years before dolly. 
Only 9.6% believe China has a gene therapy cure for cancer when both are claimed to 
have been achieved. The majority (74.2%) believes stem cell treatments will be 
available abroad before the UK, although 65.4% believe the UK will lead in using 
therapeutic cloning to cure diabetes. Only 28.2% believe the UK population supports 
the creation of human embryos for research, although over half say they themselves do. 
These results suggest the population in the UK has some knowledge of what is legal in 
the UK but very little about China. They appear to have little faith or trust in China from 
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the answers given, one in five believing China to be undertaking human cloning. Very 
few people appear to consider China to be capable of any advance in therapeutic 
cloning, including a cure for diabetes. People are individually twice as likely to support 
the creation of human embryos for research as they consider the UK population to be. 
The third approach to NSI involved email/telephone and personal interviews with senior 
policy leaders and scientists leading stem cell research. This approach was successful 
in obtaining comment for both the UK and China. 
Amongst the researchers the UK is regarded as having strong, clear legislation for 
therapeutic cloning, with some skepticism about the corresponding legislation and 
enforcement of breaches in China. Some researchers regard the Chinese approach as 
unethical whilst others, who work there or have visited, report a very responsible 
approach to therapeutic cloning. Human cloning is illegal in both countries and 
therapeutic cloning is operated under license in both, with the difference said to be 
enforcement (East of England Network 2007). In the UK, enforcement is said to be so 
tight as to suggest a lack of trust, which in turn causes tension. The reality is 
unregulated tissue procurement is happening across the world with Chinese research 
reported to be well and legally organised from those with first-hand experience (Minger). 
Overall, these results suggest the UK population believe more money should be spent 
on stem cell research if it wants to compete successfully with other countries. And whilst 
they regard the UK as a great innovator, they do not see it as an implementer of 
invention in stem cell therapies. Most people do not consider China to be capable of 
comparable results in this field of science. These views are at odds with the scientists 
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and policy representatives, most of who say the UK is well resourced for stem cell 
research but has a poor history of turning science to commercial advantage. They say 
that China enjoys more and longer-term funding and has state-of-the-art laboratories, 
which are mostly government funded. Although the UK is said to be planning on moving 
towards longer-term funding for stem cell projects, any potential results from the 
investment are a long way from entering the UK market. They say the UK is clearly 
reported as having the advantage in terms of mechanisms, but that China has the 
advantage in terms of application. China is reportedly using stem cell therapies in a 
clinical setting with most of the research led by doctors, which has brought rapid 
progress in this field. They are reported to be undertaking procedures on patients that 
are shown to work, but they do not have a detailed understanding of how or why. 
Part One Summary - Strengths and Weakness of NSI 
National Systems of Innovation is defined in this study by the economic; political and 
social systems that underpin the legislative and research structures for stem cell 
science. Their strengths and weaknesses within the NSI for the UK and China have 
been explored in this section and are summarized for each country. 
China's economic profile has changed rapidly during the time frame of this study. It has 
delivered a five-fold increase in its research investment with its GDP spend rising from 
0.7% to 1.3% between 1990 and 2002 and, since December 2006, has the second 
highest spend in the world (Lombardi 2006). Research spend has been shown in the 
analysis of this research to make a statistically significant contribution to GPD 
performance, which is steady at 8/10% in China. The second area found to be of 
significance to economic performance in China is education, which has increased from 
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2.3% of GDP in 1990 to match that of the UK at 5% by 2002. Expenditure on workforce 
and computer ownership in its population is also found to make a statistical contribution 
to GDP performance and to have increased rapidly. The importance of research 
investment in China is seen in its trade balance, which is positive in contrast to the UK 
and has an inflation rate below 1%. Strategically China's economic performance has 
been seen to translate to state-of-the-art-research facilities and long-term investment 
commitments for its researchers. 
Its economic advance has enabled new research facilities and its investment strategies 
have attracted international researchers to locate their work in China. US investment in 
China has increased from $7 in 1994 to 500m in 2000 (OECDc 2004), thereby 
increasing its market share in the biotechnology industry (Christiansen et al 2005). Its 
research investment is, however, skewed towards discovery rather than understanding, 
spending 5% of its total resource on basis science this compares to 16-22% of total 
spends in the UK (OECD 2002; Hepeng 2002). It has set up science and technology 
parks and knowledge transfer entities (OECDb 2004), supported by public funding for 
stem cell research from higher technology R&D programmes, National Natural Science 
Foundation, Ministry of Science and Technology, and Chinese Academy of Science 
(Hsiao 2004). Collectively these findings support a strong economic context for China in 
advancing stem cell research. 
The social context is an interesting one. China is reported to have cloned a fish 37 
years before Dolly the Sheep (Poo 2004), to have synthesised insulin before the 
Americans, and to have cured solid cancer tumors (Pearson el al 2004). China is 
currently working to cure diabetes in primates (Hepeng 2005) and has expanded 
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progenitor cells within human or primate pancreatic cells, aiming to find the optimal 
number of cells necessary to cure the disease. It has published its intentions to become 
a leader in biotechnology (Jing 2003; Mann 2003; Quiming 2005), and it plans to 
maximise its advantages in having a relaxed ethics stance (Yank 2004) and access to 
primate and human research (Chien 2004). Its population has no ethical objection to the 
use of human embryos in this type of research (Dennis 2002), since the foetus is not 
considered human (Yank 2004). Neither does it face public opposition to the use of cells 
taken from terminated second-trimester foetuses (DTI 2004 BBC 2005). 
The main strength of China's NSI identified in this research is its application of its stem 
cell science in the clinic (Salter 2007). It is already using stem cell techniques on 
humans with reported success. Its stem cell science is clinically led by qualified doctors, 
bringing significant advantage in knowing how to translate the findings in the laboratory 
into a clinical setting. Its patient studies are reportedly ethically approved in a societal 
context that suggests it is almost criminal to withhold a treatment that may help. Their 
research is reported by those who have been to China as both ethically and carefully 
controlled with an awareness and sensitivity to the views in Europe. In addition, China 
has excellent animal model research facilities and access to human subjects who, due 
to the historic isolation of China, afford homogeneous gene traits and a cheap research 
base (Mann 2004). With clinical trials only taking five years compared to 15 in the US 
and 20 in the UK (Yank 2004), a potential cure may be available to those able and 
willing to travel. 
There are a number of weaknesses in China, one being the communication of its 
research (including published research findings), which reduces its credibility within the 
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international scientific community (Wu 2002). It is also said to suffer from structural 
vulnerabilities in reliance on imported technologies and to lag behind R&D intensity 
(Wilsdon 206). Compliance with legislation and regulation is said to have blighted their 
systems with plagiarism and research misconduct (Wilsdon 2006; Salter 2007). 
Although it has strong government support in terms of long-term funding and-state-of-
the-art laboratories (DTI 2004), it is criticised for spending only 5% on basic research 
compared to 22% in the UK (OECD 2002 Hepeng 2002). 
The UK has worked longer in the field of genetics (Best 2005), and its legislative and 
regulatory framework is regarded in the UK to be the best for therapeutic cloning (PHGU 
2002). It was first to licence therapeutic cloning (Pincock 2004), and is said to have 
cost-effective research facilities (Best 2005) and accounts for 9% of global research 
(OECD 2000). Its scientists agree they are working within the best regulation in the 
world, with clearly structured research processes to apply for a licence for embryo stem 
cell research. The quality of science and its scientists are said to be high, with many 
centres of excellence. This enables a strong and stimulating work environment with 
clear guidelines and the ability to attract high quality recruits. The UK's academic links 
are reportedly strong, with easy communication, a prestigious reputation, and plans to 
increase its science budget from 3.9bn to 5bn by 2008. Researchers report the UK to 
have strong academic links, affords independent research, prestige, critical mass, and 
easy communication. 
The NSI for the UK is shown to have a strong economic base against which to place 
stem cell research. Its main economic weaknesses are its investment in research as a 
proportion of GDP having fallen during 1990 and 2002 from 2.2 to 1.9% (OECD 2002). 
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The UK has explicit aims to reach 3% by 2014 (Brown 2004), although to date it's 
reported to be behind target. The analysis shows research investment to make a 
statistically significant contribution to GDP growth in the UK, which is suggested by the 
literature to affect economic performance (OECD 2004). Investment in education was 
the second area found to impact GDP growth with the analysis shows an increase in 
spends as a percent of GDP by 1995 to 5.5%, but a fall back to the 1990 level of 5% by 
2002. 
The UK is reputed for its strong government support for therapeutic cloning, having led 
the world in passing legislation to clarify the context for this work, and was first to issue a 
license to legalise it. It has been successful in cloning cells (BBC 2005), and this 
research found strong support amongst its scientists. The strength in regulation and 
policy is underpinned by increases in funding that aim to stimulation both innovation and 
its translation to commercial and therefore economic advantage (DoH 2002; DTI 2000; 
DTI 2002). From the public survey, these views are not always supported with many 
saying more investment is needed to compete with other countries. Interestingly, over 
half of the survey supports the use of human embryos and over 75% believe the UK will 
lead in finding a cure for diabetes, suggesting enormous confidence in its scientists. 
Amongst the researchers, there is a view that more money and longer-term commitment 
to research programmes are this field is needed. Some even claims that the UK is 
being short-sighted in failing to provide sufficient infrastructure for stem cell research in 
comparison to other countries calling specifically for longer-term financial commitment. 
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Weaknesses include realisation of new technologies, as these are said to take 15-20 
years longer in the UK (Dargie 2000; Raferty 2001; Wanless 2002; Dyers 2003; May 
2003) , with the House of Commons concluding in 2005 that many new technologies are 
simply not being implemented. It is this difference in clinical trials and market regulation 
that explains why gene therapy is available in China for cancer and not the UK (Luck 
2004) . Indeed the UK's approach to research funding and tight regulation is said by 
some to threaten the UK's global leadership position as well, and it has been suggested 
that China may make the steps more quickly (Mathur 2005). Culture and ethics are also 
highlighted as areas of concern in the UK (Knight 2004); its research trials take longer 
(Dyer 2003) and it has a poor history of turning its science to commercial advantage 
(DTI 2001). 
In conclusion, the UK has led the world in developing stem cell science and has strong 
legislation, regulation and government support. Its economic climate is stable, growing 
at around 2.5% annually, and research funding for stem cell science is reported to be 
'improving'. It is highly regarded internationally and has been a major player in the most 
significant genetic advances, such as decoding the human genome (Goodfellow 2001) 
and creating Dolly the Sheep (PHGU 2002). Its weaknesses are found to be its ability to 
commercialise its research; reduce GDP spend on research, the short-term nature of 
such investment, and the ethical values which hold stem cell science within the 
laboratory. Where China appears to have strength is in its economic growth that 
averages 10% (Wilsdon 2006) and its ethical context, which enables primate and human 
research (Chien 2004 Yank 2004). With much of this led by its clinicians, stem cell 
therapies have already advanced to the clinic. 
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Part 2 - How do the National Systems of Innovations in the UK and China 
influence the translation of stem cell science into clinical treatment? 
The NSI of a country sets the boundary within which its stem cell science is organised 
and may advance. This covers its government policy, its translation to research 
strategies and funds, and the cultural values of its society. Each will influence what is 
permissive, its pace, and the organisation of science and its ultimate advance to cures 
for human disease. There are notable differences, as discussed in question one, 
between the UK and China in each of these. 
This part of the research is concerned with understanding which aspects of the National 
Systems of Innovation enable the creation of the science of therapeutic cloning and its 
diffusion. Although some of this is speculative, as therapeutic cloning for diabetes is not 
currently available in either county, there are indications of the issues to be understood 
or redressed from the introduction of related medical science. These include legislation 
and regulation, investment strategies, alternative access, and public opinion, which 
include acceptance and societal ethics. 
Both the UK and China have strong political support for therapeutic cloning; suggesting 
the legislative pathway for stem cell therapies is permissive. This is evidenced in China 
by strategic intentions and long-term research investment (Wilsdon 2006) and in the UK 
by leading the world in major advances that stimulate public and private innovations. 
This is validated by the questionnaire where over 50% believe the UK has a strong 
legislative and regulatory environment for stem cell research and the scientists 
interviewed reported the situation as 'sorted and stable'. From the questionnaire results 
it is shown the UK public has little knowledge about the legislation in China, with only 
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21 % sure that human cloning was not legal there, too. The reality is much of the 
legislative structures for stem cell science are adapted from European structures (Salter 
2007), so a degree of consistency with UK standards is to be expected. 
Patent legislation is a proxy for stem cell technologies ownership and their translation 
within the innovation system (Brown 2003; OECD 2005). This offers a view on how 
money and power are distributed between countries (Baird 1998; ICC 2003). Human 
genes have been distinguished in many Western countries, including the UK, from being 
patented by the separation of discovery from invention (Burham 1997). It is a complex 
area of law, surrounded by concerns about the control of human life and scientific 
advance and an absence of prescriptive direction (Jenson 2005). UK patents provide 
protection for 20 years whilst the Chinese had been 7.5 years (Qiming 2005), although 
they have recently aligned this to European standards (Salter 2007). All research 
centers in the UK are encouraged under the 2002 science and technology regulation to 
exploit their 'findings' using patent registrations, but many report its application to stem 
cell research as being 'horribly complicated'. Some argue the patent system is impeding 
developments and point out that patenting the IVF process was resisted. UK 
researchers say 'the system is a minefield and far from adequate', some suggesting that 
an alternative system needs to be designed that is license-based. Of those questioned 
in the survey, 52.4% believe patent registration in this area of science is necessary while 
14.2% do not. 
In China, lax enforcement of its patent legislation (Giannakas 2003; Wilsdon 2006) is 
having an influence on how stem cell technologies are operating. This is evidenced by 
the effect on those organisations willing to set up research institutions in China and the 
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accuracy of the corresponding patent details so registered. The most public example is 
that of Pfizer, and its dispute surrounding Viagra when they refused to register the entire 
details of their product in their patent licence (Mooney 2004). China is working hard to 
improve the regulation of their patent market under the control of its national science and 
technology programmes. Its current enforcement, although improved since joining the 
World Health Organisation in 2002 (Hsiao 2004), reduces the effectiveness and 
attraction of its stem cell science. 
The regulatory system is seen to be permissive in both systems, with strong government 
support, although enforcement undermines the Chinese credibility. 
Societal values and culture are the next major aspects of the NSI that influence how 
stem cell research is translated to clinical treatments. This is where the greatest 
difference is found between the UK and China and the area suggested by many to 
separate the potential between the two countries (Mann 2004). The ethical climate of 
the UK is very different. From the questionnaire, just under half of the UK population 
support human embryo research in the UK, believing it to be essential to find cures for 
existing disease, but less than a third believe this to be the universal view of the UK 
population. That is an interesting position, as essentially people are saying they are 
supportive of this type of research but they believe it is other people who are not. 
60.3% believe stem cell technologies will cure existing disease, 42.9% say human 
embryo research will lead to a cure for diabetes, and 43.6% agree the creation of human 
embryos is worthwhile to cure diabetes. The majority think a cure will be available 
abroad before it happens in the UK. UK scientists say that people will not travel abroad 
for such treatments and the risks of managing peoples' expectations will be harder than 
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any health risk. Many of its scientists believe the ethical focus is misplaced and does 
not help the position of UK stem cell research, urging social scientists to take on this 
focus. Others claim there is no future for stem cell therapies in any country because the 
medical, legal, ethical and religious objections are all too great to overcome. Put 
simply, the UK is said to have the advantage in terms of legislation and operational 
practice, while the Chinese are putting their research into practice. 
The public survey found that almost 90% of people believe that ethical concerns will 
slow the advance of stem cell science in the UK. The survey found 43% supported the 
creation of human embryos for research, a proportion that rose when separated by 
those with diabetes or other genetic illness. The ethical context is wider than personal 
opinion in the West, as it underpins religious belief and values and challenges, some 
believe, the very structure of human civilisation. In the West the science of genetics (of 
which stem cell techniques are a major part) afford the potential use of these 
technologies to promote ethnic prejudice (Pinnick 2002) as weapons of mass destruction 
(OECDc 2004) and playing God in selecting to destroy human life (Epstein 2002). There 
is an analogy here to the creation of human embryos for IVF where many fertilised eggs 
are destroyed, but this technique was never given public sanction (Ridley 1999). Once 
the first 'test tube baby', Louise Brown, was born this procedure was largely accepted. 
This study found a clear division between those holding religious beliefs and those who 
do not in the issue of embryonic stem cell research. 
In China there is no such concern. The Chinese see only prestige and economic 
advantage in advancing stem cell science in the clinic. Indeed they are counting on this 
aspect of their national innovation system above all others to give them a lead (Mann 
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2003; Hsiao 2004). The ethics in China are that if somebody is sick and there is a 
possibility a new intervention may help, it is almost criminal to withhold it. China is said 
to be approaching this responsibly and it should not raise any concern, although ethical 
controls are considered by many to be looser in China, with doctors said by some to be 
unable to guarantee safety in their work. The social aspect of the NSI is shown to be 
restricted in the UK and permissive in China, affording a distinct advantage. 
Part Two Summary - How do the NSI of the UK and China influence the advance 
of stem cell science? 
Ultimately the NSI for each country influences how stem cell advances by determining 
the boundaries of acceptability. In China the permissive nature of its societal culture and 
values alongside government funding has enabled it to translate its science into human 
treatments. Dr Xia Wang from Newcastle Life Sciences believes this application of its 
research in a clinical setting is China's most notable advantage. Chinese scientists are 
said to be a bit more adventurous, especially if the patient has end-stage disease. 
Its research systems are found to be as advanced as the UK and to benefit from clear 
long-term funding strategies. It political and legislative systems are also permissive and 
advanced, with strong long-term research funding. These aspects translate to enable 
the application of stem cell science in a clinical setting, within a strong regulatory 
structure. The NSI for China is found to be permissive and operational. 
The UK NSI is highly organised, having led in determining the structures for managing 
the control and ethics of stem cell research in the Western world. Its political system is 
also supportive, but it is more cautious. This is evidenced by the current debate on 
chimera research, which was almost banned in the UK, but subsequently approved 
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under licence. Research investment is still short-term and within a failing GDP target 
that looks unlikely to reach 3% by 2014 (OECD 2004f; National Statistics 2007). Its 
stem cell research remains largely laboratory-based, although there are examples of 
stem cell trials. Its NSI is broadly facilitative but limited by long-term funding, cultural 
ethics, and clinical regulation. 
Part 3 - Due to the NSI, which Country will first develop a stem cell cure for 
Diabetes? 
In the UK Stem Cell research is led by the Newcastle Life Sciences and Kings College 
London where their work is still currently focused on the use of adult stem cells in the 
process of therapeutic cloning. Work in China has already advanced to curing diabetes 
in primates at Xuan Wu Hospital Stem Cell Therapy Centre. One of the main reasons 
for this difference is cultural ethics, as evidenced by almost 90% of people in the UK 
questionnaire who say the ethical stance of the UK will slow progress in stem cell 
research in the UK. China has excellent animal facilities, making research cheaper. 
They tend, therefore, to be more adventurous, although some scientists claim this 
approach makes their controls too loose and gives too much power to doctors who 
cannot always guarantee safety. Those who have witnessed this work in China say 
these claims are not true and that China has clear and proper ethical control. However 
whatever the advances in China, they would not be permitted in the UK due to controls 
and clinical trial regulations. Indeed many in the UK now say past advances such as 
percutaneous angioplasty are no longer possible because of tight clinical trial regulation. 
The challenge of this work is to explore whether the UK will advance therapeutic cloning 
into a clinical setting for diabetes ahead of China. Of those responding to the UK 
questionnaire, 6.6% are diabetic. Their views can be distinguished from all other 
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categories in the analysis in believing consistently that China would be the first country 
to cure diabetes. They also agreed that embryo stem cell research was essential to 
advance this. 29% of the study had a family member with diabetes, and they too 
supported human embryo research more than the average. There are many scientists 
who also believe China will advance clinical services more quickly than the UK, although 
it is suggested that China may lack an understanding about how these work. The 
requirement of clinical trials at a European level will control the translation of these in the 
Western World (Neergaard 2006). 
The Chinese appear to have a number of advantages that are driving their research into 
clinical practice. Access to primate research, strong long-term government funding, and 
a cultural acceptance that appears to make therapeutic cloning more easily translated 
into clinical therapies. In China, stem cell therapies have advanced to the clinic with 
many therapies advertised on the internet, encouraged by reported success in curing 
diseases such as motor neurone disease (Goldkorn 2005). Evidence in this work 
appears to suggest the Chinese have an environment fuelled by strong government 
funding, economic growth, public compliance, and clinically-led science. Opinions 
gathered from senior science and policy-makers do vary, but all those with connections 
to China believe it will be first in using therapeutic cloning. In this study the majority of 
the UK public did not. Because of this difference of opinion, it is helpful to use 
innovation theory to answer the question of which country will lead. 
Nelson and Roseberg (1993) and Nelson (1992) studied the process used to get 
innovation into practice, suggesting the need to understand the system in which they are 
to be introduced. Understanding the internal dynamics of the innovation sequence is 
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said by Mina et al (2004) to happen over time and involves an understanding between 
investment, knowledge creation, and process interactions (Fagerberg 2004). In applying 
this approach to the question of which country will achieve a cure first, it is helpful to 
order the respective strengths of the National Systems of Innovation along a simple 
innovation sequence. 
UK China 
Economic Infrastructure (2002) 
Current GDP Performance equal equal but growing at + 8% 
Trade in Goods and Services -1.6% 24% 
Inflation 3% stable 2% stable 
Balance of Payments Negative Positive 
Investment in Education (GDP) 4.9% 5.23% 
Investment in Health (GDP) 7.7% 5.8% 
Spend on Research (GDP) 1.89% 1.31% 
Legislation/Regulation permissive permissive 
Research Investment short term long term 
Research Workforce academic clinical researchers/doctors 
Culture ethical concerns ethics an advantage 
Existing Research Evidence laboratory only cured diabetes in monkeys 
Work/evaluate islet cell required 
Some treatments in clinic 
This design sequence captures the values for the NSI of China and the UK. It illustrates 
clearly that China has a stronger overall economic context for research investment, 
equals the UK with permissive legislation, and has been able to advance to the clinic 
due primarily to the absence of ethical concern. The UK leads in legislation and 
research investment but has lower measures of economic performance and growth. 
Using these measures, the innovation sequence is weighted in China's favour. 
Conclusions 
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Three approaches have been used to explore the research question of understanding 
how the National System of Innovation for the UK and China is influencing their work in 
stem cell science. The definition and structure of the design is taken from the 
innovations literature and extended to this clinical research. The economic aspects of 
national innovation are structured in an historic time series from 1990 to 2002 and show 
the UK statistically to have stronger economic factors of innovation. GDP investment in 
education and research were found for both the UK and China to make a statistical 
contribution to economic growth. 
In China, this increased during the research period of 1990 to 2002 from 2.3% to 5% 
and from 5.5% to 5% in the UK. UK spends for the same period on research fell from 
2.2% to 1.9% whilst it rose from 0.7% to 1.3% in China. There is further evidential 
improvement in China during the time of this study, most notably in the area of research 
investment, which rose to 1.3% in 2005, becoming the second largest research spend 
globally (Wilsden 2006; BBC 2006a). The UK-based research interviews expose further 
the differences in the two NSI, most notably the relaxed ethical stance in China and the 
strong regulatory leadership in the UK. The various strengths and weaknesses 
between the two systems are compared in an innovation sequence in the final section of 
analysis, where diabetes is used as a model to make the comparison. This result 
suggests when all the factors of innovation are taken together that China has a stronger 
NSI for stem cell research. 
The strengths in the NSI for China are shown to be the size and long-term nature of its 
research investment, it's historic and projected economic growth, its state-of-the-art 
infrastructure, doctors leading its stem cell research, adoption of European legislation, 
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its relaxed and permissive ethical stance, and how these have enabled it to translate the 
science to clinical practice. The weaknesses that undermine these are its lax 
enforcement of Intellectual Property Law, the absence of creditable publications and 
suspicion of its operational culture (due to Korean fraud). The corresponding position for 
the UK shows it strengths to be its high global reputation, historic leadership in science, 
and strong government support. Its weaknesses are found to be its short-term 
investment strategy, decline in research investment as a proportion of GDP, societal 
concerns, and the requirement of its clinical trails, which prevent the advance of much of 
its science to the clinic. 
These can be summarised using the same framework from Chapter Three used to 
structure the research question. 
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Factors of Innovations 
Economic Systems 
(National Investment Strategies) 
Political Systems 
(Legislation and Regulation) 
Social Systems 
(Disease and Morbidity 2002) 
Research Environment 
(Investment Strategies) 
Culture and Ethics 
(Societal Acceptance) 
UK 
Improving 
Permissive 
Global leader 
IPR system regarded 
Reputable and trusted 
Access to health care 
2.2m 
Laboratory based 
short-term 
Global leader in science 
Moral and Religious 
objections 
China 
Significant strength 
Permissive 
Adopt European 
Weak IPR system 
Western Distrust 
Limited access to health 
40m 
Treatments in clinic 
long-term 
Little published research 
Low investment in basic 
Cloned hybrid 2003 
Societal acceptance 
Primate and human research 
The importance of this study and its findings are in offering an insight to the policy 
position and opportunity for an area of science considered by many to be potentially the 
most important scientific advance to man. Its importance is more than social, in 
affording cures for diseases such as cancer and heart disease (Hepeng 2005) with 
economic advancement is shown to correlate to research and development (OECD 
2004a). The NSI of a country is found in this research to impact the advance of stem 
cell science in a number of ways. When taking the NSI to be its economic, legal, and 
social features, it can be shown that some aspects are more permissive and enabling for 
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stem cell research. These include societal positions on the use of human embryos, the 
application of cures that cannot yet be explained, the nature and stability of research 
investment and the underlying economic position of a country. As the business problem 
is defined in two parts, so too is the importance of the contribution of this study. 
On an economic level, investment in research and its focus on marketable outcomes are 
shown to be vital if a country is to improve its performance (and all the life quality issues 
that are associated with this). China is found in both to have stronger underlying 
economic performance and growth and to have a stable, long-term commitment to its 
research funding for stem cell science. The second aspect is in providing an 
understanding of the societal context, which is evidenced by the values and ethics of a 
government and its population. The UK, like many Western cultures, struggles to 
advance its genetic science exampled by its hybrid research (BBC 2008) whilst China 
has no such concern (Poo 2004). This research found about half of the UK sample did 
in fact support embryo research, a finding substantiated by a subsequent study on-line. 
The two difficulties it faces that need to be understood further are the communication of 
complex issues and the relationship with those people holding religious beliefs. 
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DBA Chapter Five 
Summary and Conclusion 
Review 
This research set out to explore the advance of stem cell science in the UK and China 
from a UK perspective using National Systems of Innovation as a theoretical structure 
and diabetes as the clinical model. Although stem cell research applies largely to Type 
1 diabetes, work reported in the BMJ shows its advance will have significant application 
to both types of the disease (Serup et al 2001). This case study between the UK and 
China has been undertaken from a UK perspective, with Chinese information taken from 
the creation of a new economic data set from 1990 to 2002 and interviews with scientists 
who work in both countries. 
Therapeutic cloning has, since the US cloned human embryo cells in 1998, offered 
major opportunity to cure human disease and disability (Shamblott and Thompson 
1998). In this type of research the cells are undifferentiated affording the potential to 
grow into any cell or tissue type. The technique of using human embryos for research 
offends many, including religious and pro-life groups covering swathes of Western 
populations. This leaves governments with the challenge of regulating this new 
science, of managing public opinion, and advancing its potential. This research found 
strong and consistent objection to the use of human embryos amongst those holding 
religious belief. 
The US did this by prohibiting the use of public research funds on embryos, except 
those created for use in IVF prior to 2002. The European Union issued a one-year 
moratorium before issuing new guidance that permits the use of government funds for 
Gail Newmarch 175 
D B A Final November 2008 
human embryo research, although this is objected to in Germany, Austria, Lithuania, 
Malta, Poland, Slovakia, and Luxemburg (BBC 2006). The UK adopted European 
guidelines into its legislation and permits embryos to be used and created for the 
purpose of research under licence by the Human Embryo Fertilisation Authority up to 14 
days from fertilisation. It succeeded in cloning for therapeutic purposes its first human 
embryo in 2005 (Lawless 2005). China has also introduced permissive legislation for 
human embryo research and has, since 1999, been successful in cloning human 
embryos (Yank 2004), implementing European regulation to support this. It has 
reportedly translated this to clinical practice, since its first gene therapy cure for cancer 
in 2004 (Pearson) to many advertised conditions including Epilepsy, Muscular 
Dystrophy, Cerebral Palsy, and Motor Neurone Disease at Medra (www.medra.com). 
This research is structured around the Systems of Innovation, as they relate to stem cell 
therapies at a National level for each country. The definition of NSI as it relates to 
therapeutic cloning was framed from the literature and covers the political context, 
including economics and legislation, intellectual property, public culture, demography, 
knowledge, and the relationship to diabetes, the disease area being studied. These 
were taken from the works of several, including Edquist (1997), Freeman (1997), and 
Fagerberg (2004). 
The first area examined was the relative strengths and weaknesses of these for the UK 
and China as they relate to therapeutic cloning. This established that the UK has a 
stronger economic background, but China is growing at a far greater rate, with total GDP 
growth in China being more than twice that of the UK. Perhaps of most significance in 
the economic indicators is spend on research, which has doubled as a percent of GDP 
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between 1990 and 2002, while the UK spend reduced from 2.2 to 1.76 (National 
Statistics). Indeed, China had by the end of 2006 the second highest international spend 
on research (Lombardi 2006). Despite policy to reform research investment in the UK, 
on current projections China will equal GDP performance with the UK by 2010. China 
also has inflation rates at less than half that of the UK and a positive balance of payment 
while the UK is negative, suggesting a stronger underlying economy. 
The relationship between research investment and GDP performance was found in this 
work to be statistically significant, suggesting potential economic weaknesses in the UK 
position. The respective strengths were explored using a public questionnaire and 
email/telephone interviews with researchers. These found that the majority of the UK 
public are suspicious of China and believe very little of its achievements or possibilities. 
This varied when people living with diabetes were separated from the samples, as they 
were found to have a more positive perception of Chinese science. Amongst the 
scientists themselves the views were mixed. Those who have visited or worked in China 
appeared to hold their science with respect and admiration. 
The UK was well-regarded too, especially in system areas such as legislation and 
organisation of the science, although funding is said by some to limit their work. Ethical 
concerns are said to restrict UK science, as evidenced by the debate on Chimera 
cloning and changes in the legislation to permit women to donate embryos outside of 
clinical treatments (HEFA 2006). Chimera cloning involves using a rabbit or cow embryo 
and was expected to be banned in January 2007. While a decision was awaited, a 
public survey was carried out on AOL on 14 t h January 2007 asking 'do you support the 
use of embryos for research?' 66% replied yes, which is a very similar result to this 
study. UK approval was finally granted (BBC 2008). The interesting point is public 
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support appears, from both studies, to be stronger than the government appears to 
recognise. 
The Chinese Government, in contrast, is said to have substantial and long-term financial 
support leading to some of the best quality laboratories in the world. But overall it 
appears to be the relaxed ethical stance of China that has enabled major advances in 
therapeutic cloning and has offered the advantage. China is found to have moved into 
the clinical setting to treat patients (Ning 2005), is reported to have cured cancer using 
gene therapy (Pearson et al 2004), and is reported to have advanced to treating 
leukaemia with plans to progress shortly to working on diabetes (Hepeng 2005). 
This work considered whether any of the factors of innovation, as identified, were able to 
predict the trend in diabetic prevalence, which is a major economic and social threat to 
human health (WHO 2002). This found that growth in GDP and trade in goods and 
service gave the strongest indication, suggesting China might be facing significant and 
rapid increase in the disease if alignment to its economic success continues. The next 
area to be examined was how the respective National Systems of Innovation might 
influence the translation of therapeutic cloning in the treatment of diabetes. This found 
the UK legislative system to take at least 20 years compared to 5 in China for clinical 
trials and research (Yank 2004). China's lack of investment in basic research is thought 
to restrict its credibility in its stem cell and scientific advance. 
Those aspects of the NSI found to influence the translation of the science to treatment 
includes investment in the research, legislation of the clinical trials, and societal values. 
The questionnaire results found most of the population did not consider China capable 
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of curing diabetes (85%), a view supported by some of the researchers. However, those 
who have visited or worked in China were confident it not only could, but that it would. 
The issue here appears to be that even if China does cure diabetes; European 
legislation of clinical trials would require the results to be replicated before they could be 
considered. This study found that most people with (or having family members with) 
diabetes would be willing to travel to China to find a cure, believing such therapy would 
not ever be available on the NHS. 
The respective strengths and weaknesses of therapeutic cloning between the UK and 
China were also compared. The advantage the UK was found to have is a prestigious 
reputation, first class scientists and institutions, strong government support, and a strong 
history of invention (PHGU 2002; Best 2005). Already it accounts for 9% of global 
research whilst having only 1% of the world's population (OECD 2000). It has worked in 
the field of genetics longer than anywhere else (Best 2005) and is reported to have the 
best regulation of stem cell science in the orld. Its disadvantages were found to be 
short-term research funding strategies, a decline in research investment as a proportion 
of GDP (Dasgupta), the length of its clinical trials (Dyers 2003), and a poor history of 
turning innovation to commercial advantage (DTI 2001). Indeed, some will go as far as 
to suggest the UK is in serious danger of losing any perceived advantage it may have 
because of its tight funding and regulation regime (Mathur 2005). 
The advantages of the Chinese in therapeutic cloning are said to be its evident success 
in application of the science in the clinic (Hepeng 2005), its relaxed ethics (Yank 2004), 
the length of its clinical trials (Yank 2004), and their advanced infrastructure (OECDb 
2004). They also have access to human and primate research (Chien 2004) (making 
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their cost base cheaper), strong and long-term Government funding (Hsiao 2004), and a 
strong advancing economic base. Their weaknesses are said to be in their basic 
science, which has been greatly affected by their isolated history and the absence of 
focus on the communication of their research in the published literature (Wu 2002). 
The final question for this research was which country is likely to cure diabetes first. The 
national factors of innovation were summarised and compared. This found GDP 
performance to be equal but growing at a far greater rate in China and for trade in goods 
and services to be far stronger. Inflation is slightly lower in China but stable in both, 
balance of payments is negative for the UK but positive for China, and investment in 
education is equal. Research as a proportion of GDP is higher in the UK, but both 
countries have permissive legislation. China's research investment is long-term while the 
UK's is short-term. China has an advantage in its ethical stance and is already treating 
patients while the UK research is still laboratory based. 
These findings should be taken in context with China's economic growth of over 10% of 
GDP for the last five years 10.5% in 2006 - which suggests it is, has a far stronger 
investment potential to support its stem cell research. Aside from some very serious 
social issues to manage within its economic success (Zheng and Chen 2006), it has 
played a major part in Asia taking over from Europe as the second largest spender on 
research as 32% of the world total (Wagdy 2006). By the end of 2006, China will have 
taken over Japan to become the second highest spender on research, spending $136bn 
in 2006 (a 77% increase between 1995 and 2004) compared to $330bn in the United 
States. They now employ 926,000 researchers compared to 1.3bn in the US (Lombardi 
C 2006). It is against this backdrop of investment and personnel that China's strength 
to succeed appears greater. 
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Policy Implications 
During the six years of this research thesis, there have been many views on the position 
of China's role in stem cell treatments, some based on experience, others from the 
absence of evidence available. Indeed, current news now regularly reports on variable 
treatments. What is clear from this is that there are a number of policy implications from 
this work that will shape the NSI in both China and the UK, as the science advances. 
These are: 
• The length of time taken for clinical trials in the UK is suggested to threaten its 
position in leading innovation 
• Stem cell research in the UK needs to advance into human clinical trials more 
quickly 
• Tight regulation in the UK is important for public safety but maybe slowing the 
pace of innovation 
• Research funding for stem cell science needs a longer term financial strategy. 
In this study half of those responding believed the UK needed to spend 
more on stem cell research 
• The UK needs to align its research funding with clear commercial strategies 
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• There needs to be more meaningful and simple communication with the public 
about stem cell science, the use of human embryos, and clinical trials. There may 
be more public support for embryonic stem cell research than reported. 
• 75% of people said they would access a stem cell cure abroad if it were not 
available in the UK. Current structures are restricting innovations for many years 
in the UK without any real debate with the public. New health innovations need 
to be available more quickly in the UK, which will require opening up market 
opportunities for the independent sector and changes in legislation. This is an 
issue that goes wider than stem cell science, involving the containment of 
innovation in the UK NHS system. 
• For China, its spend on health care and the percentage contributed by its 
government were shown statistically to impact its performance in trade in goods 
and service, suggesting its health system is having a far greater influence on 
economic productivity than the UK. Finding long-term solutions to its health 
structures is suggested to be essential to its sustained economic performance. 
• China already knows detection of fraud and enforcement of its legislation and 
regulation of its stem cell science go to the heart of its credibility 
• China needs to publish more data on its current work, using standards for clinical 
trials that are recognised by the Western world 
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Future Work 
There are many ways this work might be taken forward. An obvious one is repeating the 
public questionnaire and research interviews in China to obtain some comparison, but 
my suspicion is that their relaxed approach to the ethics of embryo research would 
prevail and strengthen the Chinese position. Another area of significant interest from this 
study would be to explore further whether people really are willing to travel to China for 
treatment and cure and how real the concerns of safety are. Most people, whether of 
the public or researchers in this field, do not think this is likely, but it would be interesting 
to understand the basis on which people might make such a choice against going. 
Probably the biggest question arising from this work is whether the highly regulated 
environment of the UK is an advantage or disadvantage in therapeutic cloning. Clearly 
the complexity and ethical concerns demand such accountability, but with thesis comes 
restrictions such as clinical trial regulation and the assessment body, NICE. 
There appears to be a strong possibility that therapeutic cloning will cure disease long 
before science is able to explain why; indeed, this is already happening in China 
(Medal). I wonder how long people in the UK might wait before the function of all genes 
is understood with their relationship to human characteristics, including systematic 
mutation, or for the calculation of activity in proteins produced by specific cells or tissue, 
and how these proteins combine to perform specific functions. Indeed some of the 
research scientists interviewed in this study also questioned whether an explanation was 
really necessary. History shows many innovations have advanced outside formal 
clinical trials and without explicit public debate. The birth of Louise Brown was the event 
that made IVF a reality but was not a technique agreed publicly (Ridley 1999), with both 
stents in heart surgery and bone marrow transplants surviving disastrous early results to 
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become mainstream procedures. From this research China suffers from neither the 
social nor regulatory restriction making it well placed for the next major step-change in 
the management of human health. 
Strengths and Weaknesses of the Research 
There are a number of strengths in this research, most notably in its construction. It was 
a difficult area to place a study, as there was nothing in the historic literature to afford a 
structure. This was achieved in a tripartite approach in the research design, taking the 
key components from the literature. This has extended the use of NSI to a new clinical 
area and offered an empirical framework in its design. The research provides an insight 
to the views of the UK public in the area of stem cell research and establishes links 
between the views held and the personal characteristics of an individual. For example, 
the relationship between people and their families living with an incurable disease and 
those with religious belief is established. This research also includes comment from 
some of the most eminent policy and scientific researchers in the field of stem cells. 
The structure and design would be easy to follow if another study was taken to replicate 
or extend the results. It also provides a database of economic information for the UK 
and China that did not previously exist. It would be easy to extend the statistical 
analysis and show change since 2002. 
Its weaknesses include not extending the public questionnaire to the Chinese population 
and limiting the data to 2002. Although the study was not designed to include the 
Chinese public, two attempts were made to distribute the questionnaire in China, neither 
proving successful. Although this is redressed somewhat in the policy and research 
interviews, it would have added a useful dimension to the results. Limiting the economic 
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data to 2002 occurred because it was simply the most recent date at the time of 
analysis. This has been strengthened by including reference to the more recent 
statistics, where available, in the discussion (National Statistics 2007). 
Reflections on Learning 
It has been a fascinating six years studying both the advance in stem cell science and 
the position of China in the global market. Perhaps earlier in these studies it was more 
difficult to justify the research interest to business, but this is not apparent in areas far 
wider than this research. It is an Interesting and stimulating research topic as it touches 
on the concept of life, its creation, and manipulation, and at a level no other species on 
earth could come close to. The ethical aspects of eugenics, equity and human suffering 
are all incorporated, as are the philosophical aspects of right and wrong, good and evil. 
In addition, building an economic comparison for the UK and China in a way that had not 
previously been achieved highlighted some fascinating trends, such as the strength of 
China's economic foundation and this pace of its advance. 
It was a difficult study that suffered from many blind alleys and time on work that never 
found its way into the thesis. Developing a theoretical framework over the first two years 
was complicated, involving many structures and drafts that were too vague. Using NSI 
was not a simple transfer, requiring absolute clarity about how it was used in other 
clinical studies and the justification of extending this to stem cell science. Building a 
database on economic factors of innovation for the UK and China was difficult, as many 
of the indicators were not routinely available and I had to search many databases and 
publications to build, in some cases, year-by-year numbers. Having built this great 
economic data and a list of all stem cell research in the UK and China involved in 
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diabetes, I couldn't get many of the science and policy leaders to speak to me. 
Professor Cathy Prescott from Avlar Bio Ventures Limited changed this and enabled 
many contacts, including Professors Murdoch and Minger. 
Contribution to Knowledge and Learning 
There are a number of ways this work contributes to knowledge and learning: 
• It provides an economic comparison between the UK and China that had not 
previously been achieved 
• It provides a framework and an empirical structure for the use of National 
Systems of Innovation in stem cell science 
• It proves the relationship between religious belief and the absence of support for 
embryo stem cell research 
• It proves that half of the sample population supports therapeutic cloning 
• It proves further evidence of the position and role of China in stem cell science in 
identifying and validating the strengths of its national system 
• It provides further validation of the importance of research to economic 
performance and highlights the decline, as a portion of GDP performance, in the 
UK 
• It provides evidence of the contributions GDP spend on research and education 
are making to economic performance 
• It provides evidence of the translation of stem cell procedures in clinical practice 
that is already happening in China yet restricted by European legislation in the UK 
• It identifies the strengths and weakness of the NSI for the UK and China as they 
relate to stem cell science 
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Conclusion 
This work set out to explore the relationship between the National Systems of Innovation 
in the UK and China and the advance of stem cell research. It found strengths and 
weakness in both systems and describes how these are influencing their science, 
offering an opinion on which country is likely to advance a cure for diabetes. The UK 
clearly has a global reputation with much attributed success in the field of stem cell 
research (DoH 2003; PHGU 2002; Best 2005). 
In this work, China is found to have a stronger economic future, greater and faster 
research investment, and perhaps most significantly, an ethical and political advantage. 
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Appendix A 
Questionnaire 
Stem Cell Technologies and Health 
Questionnaire - Stem Cell Technologies and Health 
Personal Details What is your Nationality? 
Male 
Female 
Gender 
• 
• 
Please indicate your age: 
What is your occupation? 
Student • 
Clinical • 
Other Professional • 
Non-Professional • 
Other • 
British 
American 
European 
East Asia 
Other 
• 
• 
• 
• 
• 
Do you have any religious 
beliefs? 
Do you have diabetes? 
Do you have a family 
member with diabetes? 
Do you have any other 
genetic illnesses? 
Do any members of your 
family have genetic 
illnesses? 
Yes 
• 
• 
• 
• 
• 
No 
• 
• 
• 
• 
• 
Please indicate your views about the following statements by ticking the corresponding box 
Dolly the sheep was the first cloned The UK lead the world in stem cell 
creature in the world? 
• True 
• False 
• Not Sure 
research 
• True 
• False 
• Not Sure 
China cloned a fish 30 years before Dolly 
was born 
Human cloning is illegal in the UK 
• True 
• False 
• Not Sure 
• True 
• False 
• Not Sure 
Human cloning is legal in China The UK has the world's first licence for 
therapeutic cloning 
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• True 
• False 
• Not Sure 
China has produced a gene therapy cure 
for Cancer 
• True 
• False 
• Not Sure 
China will lead the world in producing a 
cure for diabetes 
• True 
• False 
• Not Sure 
Therapeutic cloning is legal in the UK 
• True 
• False 
• Not Sure 
• True 
• False 
• Not Sure 
Human embryo research is legal in the UK 
under license 
• True 
• False 
• Not Sure 
Please indicate how strongly you agree or disagree with the 
following statements 
The UK Government spends enough 
money on research 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The amount of money the UK Government 
spends on research has increased in 
recent years 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The UK Government spends as much on 
research as other countries 
The UK Government needs to spend more 
on stem cell research if it wants to 
compete with other countries 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The UK has a strong legislative 
framework to manage and control stem 
cell research 
• Strongly Agree 
• Agree 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
More centres should be allowed to carry 
out human embryo research in the UK 
• Strongly Agree 
• Agree 
• No Opinion 
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• No Opinion 
• Disagree 
• Strongly Disagree 
New genetic discoveries should be 
available to the public from the internet 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Human embryo research will in time cure 
diabetes 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Finding a cure for diabetes is worth the 
creation of embryos for research 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Stem Cell Therapies will be available in 
the clinical area of diabetes within the 
next 10 years 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Stem Cell Therapy for diabetes will be 
available abroad before is it in the UK 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Human Embryo research will produce 
cures for existing diseases 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Any potential cure for diabetes will not be 
affordable under the UK NHS 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
A stem cell cure would replace existing 
therapies for diabetes 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
When stem cell therapy for Diabetes is 
found it will be available in the NHS 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The UK is highly motivated towards finding 
new innovations 
• Strongly Agree 
• Agree 
• No Opinion 
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• Disagree 
• Strongly Disagree 
I use the internet to find out about health 
services abroad 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
I would go abroad for treatment that is not 
available in the UK 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Human embryo research is essential to 
find cures for existing diseases 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Ethical concerns about creating embryos 
for research in the UK will slow down 
discoveries 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Embryo stem cell research will find a cure 
for diabetes 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The first country to find a stem cell cure 
for Diabetes will be China 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
• Disagree 
• Strongly Disagree 
I would buy genetic tests using the internet 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
I would not have any concerns about 
accessing stem cell treatments abroad 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The UK population supports human 
embryo research 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
Patent Registration for genetic discoveries 
is essential to support investment in 
discovery 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
The UK will be first country to find a cure 
for diabetes 
• Strongly Agree 
• Agree 
• No Opinion 
• Disagree 
• Strongly Disagree 
PLEASE RETURN BY EMAIL TO 
Gail.newmarch(S>dur.ac.uk 
Or post to Four Elms Brook Road 
Tolleshunt Knights 
Maldon 
CM98EX 
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Pilot Questionnaire - Histograms 
Appendix B 
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Appendix C: Data from Questionnaire Analysis 
4 . 0 
3 . 0 
2 . 0 
1 . 0 
M a l e 
Age of Questionnaire Responses 
Sid Dev = 15.04 
Mean = 42 
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Histograms - Answers People w i t h Diabetes 
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China will be first find a cure for diabetes will be China 
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Tests ot Normality 
KolmrjQorov-Smimov 6 Shapirc-Wilk 
gender Statistic df Siq. Statistic df Sig. 
dolly Ihe sheep was the 
first cloned creature in the 
1 .273 84 .000 .784 84 .000 
world .342 69 .000 .732 69 .000 
the uk lead te world in 1 .321 84 .000 .745 84 .000 
stem cell research 
.350 69 .000 .724 69 .000 
china cloned a fish 30 1 .364 84 .000 .700 84 .000 
years before dolly the .377 69 .000 686 69 .000 
human cloning is illegal 1 .404 84 .000 .345 84 000 
in the UK 486 69 .000 .486 69 000 
Human cloning is legal in 1 .355 84 .000 .713 84 000 
China .368 69 .000 .700 69 .000 
Ihe UK has the world's 1 .402 84 .000 .656 84 .000 
first license for .490 69 .000 .204 69 .000 
china has produced a 1 .347 84 .000 .727 84 .000 
gene therapy cure for .431 69 .000 .614 69 .000 
china will lead the world 1 .470 84 .000 .532 84 .000 
in producing cures for .411 69 .000 .677 69 .000 
theraeutic cloning is legal 1 .263 84 .000 .773 84 .000 
in the UK .361 69 .000 .729 69 .000 
human embryo research 1 .432 84 .000 .621 84 .000 
b legal in the UK under .391 69 .000 686 69 .000 
the uk government 1 247 84 .000 893 84 000 
spends enough money 288 69 000 865 69 .000 
The amount of money Ihe 1 .207 84 .000 .892 84 .000 
UK Gov spends on .210 69 .000 .883 69 .000 
The UK Government 1 .232 84 .000 .876 84 .000 
spends as much on .291 69 .000 .839 69 .000 
The UK Government 1 .238 84 .000 .875 84 .000 
needs to spend more on .276 69 .000 .843 69 .000 
The UK has a strong 1 .266 84 .000 .862 84 .000 
legislative framework to .267 69 .000 .866 69 .000 
More Centres should be 1 .307 84 .000 .851 84 .000 
allowed to carry out .244 69 .000 .877 69 .000 
New genetic discoveries 1 .305 84 .000 .834 84 .000 
should be available to the .350 69 .000 .811 69 .000 
Human Embryo research 1 308 84 .000 780 84 000 
will produce cures for 346 69 .000 .803 69 000 
Human Embryo research 1 .303 84 .000 804 84 .000 
will in time cure diabetes .267 69 .000 828 69 .000 
Any potential cure for 1 .234 84 .000 901 84 .000 
diabetes will not be .289 69 .000 .839 69 .000 
Finding a cure for 1 .277 84 .000 .864 84 .000 
diabetes is worth the .266 69 .000 .865 69 .000 
A stem cell cure would 1 .290 84 .000 .861 84 .000 
replace existing therapies .216 69 .000 .883 69 .000 
Stem Cell Therapies will 1 .307 84 .000 .798 84 .000 
be available in the clinical .310 69 .000 .821 69 .000 
When stem cell therapy 1 
for diabetes is found it will 2 
.228 
.239 
84 
69 
.000 
.000 
.891 
785 
84 
69 
.000 
.000 
Stem Cell Therapy for 1 339 84 .000 784 84 .000 
diabetes will be available .357 69 .000 778 69 000 
The UK is highly 1 .280 84 .000 866 84 .000 
motivated towards finding .314 69 .000 816 69 .000 
I use the internet to find 1 .234 84 .000 .896 84 .000 
out about health services .252 69 .000 .883 69 .000 
I would buy genetic tests 1 .268 84 .000 .855 84 .000 
using the internet .285 69 .000 .868 69 .000 
I would go abroad for 1 .306 84 .000 .848 84 .000 
treatment that is not .371 69 .000 .781 69 .000 
I would not have any 1 .277 84 .000 .863 84 .000 
concerns about .196 69 .000 894 69 .000 
Human embyro research 1 .263 84 .000 883 84 .000 
is essential to find cures .293 69 .000 .848 69 .000 
The UK papulation 1 .188 84 .000 .884 84 .000 
supports human embryo .275 69 .000 855 69 .000 
Ethical concerns about 1 .414 84 .000 .688 84 .000 
creating embryos for .368 69 .000 783 69 .000 
Patent registration for 1 .209 84 .000 900 84 .000 
genetic discoveries is .294 69 .000 .837 69 .000 
Embryo stem cell 1 
research will find a cure 2 
.283 
.261 
84 
69 
.000 
.000 
.797 
.828 
84 
69 
.000 
.000 
The UK will be the first 1 .358 84 .000 .761 84 .000 
Country to find a cure for .307 69 .000 .800 69 .000 
The first Country to find a 1 .414 84 .000 .669 84 .000 
cure for diabetes will be 2 .384 69 .000 .713 69 .000 
a- Lilliefors Significance Correction 
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Descript ive Stat ist ics 
No. Min.Maxi Mean Std. Ske Kurtosi 
mu Devi wne 
m atio ss 
Stati Statistic 
n 
Stati Stati Std. Error Statisti Std. Error 
stic stic stic c 
nationality 157 1 5 1.24 .880 3.73 
ft 
.194 12.888 .385 
do you have religious beliefs 157 1 4 1.55 .536 
D 
.438 .194 .658 .385 
do you have diabetes 157 1 2 1.93 .256 - .194 9.692 .385 
3.40 
A 
do you have a family member with diabetes 157 1 2 1.69 .465 
\ 
.194 -1.347 .385 
.819 
do you have any other genetic illness 157 1 2 1.94 .233 - .194 12.952 .385 
3.84 
5 
do any family members have genetic illnesses 157 1 2 1.78 .413 - .194 -.070 .385 
1.39 
0 
age 157 17 78 41.66 15.0 
AC\ 
.178 .194 -.925 .385 
occupation 156 1 5 3.43 
*HJ 
1.33 _ .194 -.765 .386 
0 .480 
dolly the sheep was the first cloned creature in 157 1 3 1.70 .772 .574 .194 -1.097 .385 
the world 
the uk lead te world in stem cell research 157 1 3 2.36 .768 .194 -.953 .385 
china cloned a fish 30 years before dolly the 157 1 3 2.38 .813 
. m 
.194 -1.004 .385 
sheep .809 
human cloning is illegal in the UK 157 1 11 1.36 1.00 6.24 
A 
.194 55.291 .385 
Human cloning is legal in China 157 1 3 2.39 
u 
.791 
** 
.194 -.897 .385 
.830 
the UK has the world's first license for therapeutic 157 1 33 2.72 2.54 10.8 .194 130.14 .385 
cloning 7 63 2 
china has produced a gene therapy cure for 157 1 3 2.53 .666 - .194 .002 .385 
cancer 1.09 
7 
china will lead the world in producing cures for 156 1 4 2.61 .724 
1 
.194 .609 .386 
diabetes 1.42 
therapeutic cloning is legal in the UK 156 1 4 2.22 .867 
o 
.194 -1.454 .386 
.379 
human embryo research is legal in the UK under 156 1 5 1.60 .962 1.31 .194 .519 .386 
license 3 
the uk government spends enough money on 156 1 5 3.57 1.01 - .194 -.159 .386 
research 0 .575 
The amount of money the UK Gov spends on 156 1 5 2.88 .880 .113 .194 -.395 .386 
research has increased in recent years 
The UK Government spends as much on 156 1 5 3.34 .876 - .194 .142 .386 
research as other Countries .606 
The UK Government needs to spend more on 156 1 4 2.40 .825 .173 .194 -.462 .386 
stem cell research to compete with others 
The UK has a strong legislative framework to 156 1 5 2.53 .853 .309 .194 -.347 .386 
manage and control stem cell research 
More Centers should be allowed to carry out 156 1 5 2.64 1.02 .407 .194 -.708 .386 
human embryo research in the UK 8 
New genetic discoveries should be available to 156 1 5 2.35 1.09 .812 .194 -.154 .386 
the public from the internet 9 
Human Embryo research will produce cures for 156 1 4 2.12 .694 .419 .194 .404 .386 
existing disease 
Human Embryo research will in time cure 156 1 4 2.50 677 - .194 -.190 .386 
diabetes .126 
Any potential cure for diabetes will not be 156 1 5 2.79 916 .128 .194 -.367 .386 
affordable under the UK NHS 
Finding a cure for diabetes is worth the creation 156 1 5 2.58 1.06 .493 .194 -.521 .386 
of embryos for research 6 
A stem cell cure would replace existing therapies 156 1 5 2.70 830 - .194 .009 .386 
for diabetes .002 
Stem Cell Therapies will be available in the 156 1 5 2.82 667 .089 .194 .308 .386 
clinical area of diabetes within 10 years 
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When stem cell therapy for diabetes is found it will 156 1 5 2.83 900 .121 .194 -.876 .386 
be available in the NHS 
Stem Cell Therapy for diabetes will be available 155 1 4 2.17 .633 .318 .195 .449 .387 
abroad before the UK 
The UK is highly motivated towards finding new 156 1 5 2.63 .937 .507 .194 -.604 .386 
innovations 
1 use the internet to find out about health services 155 1 5 3.28 1.11 - .195 -.882 .387 
abroad 5 .269 
1 would buy genetic tests using the internet 156 1 5 3.61 1.11 - .194 -.776 .386 
6 .503 
1 would go abroad for treatment that is not 156 1 5 2.31 .941 .759 .194 .034 .386 
available in the UK 
1 would not have any concerns about assessing 156 1 5 3.12 1.12 - .194 -1.020 .386 
stem cell treatments abroad 6 .188 
Human embryo research is essential to find cures 156 1 5 2.55 .972 .493 .194 -.366 .386 
for existing disease 
The UK population supports human embryo 156 1 5 3.13 .914 - .194 -.814 .386 
research .104 
Ethical concerns about creating embryos for 156 1 5 2.24 .780 1.12 .194 1.388 .386 
research in the UK will slow down discoveries 9 
Patent registration for genetic discoveries is 155 1 5 2.52 .900 .284 .195 -.283 .387 
essential to support investment in discovery 
Embryo stem cell research will find a cure for 156 1 4 2.53 .676 .033 .194 -.196 .386 
diabetes 
The UK will be the first country to find a cure for 156 2 5 3.30 .616 .211 .194 .039 .386 
diabetes 
The first country to find a cure for diabetes will be 156 1 4 2.93 .569 - .194 2.730 .386 
China .862 
Valid N (list wise) 152 
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Tests of Normality 
KolmoQorov-Smimov a Shapiro- Wilk 
gender Statistic df Sid. Statistic df Sig. 
dolly the sheep was the 1 .273 84 .000 .784 84 .000 
first cloned creature in the 
world 342 69 000 .732 69 .000 
the uk lead te world in t .321 84 .000 .745 84 .000 
stem cell research 
350 69 .000 724 69 .000 
china cloned a fish 30 1 364 84 .000 .700 84 .000 
years before dolly the .377 69 .000 .686 69 .000 
human cloning is illegal 1 404 84 .000 .345 84 .000 
in the UK .488 69 .000 .486 69 .000 
Human cloning is legal in 1 .355 84 .000 .713 84 .000 
China .368 69 .000 .700 69 .000 
the UK has the world's 1 .402 84 .000 .656 84 .000 
first license for .490 69 000 .204 69 000 
china has produced a 1 .347 84 000 727 84 000 
gene therapy cure for 431 69 .000 .614 69 .000 
china will lead the world 1 470 84 .000 .532 84 .000 
in producing cures for 411 69 .000 .677 69 .000 
theraeutic cloning is legBl 1 .263 84 .000 .773 84 .000 
in the UK .361 69 .000 .729 69 .000 
human embryo research 1 .432 84 .000 .621 84 .000 
is legal in the UK under .391 69 .000 .686 69 .000 
the uk government 1 .247 84 .000 .893 84 .000 
spends enough money .288 69 .000 .865 69 .000 
The amount of money the 1 .207 84 000 892 84 .000 
UK Gov spends on 210 69 .000 .883 69 000 
The UK Government 1 232 84 .000 876 84 000 
spends as much on .291 69 .000 839 69 .000 
The UK Government 1 .238 84 .000 .875 84 .000 
needs to spend more on .276 69 .000 .843 69 .000 
The UK has a strong 1 .266 84 .000 .862 84 .000 
legislative framework to .267 69 .000 .866 69 .000 
More Centres should be 1 .307 84 .000 .851 84 .000 
allowed to carry out .244 69 .000 .877 69 .000 
New genetic discoveries 1 .305 84 .000 .834 84 .000 
should be available to the .350 69 .000 .811 69 000 
Human Embryo research 1 308 84 .000 .780 84 000 
will produce cures for 346 69 000 803 69 000 
Human Embryo research 1 303 84 .000 804 84 .000 
will in time curB diabetes 267 69 .000 .828 69 .000 
Any potential cure tor 1 .234 84 .000 .901 84 .000 
diabetes will not be .289 69 .000 .839 69 .000 
Finding a cure for 1 .277 84 .000 .864 84 .000 
diabetes is worth the .266 69 .000 .865 69 .000 
A stem cell cure would 1 .290 84 .000 .861 84 .000 
replace existing therapies 216 69 .000 .883 69 .000 
Stem Cell Therapies will 1 .307 84 000 .798 84 000 
be available in the clinical .310 69 000 .821 69 .000 
When stem cell therapy 1 .228 84 .000 .891 84 000 
for diabetes is found it will 239 69 .000 .785 69 000 
Stem Cell Therapy for 1 339 84 000 .784 84 .000 
diabetes will be available 357 69 .000 .778 69 .000 
The UK is highly 1 .280 84 .000 .866 84 .000 
motivated towards finding .314 69 .000 .816 69 .000 
1 use the internet to find 1 .234 84 .000 .896 84 .000 
out about health services .252 69 .000 .883 69 .000 
1 would buy genetic tests 1 268 84 .000 .855 84 .000 
using the internet 285 69 000 .868 69 .000 
1 would go abroad for 1 .306 84 .000 .848 84 000 
treatment that is not .371 69 .000 .781 69 000 
1 would not have any 1 .277 84 .000 863 84 .000 
concerns about 198 69 .000 .894 69 .000 
Human embyro research 1 263 84 .000 .883 84 .000 
is essential to find cures .293 69 .000 .848 69 .000 
The UK population 1 .188 84 .000 .884 84 .000 
supports human embryo .275 69 .000 .855 69 .000 
Ethical concerns about 1 .414 84 .000 .688 84 .000 
creating embryos for .368 69 .000 .783 69 .000 
Patent registration for 1 209 84 .000 .900 84 .000 
genetic discoveries is 294 69 000 837 69 .000 
Embryo stem cell 1 283 84 .000 797 84 .000 
research win find a cure .261 69 .000 .828 69 .000 
The UK will be the first 1 .358 84 .000 .761 84 .000 
Country to find a cure for .307 69 .000 .800 69 .000 
The first Country to find a 1 .414 84 .000 .669 84 .000 
cure for diabetes will be 2 .384 69 .000 .713 69 .000 
a- Ulliefors Significance Correction 
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Reliability Analysis - Alpha 
R E L I A B I L I T Y A N A L Y S I S - S C A L E (A 
Mean Std Dev Cases 
1. DOLLY 1 .7059 .7685 153. .0 
2. UKLEAD 2 .3595 .7662 153. .0 
3. CHINAFIS 2 . 3791 .8192 153. .0 
4 . CLONING 1 . 3660 1.0115 153. 0 
5. CLONINCN 2 .3856 .7957 153. .0 
6. LICENUK 2 . 7386 2.5746 153. .0 
7 . CANCER 2 .5294 . 6694 153. ,0 
8 . CNDIABET 2 . 6078 .7276 153. ,0 
9. CLONINUK 2 .2092 . 8710 153. . 0 
10. LICENUK2 1 . 6013 . 9620 153. . 0 
11. RESEARCH 3 . 5490 1.0062 153. , 0 
12. INCREASE 2 . 8758 .8835 153. , 0 
13. SAME£ 3 . 3333 .8811 153. . 0 
14 . COMPETE 2 .4183 .8241 153. . 0 
15. STRONGLE 2 .5425 .8506 153. .0 
16. CENTRES 2 . 6471 1.0226 153. .0 
17 . INTERNET 2 . 3268 1.0872 153. .0 
18. CURE 2 . 1242 . 6913 153. .0 
19. DIABETES 2 .5033 . 6798 153. .0 
20. NHS 2 .7843 . 9244 153. .0 
21. WORTH 2 .5882 1. 0546 153, .0 
22 . REPLACE 2 . 6993 .8358 153. .0 
23. YEARS10 2 .8170 . 6731 153. .0 
24. NHS2 2 . 8497 . 9015 153. . 0 
25. ABROAD 2 .1634 . 6331 153. . 0 
26. INNOVATI 2 . 6471 . 9422 153. . 0 
27 . USEINTER 3 .2680 1.1122 153. .0 
28. BUYINTER 3 . 6013 1.1082 153. .0 
29. ABROAD2 2 . 3072 . 9339 153. .0 
30. NOCONVER 3 . 1242 1.1199 153. .0 
31. ESSENTIA 2 .5686 . 9717 153. .0 
32. SUPPORTS 3 .1373 . 9181 153. .0 
33. ETHICALC 2 .2484 . 7804 153, .0 
34 . PATENT 2 .5294 .8963 153. .0 
35. CUREDIAB 2 .5294 . 6792 153, . 0 
36. LEADUK 3 . 3072 . 6207 153. .0 
37 . LEADCN 2 .9281 .5747 153 .0 
N of 
S t a t i s t i c s f o r Mean V a r i a n c e Std Dev V a r i a b l e s 
SCALE 96.3007 105.4222 10.2675 37 
R E L I A B I L I T Y A 1 N A L Y S I S - S C A L E (A A L P H A ) 
I t e m - t o t a l S t a t i s t i c s 
S c a l e 
Mean 
i f Item 
Del e t e d 
S c a l e 
V a r i a n c e 
i f Item 
Del e t e d 
C o r r e c t e d 
Item-
T o t a l 
C o r r e l a t i o n 
Alpha 
i f Item 
Deleted 
DOLLY 
UKLEAD 
CHINAFIS 
CLONING 
CLONINCN 
LICENUK 
CANCER 
CNDIABET 
CLONINUK 
LICENUK2 
RESEARCH 
INCREASE 
SAMEt 
COMPETE 
STRONGLE 
CENTRES 
INTERNET 
CURE 
94.5948 
93.9412 
93.9216 
94.9346 
93.9150 
93.5621 
93.7712 
93.6928 
94.0915 
94.6993 
92.7516 
93.4248 
92.9673 
93.8824 
93.7582 
93.6536 
93.9739 
94.1765 
104.5847 
101.6478 
101.1649 
106.0483 
100.9598 
92.6162 
101.4407 
100.5563 
103.5047 
104.9222 
106.2669 
106.2460 
103.7423 
98.0255 
101.9872 
94.5832 
98.5256 
97.4884 
.0157 
.2063 
.2176 
-.0792 
.2395 
. 1247 
.2620 
.2972 
. 0654 
-.0216 
-.0895 
-.0881 
.0503 
.4117 
. 1578 
.4924 
.2648 
.5462 
. 6988 
. 6892 
. 6885 
.7075 
. 6874 
.7232 
. 6871 
. 6850 
.6970 
.7031 
.7081 
.7058 
. 6980 
. 6777 
. 6917 
. 6689 
. 6847 
. 6736 
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DIABETES 93 7974 98 8205 .4542 .6782 
NHS 93 5163 100 6724 .2100 .6887 
WORTH 93 7124 97 3904 .3324 .6799 
REPLACE 93 6013 97 2018 .4564 .6749 
YEARS10 93 4837 101 8961 .2261 . 6887 
NHS2 93 4510 102 8676 .0952 .6955 
ABROAD 94 .1373 101 2113 .2991 .6859 
INNOVATI 93 . 6536 104 7542 -.0114 .7022 
USEINTER 93 0327 97 4660 .3060 . 6815 
BUYINTER 92 6993 96 3564 .3602 . 6774 
ABROAD2 93 9935 99 8223 .2533 . 6860 
NOCONVER 93 1765 95 6331 .3897 . 6751 
ESSENTIA 93 7320 94 3948 .5340 . 6670 
SUPPORTS 93 1634 99 0587 .3021 . 6830 
ETHICALC 94 0523 103 9709 .0529 . 6970 
PATENT 93 7712 100 3223 .2393 . 6870 
CUREDIAB 93 7712 97 9276 .5232 . 6750 
LEADUK 92 9935 105 7829 -.0584 .7005 
LEADCN 93 3725 104 0379 . 0899 . 6945 
R E L I A B I L I T Y A N A L Y S I S S C A L E (A L 
R e l i a b i l i t y C o e f f i c i e n t s 
N of Cases = 153.0 N of Items = 37 
Alpha = .6951 
dolly the sheep was the first cloned creature in the world 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 77 49.0 49.0 49.0 
2 50 31.8 31.8 80.9 
3 30 19.1 19.1 100.0 
Total 157 100.0 100.0 
the uk lead te world in stem cell research 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 28 17.8 17.8 17.8 
2 45 28.7 28.7 46.5 
3 84 53.5 53.5 100.0 
Total 157 100.0 100.0 
china cloned a fish 30 years before dolly the sheep 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 33 21.0 21.0 21.0 
2 31 19.7 19.7 40.8 
3 93 59.2 59.2 100.0 
Total 157 100.0 100.0 
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human cloning is illegal in the UK 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 125 79.6 79.6 79.6 
2 16 10.2 10.2 89.8 
3 15 9.6 9.6 99.4 
11 1 .6 .6 100.0 
Total 157 100.0 100.0 
Human cloning is legal in China 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 30 19.1 19.1 19.1 
2 35 22.3 22.3 41.4 
3 92 58.6 58.6 100.0 
Total 157 100.0 100.0 
the UK has the world's first license for therapeutic cloning 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 25 15.9 15.9 15.9 
2 24 15.3 15.3 31.2 
3 107 68.2 68.2 99.4 
33 1 .6 .6 100.0 
Total 157 100.0 100.0 
china has produced a gene therapy cure for cancer 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 15 9.6 9.6 9.6 
2 44 28.0 28.0 37.6 
3 98 62.4 62.4 100.0 
Total 157 100.0 100.0 
china will lead the world in producing cures for diabetes 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 21 13.4 13.5 13.5 
2 20 12.7 12.8 26.3 
3 114 72.6 73.1 99.4 
4 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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theraeutic cloning is legal in the UK 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 44 28.0 28.2 28.2 
2 35 22.3 22.4 50.6 
3 76 48.4 48.7 99.4 
4 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
human embryo research is legal in the UK under licence 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 106 67.5 67.9 67.9 
2 14 8.9 9.0 76.9 
3 29 18.5 18.6 95.5 
4 6 3.8 3.8 99.4 
5 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
the uk government spends enough money on research 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 5 3.2 3.2 3.2 
2 20 12.7 12.8 16.0 
3 37 23.6 23.7 39.7 
4 69 43.9 44.2 84.0 
5 25 15.9 16.0 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
The amount of money the UK Gov spends on research has increased in 
recent years 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 6 3.8 3.8 3.8 
2 48 30.6 30.8 34.6 
3 64 40.8 41.0 75.6 
4 34 21.7 21.8 97.4 
5 4 2.5 2.6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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The UK Government spends as much on research as other Countries 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 5 3.2 3.2 3.2 
2 20 12.7 12.8 16.0 
3 55 35.0 35.3 51.3 
4 69 43.9 44.2 95.5 
5 7 4.5 4.5 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
The UK Government needs to spend more on stem cell research to compete 
with others 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 19 12.1 12.2 12.2 
2 70 44.6 44.9 57.1 
3 52 33.1 33.3 90.4 
4 15 9.6 9.6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
The UK has a strong legislative framework to manage and control stem cell 
research 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 13 8.3 8.3 8.3 
2 70 44.6 44.9 53.2 
3 51 32.5 32.7 85.9 
4 21 13.4 13.5 99.4 
5 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
More Centres should be allowed to carry out human embryo reserach in the 
UK 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 15 9.6 9.6 9.6 
2 70 44.6 44.9 54.5 
3 32 20.4 20.5 75.0 
4 34 21.7 21.8 96.8 
5 5 3.2 3.2 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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New genetic discoveries should be available to the public fromt the internet 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 31 19.7 19.9 19.9 
2 78 49.7 50.0 69.9 
3 16 10.2 10.3 80.1 
4 24 15.3 15.4 95.5 
5 7 4.5 4.5 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Human Embryo research will produce cures for existing disease 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 24 15.3 15.4 15.4 
2 94 59.9 60.3 75.6 
3 33 21.0 21.2 96.8 
4 5 3.2 3.2 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Human Embryo research will in time cure diabetes 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 9 5.7 5.8 5.8 
2 67 42.7 42.9 48.7 
3 73 46.5 46.8 95.5 
4 7 4.5 4.5 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Any potential cure for diabetes will not be affordable under the UK NHS 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 10 6.4 6.4 6.4 
2 51 32.5 32.7 39.1 
3 61 38.9 39.1 78.2 
4 30 19.1 19.2 97.4 
5 4 2.5 2.6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Gail Newmarch 226 
D B A Final November 2008 
Finding a cure for diabetes is worth the creation of embryos for research 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 20 12.7 12.8 12.8 
2 68 43.3 43.6 56.4 
3 33 21.0 21.2 77.6 
4 28 17.8 17.9 95.5 
5 7 4.5 4.5 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
A stem cell cure would replace existing therapies for diabetes 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 11 7.0 7.1 7.1 
2 49 31.2 31.4 38.5 
3 74 47.1 47.4 85.9 
4 20 12.7 12.8 98.7 
5 2 1.3 1.3 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Stem Cell Therapies will be available in the clinical area of diabetes within 
10 years 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 2 1.3 1.3 1.3 
2 44 28.0 28.2 29.5 
3 91 58.0 58.3 87.8 
4 18 11.5 11.5 99.4 
5 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
When stem cell therapy for diabetes is found it will be available in the NHS 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 6 3.8 3.8 3.8 
2 58 36.9 37.2 41.0 
3 50 31.8 32.1 73.1 
4 40 25.5 25.6 98.7 
5 2 1.3 1.3 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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Stem Cell Therapy for diabetes will be available abroad before the UK 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 17 10.8 11.0 11.0 
2 98 62.4 63.2 74.2 
3 37 23.6 23.9 98.1 
4 3 1.9 1.9 100.0 
Total 155 98.7 100.0 
Missing System 2 1.3 
Total 157 100.0 
The UK is highly motivated towards finding new innovations 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 9 5.7 5.8 5.8 
2 77 49.0 49.4 55.1 
3 35 22.3 22.4 77.6 
4 32 20.4 20.5 98.1 
5 3 1.9 1.9 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
1 use the internet to find out about health services abroad 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 8 5.1 5.2 5.2 
2 37 23.6 23.9 29.0 
3 32 20.4 20.6 49.7 
4 59 37.6 38.1 87.7 
5 19 12.1 12.3 100.0 
Total 155 98.7 100.0 
Missing System 2 1.3 
Total 157 100.0 
1 would buy genetic tests using the internet 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 4 2.5 2.6 2.6 
2 31 19.7 19.9 22.4 
3 22 14.0 14.1 36.5 
4 64 40.8 41.0 77.6 
5 35 22.3 22.4 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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I would go abroad for treatment that is not available in the UK 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 24 15.3 15.4 15.4 
2 86 54.8 55.1 70.5 
3 22 14.0 14.1 84.6 
4 22 14.0 14.1 98.7 
5 2 1.3 1.3 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
I would not have any concerns about assessing stem cell treatments 
abroad 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 11 7.0 7.1 7.1 
2 44 28.0 28.2 35.3 
3 29 18.5 18.6 53.8 
4 59 37.6 37.8 91.7 
5 13 8.3 8.3 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Human embyro research is essential to find cures for existing disease 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 16 10.2 10.3 10.3 
2 72 45.9 46.2 56.4 
3 38 24.2 24.4 80.8 
4 26 16.6 16.7 97.4 
5 4 2.5 2.6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
The UK population supports human embryo research 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 3 1.9 1.9 1.9 
2 41 26.1 26.3 28.2 
3 51 32.5 32.7 60.9 
4 55 35.0 35.3 96.2 
5 6 3.8 3.8 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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Ethical concerns about creating embryos for research in the UK will slow 
down discoveries 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 15 9.6 9.6 9.6 
2 106 67.5 67.9 77.6 
3 19 12.1 12.2 89.7 
4 15 9.6 9.6 99.4 
5 1 .6 .6 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
Patent registration for genetic discoveries is essential to support 
investment in discovery 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 17 10.8 11.0 11.0 
2 64 40.8 41.3 52.3 
3 52 33.1 33.5 85.8 
4 20 12.7 12.9 98.7 
5 2 1.3 1.3 100.0 
Total 155 98.7 100.0 
Missing System 2 1.3 
Total 157 100.0 
Embryo stem cell research will find a cure for diabetes 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 1 7 4.5 4.5 4.5 
2 69 43.9 44.2 48.7 
3 71 45.2 45.5 94.2 
4 9 5.7 5.8 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
The UK will be the first Country to find a cure for diabetes 
Cumulative 
Frequency Percent Valid Percent Percent 
Valid 2 10 6.4 6.4 6.4 
3 92 58.6 59.0 65.4 
4 51 32.5 32.7 98.1 
5 3 1.9 1.9 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
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The first Country to find a cure for diabetes will be China 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 4 2.5 2.6 2.6 
2 19 12.1 12.2 14.7 
3 117 74.5 75.0 89.7 
4 16 10.2 10.3 100.0 
Total 156 99.4 100.0 
Missing System 1 .6 
Total 157 100.0 
dolly the sheep was the first cloned creature in 
the uk lead te world in stem cell research 
dolly the sheep was the first cloned creature in the world 
china cloned a fish 30 years before dolly the s 
the uk lead te world in stem cell research 
human cloning is illegal in the UK 
china cloned a fish 30 years before doty the sheep 
Human cloning is legal in China 
human cloning is illegal in the UK 
the UK has the world's first license for therape 
Human cloning is legal in China the UK has the world's first license for therapeutic cloning 
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theraeutic cloning is legal in the UK human embryo research is legal in the UK und 
theraeutic cloning is tegal in the UK 
the uk government spends enough money on re 
human embryo research is legal in the UK under licence 
New genetic discoveries should be available tc 
4 5 
the uk government spends enough money on research 
Human Embryo research will produce cures fc 
New genetic discoveries should be available to the public fromt t 
A stem cell cure would replace existing therapii 
1 2 3 4 
Human Embryo research wa produce cures for existing disease 
Stem Cell Therapies will be available in the clit 
A stem cell cure would replace existing therapies for diabetes 
When stem cell therapy for diabetes is found it 
Stem Cell Therapies will be available in the clinical area of diabe When stem cell therapy for diabetes is found it will be available in 
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I would go abroad for treatment that is not avE Human embyro research is essential to find cui 
1 2 3 4 5 
I would go abroad for treatment that is not available in the UK 
The UK population supports human embryo res 
Human embyro research is essential to find cures for easting disi 
Ethical concerns about creating embryos for r< 
The UK population supports human embryo research 
The UK will be the first Country to find a cure 1 
Ethical concerns about creating embryos for research in the UK 
The first Country to find a cure for diabetes wi 
The UK win be the first Country to find a cure for diabetes The first Country to find a cure for diabetes will be China 
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Correlations 
nationality do you have do you have do you have do you have do any family age 
religious diabetes a family any other members 
beliefs member with genetic have genetic 
diabetes illness illnesses 
nationality Pearson 1 -.011 -.152 .060 .068 .057 -.051 
Correlation 
Sig. (2-tailed) .891 .058 .452 .397 .479 .527 
N 157 157 157 157 157 157 157 
do you have Pearson -.011 1 .001 .099 -.004 .047 -.207 
religious Correlation 
beliefs 
Sig. (2-tailed) .891 .988 .219 .964 .559 .009 
N 157 157 157 157 157 157 157 
do you have Pearson -.152 .001 1 .246 .147 .159 -.171 
diabetes Correlation 
Sig. (2-tailed) .058 .988 .002 .066 .047 .032 
N 157 157 157 157 157 157 157 
do you have Pearson .060 .099 .246 1 .189 .380 -.042 
a family Con-elation 
member with 
diabetes 
Sig. (2-tailed) .452 .219 .002 .018 .000 .601 
N 157 157 157 157 157 157 157 
do you have Pearson .068 -.004 .147 .189 1 .403 -.031 
any other Con-elation 
genetic 
illness 
Sig. (2-tailed) .397 .964 .066 .018 .000 .698 
N 157 157 157 157 157 157 157 
do any Pearson .057 .047 .159 .380 .403 1 .133 
family Correlation 
members 
have genetic 
illnesses 
Sig. (2-tailed) .479 .559 .047 .000 .000 .096 
N 157 157 157 157 157 157 157 
age Pearson -.051 -.207 -.171 -.042 -.031 .133 1 
Correlation 
Sig. (2-tailed) .527 .009 .032 .601 .698 .096 
N 157 157 157 157 157 157 157 
** Correlation is significant at the 0.01 level (2-tailed). 
* Con-elation is significant at the 0.05 level (2-tailed). 
(.1-.29 small .30-.49 medium .50 -1 large) 
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Appendix D 
Summary of Data 
Year Pop UK PopCn Diabetes Diabetes GDP GDP Total GDP China Total GDP Research Research 
UK Cn UK Cn UK GDP Cn 
1990 57285000 1.I4E+09 933746.0 18637000 1.8 8.00 240775920000 3.44E+11 2.24 .70 
1991 57472000 1.15E+09 1034496 19563600 -1.4 8.80 263763360000 3.64E+1I 2.07 .70 
1992 57593000 1.17E+09 1151860 20970000 .3 8.80 320608000000 3.68E+11 2.01 .70 
1993 57700000 I.18E+09 1269400 22389600 3.7 8.80 418332000000 1.03E+I2 2.04 .70 
1994 57825000 1.19E+09 1445625 23836000 2.9 8.80 564865528000 1.10E+12 2.00 .60 
1995 57958000 1.20E+09 1506908 25302900 2.8 8.80 706601556000 1.16E+I2 1.95 .60 
1996 58076000 1 22E+09 1626128 26787200 2.8 9.60 820260592000 1.22E+12 1.88 .70 
1997 58204000 1.23E+09 1687916 29522400 3.3 8.80 899572130000 I.30E+I2 1.81 .71 
1998 58349000 1.25E+09 1808819 31346975 3.1 7.80 955593724690 1.36E+I2 1.80 .80 
1999 58536000 1.26E+09 1931688 32883864 2.9 7.10 998429996880 1.40E+12 1.88 1.00 
2000 58655000 1.28E+09 2052925 34430805 3.9 8.00 1.09095E+12 .49E+12 1.85 1.07 
2001 589000 1 28E+09 2057615 38549160 2.3 7.30 1.17196E+I2 .57E+12 1.90 1.29 
2002 59234000 1.29E+09 2191658 40060370 1.8 8.30 I.64303E+I2 .66E+I2 1.89 1.31 
2003 59422000 1 29E+09 2317458 41352640 2.2 9.10 I.69377E+12 .78E+12 1.76 1.31 
2004 1.3IE+09 2 I.64933E+I2 .14E+I2 1.72 1.50 
2006 2.6 8.I5800E+I2 1.87E+12 1.76 
Year Patents Patents Balance of Balance of Trade Total Trade Trade Trade Total Trade 
UK Cn Payment UK Payment Cn UK UK Cn GDP Cn Cn 
1990 3265 -3.9E+10 . -4.0 -2.5E+10 14 42.27 
1991 3307 -1.9E+10 1.30E+10 -1.8 -1.1E+10 15 40.74 1.20E+10 
1992 3331 -2.3E+10 6.00E+09 -2.1 -1.3E+10 16 41.06 5.00E+09 
1993 3019 -1.8E+10 -1.2E+10 -1.9 -9.8E+10 15 37.05 -1.2E+10 
1994 3517 -1.0E+10 8.00E+09 -1.0 -7.3E+10 21 39.45 7.00E+09 
1995 3648 45064 -1.4E+10 2.00E+09 -1.3 -5.6E+10 20 43.53 1.20E+10 
1996 2737 43780 -1.1E+10 7.00E+09 -1.0 -5.1E+10 20 45.54 1.80E+10 
1997 2792 50992 -3.0E+10 3.00E+10 -.2 1.40E+10 21 47.56 4.00E+10 
1998 3168 67889 -6.7E+10 2.90E+10 -.5 -1.3E+10 19 46.89 4.20E+10 
1999 2883 100156 -3.9E+10 2.10E+10 -2.7 -2.5E+10 21 44.82 3.10E+10 
2000 2962 105345 -3.7E+10 2.10E+10 -2.6 -2.9E+10 25 2.90E+10 
2001 2788 114251 -3.2E+10 1.70E+10 -2.2 -3.9E+10 24 2.80E+10 
2002 3310 -2.5E+10 3.50E+10 -1.6 -4.8E+10 28 3.70E+10 
2003 -2.8E+10 4.60E+10 -1.5 -5.1E+10 . 3.60E+10 
2004 -4.3E+10 6.90E+10 -2.0 -7.2E+10 . 4.90E+10 
2006 -3.8E+10 1.29E+11 -2.3 -1.0E+11 . 1.68E+10 
Year % growth % growth Inflation Inflation Education Education Computers/ Computers Imports as Imports as 
GDP Cn GDP UK UK Cn GDP UK GDP Cn 1000 pop 1000 pop proportion Proportion 
UK GDP UK GDP Cn 
1990 3.80 -.50 9.50 3.70 4.90 2.30 .43 144.79 27.00 14.00 
1991 9.30 -1.00 10.10 3.40 4.98 3.38 .68 164.95 
1992 14.20 -1.00 9.10 6.40 5.12 3.25 .92 169.51 
1993 13.50 1.00 7.50 14.70 5.15 3.07 1.17 201.32 
1994 12.70 4.00 8.20 24.10 5.11 3.19 1.65 215.96 
1995 10.50 2.60 8.20 17.10 5.50 3.27 2.27 238.92 29.00 
1996 9.70 3.00 7.80 8.30 4.90 3.38 3.61 268.41 
1997 8.80 3.00 7.10 2.80 4.70 3.46 5.99 302.51 29.00 
1998 7.80 2.50 5.50 -.80 4.50 3.83 8.91 377.81 
1999 7.10 2.70 5.10 -1.40 4.50 4.16 12.23 30.10 
2000 8.20 2.40 5.30 .40 4.40 4.36 15.90 28.10 23.20 
2001 1.80 4.90 .70 4.60 4.86 29.00 
2002 2.00 4.90 -.20 4.90 5.29 
2003 2.20 4.50 1.60 5.10 30.10 31.80 
2004 2.30 4.90 3.30 5.30 28.10 39.20 
2006 2.10 
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Year Total Imports Exports Exports Total value Total value Total Value Tot Education Tot Education T Research TResearch 
China GDP GDP Exports GDP US$ GDPUSS UK US$ Cn US$ UK US$ China USS 
UK Cn Cn UK Cn 
1990 5.33E+10 24 18 6.21E+10 9.19E+11 3.96E+11 4.50E+10 5.54E+09 2.06E+10 2.77E+09 
1991 6.38E+10 7.18E+10 9.87E+11 4.33E+11 4.91E+10 8.92E+09 2.04E+10 3.03E+09 
1992 8.06E+10 8.49E+10 1.01E+12 4.95E+11 5.17E+10 1.04E+10 2.03E+10 3.46E+09 
1993 1.04E+11 9.17E+10 1.03E+12 5.61E+11 5.32E+10 1.28E+10 2.11E+10 3.93E+09 
1994 1.16E+11 1.21E+11 1.08E+12 6.33E+11 5.50E+10 1.80E+10 2.15E+10 3.80E+09 
1995 1.32E+11 29 1.49E+11 1.16E+12 7.00E+11 6.38E+10 2.31E+10 2.26E+10 4.20E+09 
1996 1.39E+11 1.51E+11 1.22E+12 7.67E+11 5.97E+10 2.77E+10 2.29E+10 5.37E+09 
1997 1.42E+11 28 1.83E+11 1.28E+12 8.35E+11 6.01E+10 3.11E+10 2.31E+10 5.93E+09 
1998 1.40E+11 1.84E+11 1.33E+12 9.09E+11 6.01E+10 3.66E+10 2.40E+10 7.27E+09 
1999 1.66E+11 26 1.95E+11 9.72E+11 4.15E+10 9.72E+09 
2000 2.25E+11 28 26 2.49E+11 1.05E+12 4.76E+10 1.12E+10 
2001 2.44E+11 27 2.66E+11 1.17E+12 5.70E+10 1.51E+10 
2002 1.64E+12 8.69E+10 5.15E+10 
2003 25 34 1.67E+12 
2004. 40 
2006 
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Balance of Payment 1990-2005 
UK and China 
199999990000 
CO 
3 
ro 
a. 
o 
ro 
ro 
CD 
99999997000 
-99999990000 
1991 1995 1999 2003 
Trade balance UK 
Trade Balance China 
1993 1997 2001 2006 
Gail Newmarch 239 
DBA Master Final November 2008 
Correlation 
Appendix E 
Diabetes and GDP Performance/Head of Population for the UK and China 
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As the following graphs indicate investment in research in the UK and China is shown to 
loosely correlate and there is no relationship in patent registration between the two 
Countries. 
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Correlation of GDP Research Spend and Patent Registrations: UK and China 
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Analysis found there to be no relationship in the data when comparing the performance 
of Trade in Goods and Services as a percent of GDP between the UK and China of 
between their total values for Balance of Payments. There is also no relationship 
between inflation performance, or numbers of clinical staff. 
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APPENDIX G Normality Tests Data Table 
N Skewness Kurtosis Kolmogovor-
Smirov 
Statistic Std. Error Statistic Std. 
Error 
Population UK 14 .448 .597 -.616 1.154 0.089 
Population China 20 .683 -.512 -.585 .992 0.165 
Number with diabetes UK 14 -.136 .597 -1.128 1.154 0.109 
Number with diabetes China 15 .372 .580 -.997 1.121 0.117 
Percentage of pop with diabetes UK 15 .270 .580 -.274 1.121 0.077 
Percentage of pop with diabetes China 15 1.139 .580 1.638 1.121 0.115 
Cost for diabetes UK $ per person 2 
Costs for diabetes China $ 2 
% real growth in GDP per year in UK 16 -1.833 .564 3.868 1.091 0.204 
% growth in GDP per year in China 14 -.504 .597 -.301 1.154 0.272 
NHS budget by year 15 .416 .580 -1.000 1.121 0.108 
Percent of GDP on health UK 15 1.440 .580 2.891 1.121 0.161 
Percent of GDP on health China 13 .446 .616 -1.312 1.191 0.223 
GDP on health per head UK $ 13 .540 .616 -.166 1.191 0.135 
GDP per person in UK in US $ 10 1.777 .687 3.840 1.334 0.158 
Total spend on health in the UK in £ 14 .436 .597 -.943 1.154 0.820 
GDP per head of pop China in $ 15 3.623 .580 13.591 1.121 0.111 
GDP billion in US$ for China 16 3.569 .564 13.565 1.091 0.152 
% of GDP private health Cn 10 .456 .687 -1.321 1.334 0.185 
% of GDP Gov Health China 10 -2.067 .687 3.636 1.334 0.421 
Total value of GDP in the UK is US$ 16 -.526 .564 -.245 1.091 0.237 
Exchange rate yuan per dollar 14 -1.171 .597 -.528 1.154 
Exchange rate pound against the US $ 16 .779 .564 -.164 1.091 
Spend on health in China in $ 13 1.039 .616 .500 1.191 0.242 
Gov health in UK as % of total spend 14 -1.620 .597 4.884 1.154 0.315 
Gov health China as % of total spend 10 -.992 .687 -0.66 1.334 0.210 
Private health spend UK/person in $ 14 1.477 .597 4.396 1.154 0.319 
Private health spend v china/person in $ 10 .982 .687 -0.81 1.334 0.210 
Health spend per head pop Chine $ 14 .383 .597 -1.240 1.154 0.146 
R&D as % of GDP in UK 14 1.199 .597 1.627 1.154 0.141 
Expenditure Research $ UK 9 .325 .717 -1.465 1.400 0.159 
R&D as % of GDP China 14 1.042 .597 -.274 1.154 0.344 
Expenditure Research S for China 13 1.343 .616 1.463 1.191 0.174 
International rate of the dollar 13 -.051 .616 -1.657 1.191 0.178 
Number of doctors in the UK 14 3.726 .597 13.914 1.154 0.500 
Number of doctors in China 15 -0.459 .580 -1.126 1.121 0.134 
Number of nurses in UK 14 0.566 .597 -1.163 1.154 0.312 
Number of nurses in China 15 -3.781 .580 14.490 1.121 0.451 
Number of researchers in the UK 10 3.162 .687 10.000 1.334 0.492 
Number of researchers in China 13 3.553 .616 12.725 1.191 0.468 
Patients registered UK by all countries 13 -1.462 .616 -1.172 1.191 0.207 
Patients in the UK by UK resident 13 0.195 .616 -1.057 1.191 0.248 
Patent applications in China 7 0.221 .794 -2.354 1.587 0.241 
Trade balance total in $ UK 16 -.943 .564 1.616 1.091 0.213 
Trade balance total in $ China 15 2.049 .580 5.185 1.121 0.258 
Trade in Goods/Service % of GDP UK 16 -0.474 .564 1.119 1.091 0.140 
Trade in Goods/Services total $ UK 16 -0.271 .564 -0.357 1.091 0.185 
Trade in Goods/Service % GDP China 13 0.264 .616 -0.205 1.191 0.274 
% of GDP on Trade in China 10 -0.231 .687 -0.806 1.334 0.146 
Trade in Goods/Services Total $ China 15 -0.443 .580 -0.298 1.121 0.172 
% growth year on year in GDP China 11 -0.142 .661 0.017 1.279 0.164 
% growth year on year in GDP UK 16 -1.026 .564 0.268 1.091 0.304 
inflation UK 15 0.291 .580 -1.470 1.121 0.149 
inflation China 15 1.481 .580 1.513 1.121 0.166 
GDP spend on Education in the UK 15 -0.024 .580 -0.693 1.121 0.153 
GDP spend on Education in China 13 0.589 .616 0.274 1.191 0.329 
Computers/1000 population in China 11 1.219 0.661 0.362 1.279 0.254 
Computers/1000 population in the UK 9 0.887 .717 0.352 1.400 0.218 
Imports as a proportion of GDP UK 8 -0.345 .752 -0.194 1.481 0.385 
Import as a proportion of GDP China 4 -0.196 1.014 -1.256 2.619 0.260 
Import value is US & China 12 0.602 .637 0.022 1.232 0.260 
Exports as a percentage of GDP UK 6 -0.664 .845 -1.155 1.741 0.260 
Exports as a percentage of GDP China 5 0.190 .913 -0.700 2.000 0.260 
Export value in US China 12 0.339 .637 -0.892 1.232 0.260 
Total GDP in US $ in UK 9 0.319 .717 -1.208 1.400 0.156 
Total GPD in US $ in China 14 0.938 .597 0.217 1.154 0.118 
Total on education in the UK in US $ 9 -0.330 .717 -0.816 1.400 0.208 
Total on education in China in US $ 13 1.192 .616 1.544 1.191 0.170 
Total on research in the UK in US $ 9 0.325 .717 -1.465 1.400 0.159 
Total on research in China in US $ 13 1.606 .616 2.235 1.191 0.225 
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Appendix H Normality Plots Data Table 
Normal Q-Q Plot of Population UK Normal Q-Q Plot of population China 
58000000 
UJ -1.5 
58200000 
Observed Value 
Normal Q-Q Plot of number with diabetes UK 
1200000000 1220000000 1240000000 1260000000 1280000000 1300000000 
Observed Value 
Normal Q-Q Plot of number with diabetes Chii 
|3 -1.5 24000000 
1500000 1600000 1700000 1800000 1900000 2000000 2100000 
Observed Value 
Normal Q-Q Plot of total spend on health in th 
28000000 32000000 36000000 40000000 
26000000 30000000 34000000 38000000 
Observed Value 
Normal Q-Q Plot of spend on health in china ir 
l2 -1.5 
40000000000 50000000000 60000000000 70000000000 80000000000 
Observed Value 
Normal Q-Q Plot of Total G D P in US$ in UK 
20000000000 40000000000 60000001000 
30000000000 50000000000 70000001000 
Observed Value 
Normal Q-Q Plot of Total G P D in US $ in Chin 
899999980000 1099999900000 1299999900000 
999999980000 1199999900000 1399999900000 
599999980000 8 0 0 0 0 0 0 0 0 0 0 0 
l3 -1.5 
Observed Value Observed Value 
Gail Newmarch 245 
DBA Master Final November 2008 
Normal Q-Q Plot of Trade balance total in $ U Normal Q-Q Plot of Trade Balance total in $ C 
UJ -1.5 
60000000000 40000000000 -20000000000 
-50000000000 -30000000000 -10000000000 
Observed Value 
Normal Q-Q Plot of total spend on education i 
lS -15 
0 10000000000 20000000000 30000000000 40000000000 
Observed Value 
Normal Q-Q Plot of total spend on education i 
40000000000 50000000000 
Observed Value 
Normal Q-Q Plot of total number of computers 
0 10000000000 20000000000 30000000000 40000000000 
Observed Value 
Normal Q-Q Plot of total no computers in chin; 
6000000 10000000 14000000 18000000 22000000 
8000000 12000000 16000000 20000000 24000000 
Observed Value 
Normal Q-Q Plot of inflation UK 
-2000000 2000000 8000000 10000000 
0 4000000 8000000 12000000 
Observed Value 
Normal Q-Q Plot of inflation China 
l2 -15 
Observed Value Observed Value 
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Normal Q-Q Plot of patents registered in the I 
7000 8000 
Observed Value 
Normal Q-Q Plot of number of doctors in the I 
l2 -15 
90000 92000 94000 96000 98000 100000 102000 104000 106000 
Observed Value 
Normal Q-Q Plot of number of nurses in UK 
l2 -1.5 
Normal Q-Q Plot of patent applications in Chir 
U] -1.5 
2 0 0 0 0 40000 60000 
Observed Value 
Normal Q-Q Plot of number of doctors in Chin 
£ 
X 
1700000 
Observed Value 
Normal Q-Q Plot of number of nurses in China 
400000 420000 440000 460000 480000 500000 520000 
Observed Value 
Normal Q-Q Plot of total spend on research ir 
1660000 16B0OO0 1700000 1720000 1740000 1760000 1780000 1800000 
Observed Value 
Normal Q-Q Plot of total spent on research in 
UJ -1-5 
T5 
Q-
X 
2000000000 4000000000 6000000000 8000000000 
3000000000 5000000000 7000000000 
20000000000 22000000000 23999999000 
21000000000 23000000000 24999999000 
Observed Value Observed Value 
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Appendix I 
T-Test: Trends in diabetes between the UK and China 
t-value -14.113 
degree of freedom (df) 13 
probability value 0.000 
mean 1644017/293E+07 
standard deviation 440330.2398/7677655.7739 
eta squared 212.18 
Expenditure of research between the UK and China 
T 61.725 
Probability 0.000 
Df 8 
An independent-samples t-test was conducted to compare the factors of innovation 
between the UK and China. There was no significant difference in the scores for 
Inflation (UK= 6.9786 SD=1.91881 Cn=5.7714 SD=7.70499) and Total GDP 
(UK=1100000000000 SD=142000000000 China=8.70000000000 SD=403500000000). 
Total Spend on Research and Balance of Payment in the UK 
Paired Sample T-test UK China 
t-value 
degree of freedom (df) 
probability value 
mean 
standard deviation 
eta squared*** 
-7.683 
8 
0.000* 
-2.6E+10/2.2E+10** 
1.800E+10/1357896606 
0.88 
2.207 
11 
0.050 
1.5E+10 7.0E+09 
1.346E+10/5661250512 
0.302 
Total Spend on Education and Balance o f Payments in 
UK China 
Paired Sample T-test 
t-value 
degree of freedom (df) 
probability value 
mean 
standard deviation 
eta squared 
-12.841 
8 
0.000 
-2.4E+10/5.5E+10 
1.800E+10/6095702054 
0.9374 
3.797 
11 
0.003 
1.5E+10/3.7917 
1.3462+10/0.72261 
0.5672 
Total GDP, Education and Total Research on the prevalence of diabetes in China 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised 
co-efficient 
Significance 
of contribution 
Total GDP 0.963 0.002 0.309 0.875 
Total Education 0.922 0.022 -0.387 0.531 
Total Research 0.960 0.001 1.031 0.670 
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Impact do the factors of innovation have on GDP performance in the UK 
Innovation Factors Correlation Collinearity Standardised Significance 
Tolerance co-efficient of contribution 
Total Nurses 0.816 0.044 0.783 0.160 
Total Doctors 0.447 0.137 -0.352 0.200 
Total Patents -0.432 0.442 -0.131 0.288 
Balance of Trade -0.368 0.078 0.296 0.302 
Total Trade Goods & Service 0.233 0.440 0.111 0.332 
Total spend Education 0.868 0.079 0.263 0.328 
Total spend Research 0.969 0.055 0.323 0.326 
Impact do the factors of innovation have on GDP performance in China 
Innovation Factors Correlation Collinearity* Standardised Significance 
Tolerance co-efficient** of contribution 
Total Research 0.984 0.082 0.869 0.029 
Total Education 0.980 0.008 0.470 0.171 
Total Goods/Service 0.391 0.008 
Balance of Payment 0.421 0.072 -0.301 0.261 
Patents 0.952 0.423 0.067 0.361 
Total Nurses -0.293 0.502 0.081 0.138 
Total Doctors 0.989 0.222 0.746 0.000 
Total with Computers 0.921 0.158 0.318 0.002 
Factors of innovation has an impact on the prevalence of diabetes in the UK 
Innovation Factor Correlation standardised Significance of 
Co-efficient Contribution 
Total Research 0.954 0.584 0.378 
Total Education 0.902 0.093 -0.151 
Computers/1000 pop 0.947 -.239 0.512 
Inflation -0.880 -.283 -0.505 
Total trade good/services 0.054 0.356 0.181 
Balance of Payments -0.248 0.387 0.513 
Total Patents -0.337 -.021 0.124 
Factors of innovation has an impact on the prevalence of diabetes in China 
Innovation Factor Correlation standardised Significance of 
Co-efficient Contribution 
Total Education 0.994 2.044 
Total GDP 0.997 1.670 0.647 
Computers/1 OOOpop 0.942 -.964 0.80 
Inflation -0.548 0.160 0.020 
Total Goods/Services 0.790 0.137 -0.217 
Trade Balance 0.678 0.004 0.229 
Total Doctors 0.974 -1.975 -0.529 
Total Nurses -0.520 0.166 0.010 
Total Research 0.943 0.067 -
Health spend impact on total trade in goods and services in the UK 
Innovation Factors Correlation Collinearity Standardised Significance 
Tolerance co-efficient of contribution 
Spend in the NHS -0.004 0.03 12.069 0.11 
Health spend per person -0.45 0.03 -12.093 0.11 
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Health spend impact on total trade in goods and services in China 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised 
co-efficient 
Significance* 
of contribution 
% GDP on health 
GDP /head on health 
% health spend by Gov 
0.564 
0.781 
-0.253 
0.058 
0.080 
0.087 
2.170 
-0.999 
-1.744 
0.018 
0.120 
0.019 
The impact on GDP and Balance of Trade by investing in research in the UK 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised 
co-efficient 
Significance* 
of contribution 
Total GDP 
Total Trade Good/Service 
Rsquare= 0.928 
0.969 
0.146 
10.136 
-0.869 
0.989 
-0.085 
0 
0.418 
The impact on GDP and Balance of Trade by investing in research in China 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised 
co-efficient 
Significance* 
of contribution 
Total GDP 
Total Trade Goods/Service 
Rsquare=0.973 
0.968 
0.860 
0.146 
0.146 
1.192 
-0.242 
0 
0.235 
The impact on GDP and Balance of Trade of investing in Education in the UK 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised Significance* 
co-efficient of contribution 
Total GDP 
Total Trade Goods/service 
Rsquare 0.825 
0.868 
-0.057 
0.946 
0.946 
0.932 0.002 
-0.274 0.170 
The impact on GDP and Balance of 1 frade by investing in Education in China 
Innovation Factors Correlation Collinearity 
Tolerance 
Standardised 
co-efficient 
Significance* 
of contribution 
Total GDP 
Total Trade G/S 
RSQUARE= 0.995 
0.998 
0.917 
1.035 
-0.040 
0.146 
0.146 
0 
0.455 
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Stem Cell Research 
Appendix J 
Institution Research 
Area 
Contact Details 
Steering Committee UK Stem 
Cell Bank 
World's first Biobank Professor Tom Baldwin - Bio ethicist Head of 
Department York University 
Prof Sir David Carter Vice Chairman and Principal 
Edinburgh 
Prof Martin Evans Director of School of 
Biosciences Cardiff University 
Prog Douglas Higgs Director Molecular 
Haematology Oxford 
Dr Jennie Flatman Pharmaceutical assessor 
medicines and health care products regulatory 
agency 
Medical Research Council Research funder and Government 
partner 
Dr Diane Dunstan Director of Research 
Dr Mike Davis Head of molecular and cellular 
medicine board 
Dr Mathew Wakelin Programme Director 
Developmental Biology 
Mathew. wakelinfijheadoffice. mrc.ac.uk 
Dr Alf Game Head of Genetics and Biochemistry 
Branch 
Dr Ben Sykes Programme Manager Genetics and 
Biochemistry Branch 
Dr Robin Lovell-Badge Developmental Genetics 
Dr Raisman (160k)- repair brain and cord 
damage 
Dr Guillemot (310k) - repair brain cells 
European Federation of 
Biotechnology 
www.efbinternational.ora 
Prof Brian Clark 
European focus on Biotechnology 
in China 
dark (Sbiobase.dk 
wanavu@cncbd. ora.cn 
wuvihana@cncbd.ora.cn 
Dr David Bennett 
David.bennett(5)efbDublic.ora 
European Biotechnology 
Node for Interaction with 
China 
Co-ordinated by Prof Lui Qian Director 
lauian(a>Dublic.east.cn.net 
China-Britain Business 
Council 
enauires(5)cbbc.ora 
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Gene Watch Public representative body mail@aenewatch. ora 
Becky Price Researcher Dr Sue Mayer 
Dr Helen Wallace 
Ethics and Governance 
Council Members of UK 
Biobank 
Dr Sandy Thomas - Director of Nuffield Bioethics 
Professor Roger Higgs MBE Professor Emeritus 
Kings College London 
Department of Health Biotechnology Contacts biotech@idh.asi.aov.uk 
Knowledge Parks Government Centres for Policy 
and education 
Peter.areenawavOdoh.asi.aov.uk 
Newcastle Life Science Centre 
Director: Linda Conlon 
Deputy Director: Liz Dean 
Education and Outreach Manager: 
Noel Jackson 
Centre for Excellence in Life 
Sciences 
Chief Executive: Dr Fred Wright 
Ex Director: Prof John Burn 
Scientific Director of the Institute of Human 
Genetics: Prof Tom Strachan 
Policy, Ethics and Life Sciences (PEALS) 
Director of Research: Prof Erica Haimes 
Director of Outreach: Dr Tom Shakespeare 
Director of Learning: Dr Simon Woods 
Newcastle Fertility Centre at Life 
Director: Prof Alison Murdoch 
Scientific Director: Dr Mary Herbert 
Science and Industry Council for the NE 
Chairman: Richard Maudsely 
Prof Philip Home Diabetic Medicine 
Philio.home@newcastle.ac.uk 
Oxford Chairman 
Professor Andrew Wilkie [Email 
Programme Director 
Dr Jennv Tavlor rEmaill 
Principal Investiaator: Professor 
Michael Parker [Emaill rWebl 
Research Fellow in Law: Dr. Jane 
Kave rEmaill 
Research Fellow in Sociology: Dr. 
Andrew Smart [Email) 
Research Fellow in Economics: 
Sarah Wordsworth [Email] 
Research Assistant in Economics: 
Jose Leal [Emaill 
Clinical Psychologist: Dr. Amy 
Silver [Emaill 
Rhodes Reader in Organisational 
Behaviour: Dr. Sue Dopson 
[Emaill 
Principal Investiaator: Professor Huah Watkins 
[Emaill [Web) 
Consultant Clinical Geneticist: Dr. Ed Blair [Emaill 
Director Clinical Genetics Labs: Dr. Anneke Seller 
[Email| 
Research Fellow: Dr. Sebastian Carballo [Emaill 
Clinical Scientist: Dr. Kate Thomson [Emaill 
Clinical Scientist: Karen Livesey 
Genetics Counsellor: Cassie Fraser-Jones [Emaill 
Clinical Research Secretary: Sue Mercer [Emaill 
Administrative Assistant: Emma Doyle 
Principal Investiaator: Professor Rorv Collins 
[Emaill [Webl 
Deputy PI and Research Fellow: Dr. Robert Clarke 
[Email] 
Statistical Programmer. Dr. Alison Palmer 
Principal Investiaator Professor Ian Tomlinson 
[Emaill [Webl 
Lead Researcher in Learning Disability: Dr. Sam 
Kniaht [Emaill 
Head, NHS Cytogenetics Labs: Kim Smith [Emaill 
Research Fellow: Dr. William Chambers [Email] 
Senior Scientific Officer: Dr. Angela Jones 
Clinical Scientist: Dr. Regina Reqan [Email 
Cambridge Director Dr Ron Zimmern 
Director East Anglian Regional 
Genetics Service Dr Jo Whittaker 
Business manager Carol Lyon 
Industry liaison Dr Ireena Dutta 
Chief Knowledge Office Alison Stewart 
Science and Policy Philippa Brice 
Policy Dr Susan Wallace 
Senior Research Fellow Christine Patch 
cqko(3)sri.ca.. ac.uk 
North West Knowledge 
Park 
Manchester 
www.nowaen.ora.uk 
name.nametacmcc.nhs.uk 
info©nowaen. ora.uk 
Prof. Dian Donnai (Executive Director) 
Helen Middleton-Price (Director) 
Jan Dobson (Project Co-ordinator) 
Johannah Avres 
Ruth Chadwick 
Linda Davies 
Ruth Hailwood 
Kate Mathieson 
Marion McAllister 
Stuart Nicholls 
Katherine Pavne 
Elisa Pieri 
Andrew Rose 
Sarah Wilson 
Brian Wvnne 
wwww 
London IDEAS Genetic 
Park 
First Floor 
Institute of Child Health 
30 Guilford Street 
London WC1N 1EH 
http://www.londonideas.org/internet/contact/ 
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Tel/fax 020 7905 2221 
Kings Fund Leading Policy Body Dr Jenny Dixon 
Diabetes UK Diabetes UK Central Office 
Immunology: 
Teodora Staeva-Vieira, Ph.D. 
Dr Alison Wilson Macleod House, 
10 Partway, London NW1 7AA 
Tel 020 7424 1000 
Fax 020 7424 1001 
Email info@diabetes.ora.uk 
scienceinfo@diabetes.ora.uk 
212-479-7547 or tstaeva-
vieira@jdrf.org 
Magdalena Eriksson, Ph.D. 
212-479-7633 or 
meriksson@jdrf.org 
Islet Biology & Transplantation: 
Brian Flanagan, Ph.D. 
212-479-7549 or 
bflanagan@jdrf.org 
Adrianne Wong, Ph.D. 
212-479-7642 or awong@jdrf.org 
Complications/Hypoglycemia: 
Antony Horton, Ph.D. 
212-479-7662 or ahorton@idrf.ora 
Aaron Kowalski, Ph.D. 
212-479-7512 or 
akowalski(5>idrf.ora 
Industry: 
Paul Burn, Ph.D. 
212-479-7572 or Dburn@idrf.orq 
Partnerships: 
Concepcion Nierras, Ph.D. 
212-479-7589 or 
cnierras@idrf.ora 
Genetics/Genomics: 
Concepcion Nierras, Ph.D. 
212-479-7589 or 
cnierras@idrf.ora 
Islet Biology & Transplantation: 
Nikki Bagli 
212-479-7537 or nbagli@jdrf.org 
Complications: 
Richard McFarland 
212-479-7643 or rmcfarland@idrf.ora 
or 
Calissia Alvarez 
212-479-7668 or calvarez@idrf.ora 
Partnership or Industry: 
Catherine Otey 
212-479-7554 or cotev@idrf.ora 
Genetics: 
Seran Lee 
212-479-7565 or slee@jdrf.org 
info(S)diabeles.org.uk 
east.midlands®, diabetes.org.uk 
london(5!diabetes.ore.uk 
Jo Brodie Islet Project Co-ordinator at Diabetes UK 
Inst Ophthalmology Retinal Stem Therapy 
Retinal Therapy 
Dr Ali (344k) -
Prof Greenwood (315k) 
Biotechnology and Biological 
Sciences Research Council 
Science and Technology - Nigel 
Brown Bioscience for society 
Maggie Leggett 
Genetics and developmental 
biology Anne Hembery and Fran 
Caldicott Science strategy Paul 
Burrow 
Polaris House 
North Star Avenue 
Swindon 
SN21UH 
UK 
Switchboard: +44 (0)1793 413200 
Name.name@bbsrc.ac.uk 
Diabetic Research 
Laboratories 
administration@dri.ox.ax.uk 
Oxford Centre for Diabetes 
Endocrinology and 
Metabolism 
World leading centre for diabetes 
endocrinology and metablism Clinical trials rurv.holman@dtu.ox.ac.uk Others involved in stem cell research 
david.mathews@ocdem.ox.ac.uk 
Anne.clark@ocdem.ox.ac.uk 
Keith.fravn@ocdem.ox.ac.uk 
Jonathan.Lew@ocdem.ox.ac.uk 
Paul Johnson Director Islet Transplantation 
Programme Trials commenced involving transplant 
of islet cells from donated human pancreases 
www.ecdem.ox.ac.uk 
Inst Psychiatry Motor Neuron Disease Dr Shaw (329k) 
London School of Economics Anna Dixon a.Dixon@lse.ac.uk 
Ray Robinson 
Economic and Social 
Research Council 
Name.name@esrc.ac.uk 
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Human Genetic Commission Dr Stephen Bain Reader in 
diabetic medicine at Brighton 
University/Consultant Birmingham 
Heartlands 
hac@dh.asi.aov.uk 
John Sulston 
Alistair Kent Diabetic Interest Group 
Philip Webb 
Juvenile Diabetes Research 
Foundation 
Juvenile Diabetes Research Foundation International 
120 Wall Street 
New York, NY 10005-4001 
Phone: 1-800-533-CURE (2873) 
Fax:(212) 785-9595 
E-mail: info(S)idrf.onz 
National Institute of Diabetes 
and Digestive and Kidney 
Diseases 
dkwebmaster@extre.niddk.nih.gov 
School of Clinical Medicine Jim.shawf3incl.ac.uk (Diabetes and Metabolism) 
Fellow from Glaxo 
Government 
House of Commons 
London 
SWIoAA 
02072192390 
All party Parliamentary Group on 
Diabetes 
Adrian Saunders MP Chair LibDem 
Helen Southworth. Lord Harrison, Dr Desmond Turner, 
Dr Howard Stoate Dr Brian Iddon Jim Dobbin Des 
Browne Betty Williams Janet Dean Bob Laxton Labour 
Tim Loughton Desmond Swayne Cheryl Gillan Anne 
Mcintosh Angela Watkinson Philip Dunne Conservative 
Universities 
UK 
Bath Tissue regeneration JB Chaudhuri (213k) 
Birmingham diabetes related 
gene slicing 
Prof Logan (402k) 
Prof Turner (243k) 
Cambridge 
derivation of cells 
Multiple Sclerosis 
Damage C Nervous S 
Olfactory mucosa 
A Surani (220k) 
JW Fawcett (247k) -
B Gottgens (277k) 
JB Gurdon (456k) 
Prof Ffrench-Constant (194k) 
DrChandran (311k) 
Prof Fawcett (233k) 
Dr Franklin (304k) 
Cambridge Stem Cell 
Institute 
Prof Anne Cooke 
Cardiff imaging neural stem cells 
intestinal epithelial cells 
brain 
protocols for storage 
ProfDunnett (317k) 
AR Clarke (206k) 
Dr Allen (272k 
Prof Dunnett (280k) 
Durham epithelia into skin and stem cells 
from hair follicle 
Dr CA Jahoda (314k) (290k) 
University of Edinburgh (with 
MRC) Institute for Stem Cell 
Research 
maintenance axial stem cell 
differentiation and renewal 
Prof Austin Smith Director austin.smithOed.ac.uk 
embryo stem cell biology 
iosh.brickmanffied.ac.uk embryonic Datternina 
brian.hendrichffied.ac.uk mammalian development 
vkotelevffistaffmail.ed.ac.uk cardiovascular system 
mena.li@ed.ac uk - doDamineraic develoDment 
a.medvinskviSied.ac.uk ontoaenv of 
haematopoietic 
aihsffisrv).bio.ed.ac.uk Andrew smith aenome 
engineering 
v.Wilson@ed.ac.uk Val early embrvo development 
simon.Tomlinson@ed.ac.uk stem cell informatics 
VA Wilson (287k) 
J Brickman (307k) 
University of Glasgow 
Institute of Biomedical and 
genes in human disorders 
Parkinson's 
Molecular Genetics 
Dr Mark ES Bailey 
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Life Sciences Cancer 
Tandem Biology 
Huntington's 
Cancer 
Epithelial stem cells in repair 
Prof R Wayne Davies 
Dr Maria E Jackson 
Dr Darren G Monskton 
Dr Peggy Shelboume 
Dr Joanna B Wilson 
Or Bamett (322k) 
Keele Activation of stem cells AJ EL Haj (335k) 
Kings College London Second UK Licence for embryo 
stem research 
Neural differentiation 
Derivation of human Embryonic 
Stem Cells 
Dr Susan Pickering 
Prof Peter Braude 
BP Williams (354k 
Dr S Minger (365k 
Imperial College London -
Faculty of Medicine -
Genetics and Genomics 
Tricking stem cells for transplant 
Stem cell culture systems 
Fate after transplantation 
Heart 
Research Prof Tim Aitman 
Strategic Research Philippe Froguel 
Prof Maggie Dallman 
C Toumazou (672k) 
Prof Fisk (182k) 
Dr Rimoldi (265k 
Liverpool Enhancing propagation of ES cell Dr Edgar (315k) 
Manchester Characterization of development 
Cartilage and joint repair 
Surface markers in SC 
AD Whetton (472k) 
Prof Hardingham (190k) 
Dr Chopra (184k) 
Newcastle University -
Institute of Human Genetics 
Vascular development 
Change in endothelial cells 
Leukaemia 
Generating new beta cells from 
human pancreatic stem cells and 
generation of glucose responsive 
insulin producing cells from 
human and mouse embryonic 
stem cells 
Dr Helen Arthur 
Dr Helen Arthur and Dr John Burns 
Dr Colin Miles 
Dr David Basset 
Dr D Elliott 
Dr S Lindsay 
Dr Sarah Newbury 
Dr Lyle Armstrong 
Dr Miodrag Stojkovic (deputy left now in Spain) 
Tom Strachan Director 
i.a.aoodshiD@ncl.ac.uk professor of medical 
genetics 
a.p.murdoch@mcl.ac.uk professor of reproductive 
medicine & department head (Alison and Miodrag 
lead embryo stem cell licence work) 
s.c.robson(3!ncl.ac.uk professor of fetal medicine 
Dr James AM Shaw Anne Dickenson 
a.m.Dickinson@ncl.ac.uk 
Wendy Macfarlane 
w.m.macfarlane@ncl.ac.uk 
Dr Stojkovic (210k) - clinical grade hes 
lines 
M Lako (310k) - impact of telomerase 
Nottingham University PJ Scotting (221k) - neural stem cell choices 
Dr Campbell (216k) - reprogramming differentiaion 
University of Oxford 
Department of Biochemistry -
Genetics Unit 
Dr Garry Brown - genetic defects in mitochondrial 
enerav metabolism aarrv.brown@bioch.ox.ac.uk 
andre.furaer@bioch.ox.ac.uk - gene expression 
ionathan.Hodakin@biotech.ox.ac.uk -
developmental genetics 
nicholas.kent@bioch.ox.ac.uk - chromatin structure 
and function 
Detros.liaoxvaakis@bioch.ox.ac.uk - immunitv 
andreas.russ@bioch.ox.ac.uk - aenetic modellina 
of human disease & drug reaction 
alison.woollard@bioch.ox.ac.uk - cell determination 
Oxford Prof Graham (192k) - reprogramming nuclei 
adult cells 
Prof Waldmann (313k) - reprogramming immune 
sys 
Oxford Churchill Hospital 
Within Oxford Centre for 
Diabetes and Endocrinology 
and Metabolism 
Working on perfecting the 
transplant of insulin producing islet 
cells into a patient's liver. Believe 
within 5 to 10 years they will have 
a simple procedure for curing 
diabetes. Cells in research are 
donated from another person's 
pancreas 
Dr Paul Johnson 
Director of Islet Transplantation Programme 
Paul.Johnson@medsci.ox.ac.uk 
Funded by diabetic research and wellness 
foundation. Executive Director Sarah Bone 
subs@drwf.ora.uk 
www@ocdem.ox.ac.uk 
Queen Mary Lon DA Lee (214k) - differentiation 
IC Mackenzie (209k) - tissue engineering 
H Navsaria (215k) stem cell fate using skin 
Roslin Institute Edinburgh - Spin out company Geron Bio Med Dr Harry Griffin Ass Director of Science 
www.aeron.com 
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www.roslin-biocentre.com 
Dr McWhir (313K) - bone repair 
Sheffield P Andrews (376k) - mechanism differentiation 
Prof Crossman (318k) vascular repair 
Prof Placzek (176k) - differentiation of hypothalmic 
cell 
B Caterson (197k) differentiation 
P Andrews (208k) - notch signalling 
Prof Andrews (291k) - changes of HES in culture 
P Andrews (955k)- ES resource centre 
Dr Coffey (276k) - retinal 
Southampton RO Oreffo (89k) - activation of stem cells 
Dr Gray (236k) - cell proliferation 
RO Oreffo (307k) 
UCL Retinal Dr Limb (325k) 
Peninsular Medical School Development and treatment of 
diabetes molecular genetics in 
diabetes 
Professor Andrew Hattersley 
a.t.hatterslev@ex.ac.uk 
Commercial Stem Cell 
Companies 
Aastrom 
Biosciences, Inc. 
tissue repair, cancer, infectious 
disease 
Aastrom Biosciences, Inc. 
Domino's Farms, Lobby L, 24 Frank Lloyd Wright 
Drive 
Ann Arbor, Ml 48105 USA 
Telephone: (734) 930-5555 
Fax: (734) 665-0485 
mail@aastrom.com 
http://www.aastrom.com/ 
ViaCell, Inc Cord blood ViaCell, Inc. 
245 First St 
Cambridge, MA 02142 
Telephone: 1-866-842-2355 
http://www.viacellinc.com 
Email - info@viacellinc.com 
Stem Cell Therapy 
International Corp. 
SCTI is the world's largest 
manufacturer of precursor stem 
cell xeno-transplants, which have 
been used to treat a wide range of 
conditions including: complications 
of diabetes, aging disease, 
neurological disorders, genetic 
diseases and immune deficiency 
disorders 
Stem Cell Therapy International Corp. 
2203 North Lois Ave. 9th Floor 
Tampa, FL 33607 USA 
Telephone: 813.600.4088 
Fax: 813.830.6112 
E-mail: info@scticon3.com 
http://www.scticoro.com/ 
Advanced Cell Technology, 
Inc. 
leading biotech company in the 
field of regenerative medicine 
One Innovation Drive, Biotech Three 
Worcester, Mass. 48105 USA 
Telephone: (508) 756-1212 
Fax: (508) 756^468 
info@advancedcell.com 
http://www.advancedcell.com/ 
AnorMED, Inc. cancer and HIV AnorMED, Inc. 
#200 - 20353 64th Avenue 
Langley, British Columbia, V2Y 1N5 Canada 
Telephone: 604.530.1057 
Fax: 604.530.0976 
E-mail: info@anomied.com 
http://www.anormed.com/ 
AVI BioPharma drugs to treat life threatening 
disease cancer restenosis poly 
cystic kidney disease drug 
metabolism 
AVI BioPharma 
One SW Columbia Suite 1105 
Portland, Oregon, 97258 USA 
Telephone: 503-227-0554 
E-mail: avi@avibio.com 
http://www.avibio.com/ 
BioE, Inc. diagnostic therapeutic products 
predictive test for alzheimers 
BioE Technical Support Department 
4280 Centerville Road 
St. Paul, MN 55127 
United States 
Telephone: 800-350-6466 
Fax: 651-426-5740 
Email: tech@bioe.com 
htto://www. bioe. com/ 
Bio-Matrix Scientific Group, 
Inc. 
tissue engineering and gene 
therapy 
Bio-Matrix Scientific Group, Inc. 
1010 University Avenue #40 
San Diego, CA 92103 USA 
Telephone: 619.702.1404 
Fax: 619.330.2328 
E-mail: info@bio-matrix.ora 
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httD://www.bmxaonline.com// 
Brainstorm Cell 
Therapeutics, Inc. 
Parkinson and multiple S 15 Gonen St. 
P.O.Box: 7779, Petach Tikva ISRAEL, 49170 
Telephone: +1-212-946-2823 
E-mail: vbeck(3!brainstorm-cell.com 
CHEMICON International, 
Inc. 
diagnostic kits Corporate Headquarters 
28820 Single Oak Drive 
Temecula, CA 92590 
United States 
Telephone: 800-437-7500 
Fax: 800^»37-7502 
E-mail: custserv@chemicon.com 
httD://www.chemicon.com/ 
Cord Blood America Corp. cord blood Legal Counsel 
Winderweedle, Haines, Ward & Woodman, P.A. 
Attn: Gary Lipson 
390 North Orange Avenue 
Suite 1500 
Orlando, FL 32801 
Telephone: 407-246-6577 
Matthew L. Schissler 
Chairman & C E O 
E-mail: mls@cordDartners.com 
httD://www.cordblood-america.com/ 
Cord Blood Registry (CBR) cord blood Cord Blood Registry 
1200 Bayhill Drive, Suite 301 
San Bruno, California 94066 
United States 
Telephone: 1-888-932-6568 
International callers: (650) 635-1420 
Monday to Friday (6am - 9pm PST) 
Saturday (7am - 4pm PST) 
Fax: 1-800-844-2202 
General o.uestions@cordblood.com 
Corporate Website - httD://www.cordblood.com/ 
Curis, Inc. drug development kidney disease 
and cancers 
61 Moulton Street 
Cambridge, MA 02138 USA 
Telephone: (617) 503-6500 
Fax: (617) 503-6501 
Contact page on web site 
httD://www.curis.com/ 
Cryo-Cell International, Inc. cord blood Cryo-Cell International, Inc. 
700 Brooker Creek Blvd., Suite 1800 
Oldsmar, FL 34677 USA 
Telephone: (813)749-2100 
Fax: (813)855-4745 
Contact page on website 
httD://www.crvo-cell.com/ 
Cytori Therapeutics spinal injury and gastro disorders 6740 Top Gun Street 
San Diego, CA 92121 
United States 
Telephone: 858-458-0900 
Fax: 858-458-0994 
Droducts@cvtoritx.com 
Corporate Website - httD://www.cvtoritx.com/ 
Favrille, Inc. Corp. immunotherapies non-hodgkin's 
lymphoma 
10421 Pacific Center Court 
San Diego, CA 92121 
United States 
Telephone: 858-526-8000 
Fax: 858-597-7040 
hr@favrille.com 
Corporate Website - httD://www.favrille.com/ 
Genentech, Inc. founder in biotech among world 
leaders 
Barbara Lippe most senior 
medical director 
1 DNA Way 
South San Francisco, CA 94080-4990 USA 
Telephone: (650) 225-1000 
Fax: (650) 225-6000 
httD://www.aene.com/aene/index.isD 
Genzyme Corporation one of the world's leading biotech 
working in 30 countries 
500 Kendall Street 
Cambridge, MA 02142 USA 
Telephone: 617 252 7500 
Fax: 617 252 7600 
Contact page on website 
Corporate Website - httD://www.aenzvme.com/ 
Geron Corporation cancer, spinal cord, diabetes, 
osteoporosis, blood disease 
230 Constitution Drive 
Menlo Park, CA 94025 USA 
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Telephone: 650-473-7700 
Fax: 650-473-7750 
info@aeron.com 
httD://www.aeron.com/ 
LifeCell Corporation orthopaedics and bums One Millennium Way 
Branchburg, New Jersey 08876-3876 USA 
Telephone: 1-908-947-1100 
Fax: 1-908-947-1089 contact page on 
website - httD://www.lifecell.com/ 
Mesoblast Limited Contact 
Inc 
orthopaedic Level 39 - 55 Collins Street 
Melbourne, 3000 AUSTRALIA 
Telephone: +61 3 9639 6036 
Fax: 617 252 7600 
hrtD://www.mesoblast.com/ 
Email: info@mesoblast.com 
MultiCell Technologies, Inc. Liver Multicell Research & Development Headquarters 
701 George Washington Highway 
Lincoln, Rl 02865 USA 
Telephone: 401-333-0610 
info@multicelltech.com 
MultiCell Technologies, Inc. Corporate 
Headquarters 
701 George Washington Highway 
Lincoln, Rl 02865 USA 
Telephone: 401-333-0610 
Fax: 401-333-0659 
info@multicelltech.com 
httD://www.multicelltech.com/ 
Osiris Therapeutics, Inc. immune heart attach and arthritis Osiris Therapeutics, Inc. 
2001 Aliceanna Street 
Baltimore, MA 21231-3043 USA 
Telephone: (410) 522-5005 
Fax: (410) 522-6999 
osiris@osinstx.com 
httDV/www.osiristx.com 
PharmaFrontiers Corporation autologous therapies for MS 
diabetes congestive heart failure 
(clinical test and vaccine) 
2408 Timberloch Place Suite B7 
The Woodlands, TX 77380 USA 
Telephone: 281-272-9331 
Fax: 281-272-1088 
ir@DharmafrontierscorD.com 
htto://www. oharmaf rontiers. net/ 
PhereSys Therapeutics Corp. remove disease causing 
substances from blood 
chief medical advisor 
richard.sweetmd@pheresys.com 
Corporate Headquarters 
1107 Investment Boulevard 
Suite 240 
El Dorado Hills, CA 95762 
United States 
Telephone: 916-939-9550 
Fax: 916-939-9553 
httD://www.Dheresvs.com/ 
Pluristem Life Systems, Inc. expansion of stem cells T cells 
and other blood cells 
Pluristem Life Systems, Inc. 
MATAM Advanced Technology Park 
Building No. 20, Haifa 31905, Israel 
Telephone: 972^-850-1080 
Fax: 972-4-850-1085 
E-mail: info@Dluristem.com 
httDV/www.Dluristem.com/ 
Serological Corporation provide products Serological Corporation 
5655 Spalding Drive 
Norcross, GA 30092 USA 
Telephone: (678) 728-2000 
E-mail: info@seroloaicals.com 
httD://www.seroloaicals.com/ 
Stem Cells, Inc. Parkinson's Alzheimers spinal 
cord MS liver and juvenile 
diabetes 
UK Australian and Japan embryo 
stem cells 
3155 Porter Drive 
Palo Alto, California 94304-1213 USA 
Telephone: 650.475.3100 
Fax: 650.475.3101 
httD://www.stemcellsinc.com/ 
Stem Cell Sciences UK Ltd. Corporation 
Roger Land Building 
King's Building 
University of Edinburgh 
West Mains Road 
Edinburgh 
EH9 3JQ 
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UNITED KINGDOM 
Telephone: +44 (0)131 662 9829 
Facsimile: +44 (0)131 662 9779 
htto://www.stemcellsciencesltd.com 
Stem Cell Therapeutics, 
Corp. 
Huntington's Suite 1000, 1520 4th St SW 
Calgary, AB, T2R 1H5, Canada 
Telephone: 403.245.5495 
Fax: 403.245.5411 
E-mail: info@stemcellthera.com 
httD://www.stemcellthera.com/ 
Stacie Cord blood 400 Rolyn Place 
Arcadia, CA 91007 
United States 
Toll Free: (866) 783-6298 
Local Ph: (626) 821-9860 
E-mail contact@stemcvteinc.com 
httD://stemcvte.com/ 
ThermoGenesis Corp. Cord blood ThermoGenesis Corp. 
2711 Citrus Road 
Rancho Cordova, CA 95742 USA 
Telephone: (916)858-5100 
Fax: (916) 858-5199 
webfaithemoaenesis.com 
Corporate Website -
httD://www.thermoaenesis.com/ 
ThromboGenics Ltd. Cardiovascular Disease and 
evaluating and exploring licensing 
Corporate Headquarters 
14 Bridgecourt Office Park 
Walkinstown Avenue 
Dublin 12 
Ireland 
Telephone: +353-(0)1-409-7757 
Fax: +353-(0)1^»09-8179 
U.S. Headquarters 
500 7th Ave., 10th floor IB 
New York, NY 10018 
USA 
Tel: +1-212-201-0920 
Fax: +1-212-201-0921 
Thromb-X N.V. 
Building O&N; Level 9 
Herestraat 49 
3000 Leuven 
Belgium 
E-Mail: ESinfo@thromb-x.com 
httD://www.thromboaenics.com/ 
httD://www.thromb-x.com/ 
U.S. BioDefense, Inc. explore licensing U.S. BioDefense, Inc. 
13674 E. Valley Blvd. 
City of Industry, CA 91746 USA 
Telephone: 626-961-0562 
Fax: 626-961-8179 
E-mail: info@usbiodefense.co 
httD://www.usbiodefense.com/ 
U.S. BioDefense, Inc. Advanced Cell Technology, Inc. is 
the leading biotechnology 
company in the emerging field of 
regenerative medicine. 
U.S. BioDefense, Inc. 
13674 E.Valley Blvd. 
City of Industry, CA 91746 USA 
Telephone: 626-961-0562 
Fax: 626-961-8179 
E-mail: info@usbiodefense.com 
Corporate Website - http://www.usbiodefense.com/ 
China 
Health Ministry 
National People's Congress 
Ministry of health in china 
Government 
Xi xhi men and wai nan lu 
www.moh.aov.cn/ 
Hu Jintao President 
Wen Jiabao Prime Minister 
WHO Representative in China wrchn@chn.WDro.who.int 
Bioethics and Society 
Research Register 
http://www.cams.ac.en/# 
Beijing China 
zxaclx@hotmail.com xmzhai@hotmail.com 
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Health and Science Centre -
clinical research organisation 
(Shanghai Institutes for 
Biological Science Shanghai 
Second Medical University 
and Chinese Academy of 
Sciences) 
225 South Chongqing Road 
Shanghai 200025 
China 
hsc@sibs.ac.cn 
Chief Specialist Huizhen Sheng 
Research Centre Peking Stem Cell (differentiation of 
human embryonic germ cells) 
Chief Specialist Lingsong Li 
Chinese National Human 
Genome Centre at Shanghai 
4th Floor, Bldg. 1, No.351, Guo 
Shou Jing Road.Zhang-jiang Hi-
Tech Park, Pudong, Shanghai, 
201203.P.R.China 
Director Chen Zhu 
web<a>chac. sh.cn 
httD://www.chac.sh.cn Honorary Director: Jia-Zhen 
TAN (Member, Chinese Academy of Sciences) 
Director: Zhu CHEN (Member, Chinese Academy 
of Sciences) 
Executive Director: Guo-Ping zhao 
Standing Deputy Director: Wei HUANG 
Deputy Director: Long YU 
Director Assistant: Ze-Guang HAN, Gang FU, 
Shuang-Xi REN, Shen-Yue Wang 
State Council Minister for foreign affairs Li Zhaoxing 
Minister for science and technology Xu Guanhua 
Minister for health Gao Qiana www.moh.aov.cn 
Intellectual property office Director Wang 
Jingchuan 
Research office Director Wei Liqun 
Development Research Centre Director Wang 
Mengkui 
Peking University - Beijing 
China - Department of Cell 
Biology and Genetics College 
of Life Sciences. 
Working on experiments to induce 
embryonic stem cells to become 
pancreatic beta cells. 
Contact honakui denatSpku.edu.cn and 
Minaziao Dina dinamxOI (QDku.edu.cn 
China European International 
Business School Shanghai -
Health Care Management 
www.ceibs.edu 
Chinese Academy of 
Engineering 
Hou Yunde Vice Chairman (says only a small gap 
between Developed World and China in 
biomedicine. Value $2.41 bn year) 
Hou Yunde academic attracted to China since 
joining WHO, investors in bio-tech attracted to 
China due to preferential policies, improved 
investment environment and possibility of huge 
profits www.xinhaunet.com 
Beijing Chinese Academy of 
Medical Science 
In February 05 scientists approval 
for Chinas first clinical trial using 
human stem cells to treat 
Leukaemia. Most projects are 
funded solely by the government. 
In future develop other areas 
including diabetes. 
Zhao Chunh leading the team 
www.bimu.edu.cn 
Chinese Academy of Medical 
Science 
Zheng Bin researcher 
China National Centre for 
Biotechnology Development 
Li Quing Chief of the Biotech Policy at (affiliated 
with Ministry of Science and Technology) 
Director Prof Wana Yu wanavu@cncbd.ora.cn 
Hui Honq huihona@cncbd.ora.cn 
SinoCells Biotechnology Co 
Ltd (Beijing Based) 
- Dong Ziping Chief Executive 
Beijing Military Medical 
College 
Pei Xuetao Division Stem Cell Research- claim 
1284 million people can be helped annually with 
stem cell therapies 
Stem Cell Research Centre 
(Peking) 
(differentiation of human 
embyronic germ cells) 
introduced genetic material into a 
stem cell to produce a glandular 
structure that secretes chemicals 
useful to treat diabetes and 
Parkinson's 
Chief Specialist Huizhen Sheng - hsc 
Chief Specialist Lingsong Li 
China Medical University 
Shenyang 
- Prof Xinshan Jia Head of Department of 
Molecular Pathology 
University of Medical 
Sciences 
(stem cell research) - Shunong Li Sun Yat-Sen 
Peking University Stem Cell 
Research Centre 
Hongmei Peng 
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China Medical University 
Shenyoung -
Xining Pang 
Stem Cell Centre Beike biotech company funded by Beijing University and 
China State National Fund - since August 2001 
treating patients with stem cell injections. ALS (89) 
Brain Trauma (32) Cerebral Infarction (36) 
Cerebreal Hemorrhage (20) Cerebral Palsy (20) 
Diabetic Foot (152) They use cord blood injected 
into the spine. Day-care no surgery. 
Chinese Association of 
Traditional Chinese Medicine 
Research into diabetes Wu Yi Ling Director 
Sun Yat-sen University 
Research presented at 
Global Conference on Stem 
Cells Sept 04 in Boston. 
Researchers from China reported 
reversing diabetes in Mice by 
injecting fetal liver cells from other 
mice. Korea reported generating 
insulin producing cells from 
human embryos 
AMMS Stem Cell and 
Regenerative Medicine 
Centre affiliated to Beijing 
Institute of Transfusion 
Medicine. 
Research application of stem cell biology an 
regenerative medicine including tissue 
regeneration of blood, heart, liver pancreas and 
nerve. Also run cord blood therapy for leukaemia 
and haematopoiesis and limb revascularisation 
(Professor Pei) 
Dr Huang Dr Wise Young 
(Rutgers University). 
Chaoyang Hospital Beijing 500 treatments for 
spinal cord injury 150 ALS. Costs $20,000 stay 
one month 
Beijing Tiantan Puhua 
Hospital 
stem cell work focuses on Brain Trauma Spinal 
Cord Injury ALS and clinical trials for Parkinson's 
(Dr Han Xiaodi Sherwood Yang) 
Huashan Hospital Shanghai Prof Zhu research autologous application of adult 
neural stem cells in traumatic brain injury 
Institute of Haematology and 
National Centre for Stem Cell 
Engineering and Technology 
28 Nanjing Road Tianjin 
300020 
Union Stem Cell and 
Gene Engineering company 
exploiting their research in cord 
blood therapies 
treatment of blood disease in Tianjin - Prof Zhong 
Chao Han (head of centre) 
- Beijing Institute of 
Transfusion Medicine AMMS 
Stem Cell and Regeneration 
Medicine (Cancer) 
Dr Pei Xuetao 
Wu Hospital 
Medical University Shanghai 
Dr Shen Huizhen Xuan- Head of Shanghai 
Laboratory of Developmental Biology 
Stem Cell Centre Beijing 
Medical University 38 Xue 
Yuan Road Beijing 100083 
China 
Prof Li Dr Ziping Dong - neural and pancreatic 
Prof Linasona Li linasonali(a>bimu.edu.cn 
Hong Kong University spinal cord and paralysis neuronal 
degeneration 
Dr Wu Wutian -
SinoCells Biotechnologies Co 
Ltd 116Zhongguaneun North 
Street Haidian District 
100871 
Dr Ziping Dong is C E (hES for clinical application 
by 2010) 
www.sinocells.com 
Beike currently at National 
Natural Science Foundation 
of China 
Dr Yang Bo - Parkinson's Brain Injury Stroke 
StemGene Union Stem Cell 
and Gene Engineering Co 
Ltd 11 Hongkan Road Tianjin 
300073 
company focusing on research 
and commercialisation of stem cell 
technology. Established 
Tianjin Cord Blood Bank where 
people store their cord blood 
Union Stem Cell and Gene Engineering 
unionstemcell(3>vahoo.com 
Xuan Wu Hospital Cell 
Therapy Centre 
and neural cells for 
neurodegenerative disorders. 
Expects to be first to clinic 
With diabetic work 
Prof Zhang working on pancreatic progenitor 
cells as a possible therapy for diabetes 
HosDital Prof Yu Zhana vaz(3>bisap.ora (workina 
on pancreatic) emailed 5/3/06 
Institute of Zoology Chinese 
Academy of Medicine 
Main research biological 
consequence of animal cloning in 
the use of technologies 
Prof Zhou successfully cloned a rat 
Pro Qi Zhou azhoufiJioz.ac.cn 
Chinese National Human 
Genome Centre at Shanghai 
Director Chen Zhu 
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Sleeboom M (2002 Nov) 
Stem Cell Research in China: 
An Intertwinement of 
International Finances, 
Ambition and Bioethics MAS 
Newsletter 29 
China also transplanted embryo 
cells into human brain cloned 
pulsating heart cells and cured 
paralysis in mice 
HeDena Jia (2005) China 
Supports Therapeutic Clonina 
China Business Weekly 31 s t 
March China voted against the 
United Nations non-binding 
statement condemning all forms of 
human cloning. 
Yan Shi, Lingling Hou, Fochou Tang, Wie Jiang, 
Peigang Wang, Mingxiao Ding Hongkui Deng 
(2005) Inducina Embryonic Stem Cells to 
Differentiate into Pancreatic B Cells bv a Noval 
Three-Sterj ADDroach with Activin A and All-Trans 
Retinoic Acid Stem Cells 23:656-662 
m.sleeboom.let.Ieidenuniv.nl researching genomics 
in Asia 
Shanghai Institutes for 
Biological Science 
Health and Science Centre -
clinical research organisation 
(Shanghai Second Medical University and Chinese 
Academy of Sciences) 
225 South Chongqing Road 
Shanghai 200025 
China 
hsc@sibs.ac.cn 
Dr Du Life sciences Asia 
Pacific 
iianshena.du@Dera.com 
Centre for Excellence in 
Tissue Engineering 
ProfRobert Zhao Chunhua 
chunhuaz@oublic.tpt.ti.cn 
Clinical pharmacogenetics 
aeoff.iohnston@Dfizer.com 
SteDhen.minaer@kcl.ac.uk 
Stem cell sciences 
Deter.mountford@stemcellsciences.com 
Neuroscience research part 
lanacio munoz saniuan@merek.com 
Chief science officer cellcentric ltd 
cathv.Drescott@Avlar.com 
Director of Centre for Cellular Behaviour 
i.Drice@ioD.kcl.ac.uk 
Innovation and Enterprise c.auest@amul.ac.uk 
Public law a.richardson@amul.ac.uk 
World wide business development 
Malcolm.7.skinale@ask.com 
Academy of Military Medical 
Sciences 
www.amms.ac.cn prof Xuetao pei 
Chinese Academy of Medical 
Science 
Zhao Chunhua www.stemnews.com/archives/stem-
cellanddiabetes.html 
Prof Lui Depei 
biomedicine in china httD://cm bi.bimu.edu.cn 
www.chinaethics.com 
www. stemcells. abhamedDress. ora 
SinoCells Biotechnologies 
China 
hr@sinocells.com 
National Science Foundation Prof Zhu Zuoyan 
Beike Biotech Company 
Institute of Genetics C A S 
China 
Prof Yang Huanming 
Chinese Engineering 
Sciences Beijing 
Prof Hou Yunde 
China World Best Beijing Prof Wang Guihai 
Chinese National Human 
Genetic Centre 
www.chac.ch.cn 
www.chac.ora.cn 
Yang Huanming Director 
Tianjin Science and 
Technology Commission 287 
Hepping Road 300041 
Genon Bioengineering Co 
Ltd (Dr Guoxiang Cheng) 88 
Laiun Road Zhangjang 
Rudong Shanghai 
www.cnaenon.com 
Xinhua New China Hospital 
1665 Kong Jiang Road 
Shangahi 
Huashan Hosptial Fudan 
University 12Wulumuqi 
Zhong Road Shanghai 
www.huashan.ora.cn 
prof Wen Yu-Mei 
Huashan Hosptial prof Jianhong Zhu 
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200040 
Peking Union Medical 
College in co-operation with 
Tsinghua University 
(leading Chinese university in 
combining stem cell technology 
with tissue engineering) Has five 
research units an Islet Unit, heart, 
liver, adult stem cells, biomaterials 
Xinhua Hospital part of 
Shanghai second medical 
university. 
Prof Hui Sheng (she) Cell differentiation 
Xinhau Hosptial pro hui zhen sheng 
hzshena(5!sh163a.sta.net.cn 
Ru-Jin Hospital Shanghai 
Institute of Haematology 
houses key labs for human 
genome research medical 
genomics and ministry of public 
health 
Jianxi Medical College 161 
Ba Yi Street Nanchang 
330006 
China Medical University92 
Bei Er Road Heping District 
Shenyang 110001 
Nanjing University School of 
Medicine 22 Handou Road 
Nanjing 210093 
Shanghai Medical University 
138 Medical College Road 
Shanghai 200032 
San Yat Sen University of 
Medical Sciences 74 Zhong 
Shan Road 1 Guangzhou 
510089 
Tianjin Medical University 22 
Qi Xiang Tai Road Tianjin 
300070 
West China University of 
Medical Sciences 17 Section 
3 South Ren Min Road 
Chengdu 610044 
Xian Medical University West 
Xiao Zhai Road Xian 710061 
Peking University Stem Cell 
Research Centre 
Martial Medicine Academy of 
Science Transfusion 
Department 
Peking University People's 
Hospital Cell Therapy Centre 
Beijing Xuanwu Hospital 
Beijing Society of 
Biotechnology 
Beijing Biotechnology and 
New Medicine Industry 
Promotion Centre 
Beijing Society of 
Biotechnology Stem Cell 
Commission 
chenl@mail.newlifebD.ora.cn 
www.stemcell.com.cn 
Beijing Sinocells 
Biotechnologies Co Ltd 
Rest of the 
World 
Stem Cell Research into 
Diabetes 
Stamford University 
United Stated 
Researching brain cells into 
producing insulin. Tested on 
animals not humans 
Dr Seung Kim Ass Prof Dept Developmental 
Biology 
Stamford University Coax immature cells to develop 
into islet cells 
Hospital in San Nicolas, 
North of Buenos Aires. 
Cured diabetes by taking stem 
cells from ileum bone 
manipulating in lab and injecting 
into the pancreas using a catheter 
through the femoral artery 
(3/01/05) 
Fernandez Vina leads team 
Massachusetts General 
Hospital 
(Jan 05) discovered spleen might 
be source of stem cells to produce 
islet cells from 
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Harvard University developed method to provide 
individual sequence of their 
genome. Current cost 2.2m but 
project this would be E562 when 
available. 
George Church 
almlcl@receDtor.med.harvard.edu 
(ref Journal of Science) 
Harvard University to find a cure for diabetes 
working in partnership with Seoul 
National University Prof Kwang 
Woo-Kuk 
(two of Dr Meltons children have 
diabetes) 
Dr Douglas Melton 
dmelton@biohD.hav.ord.edu 
prof natural science Harvard 
University of California San 
Francisco Diabetic Centre 
Michael German 
maerman@biochem.ucsf.edu 
University of Minnesota Reversed diabetes in monkeys by 
transplants of islet from pigs. Plan 
to commence human trials in 2009 
Associate professor of surgery and lead 
investigator Bernhard Hering 
Washington University 
School of Medicine 
Cured diabetes in rats with pig 
embryonic tissue without need for 
anti-injection therapy 
Toronto University Work published in journal of 
nature biotechnology (generating 
new beta cells to produce insulin 
in mice) 
Lead Researcher Dr Simon Smukler 
Viacell Incorporated 
(NASDAQ:VIAC) Genzyme 
Corp 
Working on cure for juvenile 
diabetes 
AmCyte Inc Los Angeles 
Leads in encapsulated islet 
cell and pancreatic adult 
stem cells. Presented Bio 
2005 conference 
(Largest biotech Company in the 
World lead in transplants for type 
1 diabetes 15/3/05 first transplant 
without immune suppression 
www.amcvte.com 
Vitro diagnostic Inc Filed for new patent in US for 
procedure to generate beta cells 
France showed adult human stem cells 
are able to be differentiated into 
insulin expressing cells 
Moriscot Christine, Fraipont de Florence, Richard 
Marie-Jeanne, Merchand Melanie, Savatier Pierre, 
Bosco Domenico, Favrot M, Benhamou Pierre-
Yves (20051 Human Bone Marrow Mesenchymal 
Stem Cells can Express Insulin and Kev 
TranscriDtion Factors of the Endocrine Pancreas 
Developmental Pathway UDon Genetic and/or 
Micro environmental Manipulation in Vitro Stem 
Cells 23;594-603 
Japan (Kyoto) islet cells used to cure daughter 
WHO 
Emailed 5/3/06 
Work on diabetes in China Dr P Puska DUskaD@who.int 
Dr G Roalic roalica@who.int 
Mr D Porter Dorterd@who.int 
www.who.int 
www.unaids.orp 
www.sustainable-development.eov.uk 
Researching in the clinical area of 
diabetes in the UK and China 
Pharmaceutical 
Astra Zeneca - provides cardiac drugs 
not diabetes. Nothing on 
diabetes in their published 
research programme 
Abbots 
involved mainly in monitoring and 
management of diabetes. 
Products include freestyle, 
freestyle flash and CoZmonitor, all 
blood glucose monitoring. Co 
Pilot and precision link both health 
management system, precision 
Xtra advance diabetes 
management system, insulin 
syringes (precision sure dose) and 
a range of nutritional products. 
www.abbott.com 
Sanofi-synthelabo no research in diabetes. 
Produces insulin (lantus). 
www.sanofi-avantis.us 
Sanofi Aventis 
amaryl oral for type 2 diabetic's 
world's third largest company. 
www.sanofi-aventis.com 
Eli-Lilly Lilly is a leader in diabetes 
research, dating back to our role 
- Headquarters in Shanahai. www.lillv.com 
www.lillychina.com 
Gail Newmarch 264 
DBA Master Final November 2008 
in developing the world's first 
commercially available insulin 
product, lletin®, in 1923.They 
pursue a number of diabetes-
related targets. We're also 
working to develop a therapy to 
treat some of the complications of 
diabetes. 
Sidney Tanjel C E 
Alan Breier Medical Director 
Bryce Carmine Global Brand Development Team 
Steven Paul Senior Vice President for Science and 
Technology 
Steven R Plump Global Market 
Thomas Verhoeven Product Research and 
Development 
Bayer 1990 Glucobay (china's 
best selling medication) 
1997 Glucometer 
2003 Ascensia monitoring 
Shanghai Polymer 
Research Development 
CentreChina. Produces 
blood glucose monitoring include 
ketone testing 
www.baver.com 
info@chinaObaver-aa.de 
Novartis Novartis Institutes for Biomedical research 
Cambridge MA Novartis institute for medical 
science London www.novartis.com 
Board: Dr HC Daniel Vasella Chair and C E 
Prof Helmut Sihler Vice Chair and Lead Director 
Bruno Heynen Corporate Secretary 
Takeda - Existing products - A C T O S 
insulin sensitiser type 2 BASEN -
decrease postprandial 
hyperglycaemia in diabetes. 
Compound promotes energy 
consumption. In phase 1 clinical 
trial in US world marketing rights 
excluding China blopress TCV-
116 Diabetic Nephropathy Japan 
Phase 11 Ao-128 Voglibase 
impaired glucose intolerance 
Japan Phase 111 
Tsakuba research centre Osaka 
research centre Global Research 
and Development Centre US 
Europe Research and 
Development Centre Research at 
home with Keio University in 
genome relating to hypertension 
and diabetic organopathy joint 
research on human genome with 
cetera partnership with oxford 
diabetic centre drug related 
research on diabetes and obesity 
Harvard Medical School 
developed new anti diabetic agent 
AJ-9677 in partnership with 
Dainippon. 
www.takeda.co.irj 
Kiyoshi Kitazawa General 
Manager Pharmaceutical 
Development Makoto Yamaoka 
General Manager Marketing 
Division Yasuhiko Yamanaka 
Corporate Strategy and 
Planning Kazuaki Ikeya 
Strategic Product Planning 
Naohisa Takeda Department of Europe and Asia 
Wyeth 
no products relating to diabetes 
but involved in genetic research. 
Located in UK and China 
www.wveth.com cambridae-material@wyeth.com 
Glaxosmithkline 
anti-diabetic One of worlds largest 
research programmes 
Has genomic and new drug 
discovery technologies First 
company to fund pharmaceutical 
R&D in China 1999 launch 
Heptodin in china world first 
treatment hepatitis B Avandia type 
2 diabetes first class 1 drug in 
China for diabetes DREAM trial 
2000 to use avandai and or 
ramipril to prevent type 2 diabetes 
Canada S B 418790 beta3 
adrenergic receptor type 2 
diabetes Phase 1 
(Seretide/Advair) GW427353 
beta3 adrebergic receptor type 2 
Phase 1 (Ventolin) G1262570 
PPAR gamma agonist type 2 
Phase 3 (Seroxat/Paxil) Involved 
in pharmacogenetics Metabolic 
Research Triangle Park 
USA www.ask.com 
Dr Jean-Pierre Gamier C E 
Dr Tadataka Yamada Research and Development 
Glaxosmithkline (Tianjin) Company Limited -
aiming to enter the Chinese market 
Servier French company first 
products 1955 for 
Has Chinese base in Tianjin 
(Manufacturing) www.servier.com 
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hypertension and diabetes. 
Servier Laboratories 
Limited British subsidiary 
Buckinghamshire. 16% of 
Its product market is 
diabetes, cardiovascular 
72%. 
Servier (Tianjin) Pharmaceutical Company Limited 
producing Diamicron - for metabolic and vascular 
conditions in type 2 
Novo Nordisk 
French Company 
clinical trial in number of 
areas of diabetes. Current 
provider of NovaMix 30, Nova 
Rapid, Levemir, Actapid, 
Insulatard, 
Mixtard, GlucaGen HypoKit, Flex 
Pens, Nova Pen, Nova Pen Siver, 
Innolet, Novalet, innova Induce 
Needles, novafine novafine auto 
(Type 2) NovaNorm, Nova Let, 
also 80 year history of pioneering 
diabetic research and drug 
development. Industries broadest 
range of diabetic products. 
Research pipeline: insulin 
analogues, several anti-diabetic 
drugs, pathophysiology and new 
delivery systems for injection or 
inhalation. Also stem cell biology, 
diabetic immunity and many 
aspects of type 2 including beta 
cell stress, insulin secretion, 
glucose production by the liver 
insulin resistance. 
Also based in China www.novonordisk.co.uk 
www.novonordisk.com.cn 
Lars Rebien Sorensen C E and President 
Mads Krogsgaard Thomsen Chief Science Office 
Nova Nordisk - first biotech company to 
manufacture insulin in china 
www.novanordisk.con.cn 
Pfizer - Largest 
Pharmaceutical Company in 
the UK. 
Produce Glucotrol XL type 2 
diabetes. 
Operates in China WWW.Dfizer.com 
Corporate HQ New York, Research and 
Development UK Sandwich 
Michael S Brown - Chair in biomedical science 
William H Gray - public policy 
Merck vast research pipeline in 
diabetes. Has diabetic 
research in pre-trial 
and phase 1 trials and 
phase 111. Looking at 
lipid disorders in diabetics. 
In china (AIDS). 
- enauiriesOmerckDharma.co.uk 
Richard T Clark C E 
William N Kelley Pro Medicine Biochemistry and 
Biophysics 
Rochella B Lazarus World Marketing and 
Communications 
Samuel O Prof Medicine and Health care Policy 
Roche 
located Zhangjiang Hi Tech 
Park Pudong New District 
Shanghai 
world's largest 
manufacturer of cancer 
drugs and diagnostic tests. 
Blood monitoring systems 
for diabetes. Opened 
global R and D centre in 
Shanghai Nov 2004 
General Manager or Roche 
China Andrew Tschirky, 
www.roche.com www.roche-
diaanostics.com www.roche.com.cn 
Pudong, Shanghai - although key bands such as 
saridon, rocephin and referon are all late comers 
into the market compared with competitors 
shanghai Roche has gained a considerable market 
share year after year 
Tianjin Newscan Coast Bio-
Pharmaceutical Company ltd 
produced diabetic Hbalctests 
Tianjin Teda Biomedical 
Engineering Company 
Limited 
food products for diabetics 
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Appendix K 
Questions Asked: 
Your views on the advantages and disadvantages of your research environment 
Do you consider the current patent system to be adequate for stem cell research? 
Do you think the ethical stance of China will make it likely that they achieve success first 
in translating stem cell technologies into clinical therapies? 
If such therapies were to become available in China before the US or UK, do you 
consider there would be any risks associated with this? 
Interview List 
Dr David Bennett - Task Group on Public Perspective on Biotechnology 
Azim Surani - Cambridge and Wellcome Institute of Cancer and Developmental Biology 
Ian Young - Business Relations Manager Department of Trade and Industry 
Glyn Stacey Chief Executive Bio Bank UK 
Prof X.N.Wang Newcastle Life Sciences 
Prof Alison Murdoch Newcastle Life Sciences 
Prof Anne Clarke Oxford Centre for Diabetes Endocrinology and Metabolism 
Prof Stephen Minger Kings College London 
Prof Ornell Rimoldi Imperial College London 
Peter Holland Chief Executive Cord Blood London 
Prof A Zhang Xuan Wu Hospital Cell Therapy Centre 
Prof Cathy Prescott Avlar Bio Ventures Limited 
Peter Mountford Chief Executive Stem Cell Sciences 
Jeanette Walker Business Development Director ERBI St John's Innovation Centre 
Cowley Road Cambridge CB4 OWS www.erbi.co.uk 
Dr Stefan Przyborski Director and Chief Scientific Officer Re: innervate Limited and 
Durham School of Biological Science Durham University South Road Durham DH1 3LE 
Stefan.pryborski@reinnovate.com 
Dr Mary Archer - Chairman East of England Stem Cell Network 
Prof Martin Bobrow - Nuffield Council Bioethics/Head of Medical Genetics Cambridge 
University Former Deputy Chair Wellcome Trust 
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